

**CURRICULUM VITAE
OREGON HEALTH & SCIENCE UNIVERSITY**

NAME	Tomasz M. Beer	DATE	August 15, 2022
-------------	-----------------------	-------------	------------------------

PRESENT POSITION AND ADDRESS

Academic Rank:	Grover C. Bagby Endowed Chair for Prostate Cancer Research Professor of Medicine
Department/Division:	Medicine/Hematology & Medical Oncology
Professional Address:	3485 S Bond Avenue, OC14P Portland, OR 97239
E-Mail Address:	beert@ohsu.edu

I. BIOLOGICAL

Birthdate*:	February 2, 1965
Marital Status/ Children*:	Married, 2 children

II. EDUCATION

Undergraduate and Graduate (Include Year, Degree, and Institution):

1986	B.A.	The Johns Hopkins University
1987 – 1988		Paul H. Nitze School of Advanced International Studies Graduate training in International Relations
1991	M.D.	The Johns Hopkins University School of Medicine (23 May 1991)

Postgraduate (Include Year, Degree, and Institution):

1991 – 1992	Intern in Medicine, Oregon Health Sciences University, Portland
1992 – 1994	Resident in Medicine, Oregon Health Sciences University, Portland
1995 – 1996	Chief Resident in Medicine, Oregon Health Sciences University, Portland
1996 – 1999	Fellow in Hematology and Medical Oncology, Oregon Health Sciences University, Portland

Other – Additional Educational Activities Attended:

2005	The Foundation for Medical Excellence “Health Care Leadership for the 21 st Century – Institute One”
2005	The Foundation for Medical Excellence “Health Care Leadership for the 21 st Century – Institute Two”
2006 - 2007	OHSU Leadership Academy
2006	OHSU Clinical Service Excellence Training
2006	Real World Entrepreneurship
2007	Harvard School of Public Health: Leadership Development for Physicians in Academic Health Centers

Certification (Include Board, Number, Date, and Recertification):

1995	American Board of Internal Medicine, Certificate No. 162988
------	---

2010-Nov ABIM, Medical Oncology, Certificate No. 162988, recertification 2020

Licenses (Include State, Date, Status, Number, and Renewal Date):

1992 Oregon Medical License No. 17740, active, renewal: 12/31/2020
 1994 Washington Medical License No. 025209 MD00031918 (inactive)

III. PROFESSIONAL EXPERIENCE

Academic (Include Year, Position, and Institution):

1999 – 2000 Instructor, Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health Sciences University, Portland
 2001 - 2004 Assistant Professor, Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland
 2004 - 2009 Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland
 2007 Grover C. Bagby Endowed Chair for Prostate Cancer Research OHSU Knight Cancer Institute, September 2007
 2009 - Professor, Division of Hematology and Medical Oncology, School of Medicine, Oregon Health & Science University, Portland

Administrative (Include Year, Position, and Institution):

2003 - 2004 Acting Head, Hormone and Reproductive Malignancies Program, OHSU Cancer Institute
 2003 - Director, Prostate Cancer Research Program, OHSU Cancer Institute
 2004 - Leader, Prostate Cancer Focus Group, Solid Tumors Program, OHSU Cancer Institute
 2007 - 2009 Head, Section of Solid Tumor Oncology, Division of Hematology and Medical Oncology, OHSU Department of Medicine
 2009 - Deputy Director, OHSU Knight Cancer Institute
 2012 - 2014 Interim Division Chief, Division of Hematology & Medical Oncology, OHSU Knight Cancer Institute
 2012 - Associate Director for Clinical Research, OHSU Knight Cancer Institute
 2017- Chief Medical Officer, Center for Early Detection Advanced Research, OHSU Knight Cancer Institute

Other (Include Year, Position, and Institution):

1999 - Staff Physician, Portland VA Medical Center

IV. SCHOLARSHIP

Area(s) of Research/Scholarly Interest:

Targeted therapy in prostate cancer
 Prostate cancer outcomes
 Integrated genomics of prostate cancer

Faculty on Major Advisory Boards

Clinical Trial Endpoints in Prostate Cancer, Baltimore, MD, May 2005

Awards

1983 – 1986 Beneficial Hodson Scholar, The Johns Hopkins University
 1984 Alpha Epsilon Delta
 1985 Tau Beta Pi

1986	Departmental and General Honors, The Johns Hopkins University
1994	Alpha Omega Alpha
1994	Resident Teaching Award
1998	N.L. Tartar Research Fellow
1999	Jean and Harold Grossman – American Cancer Society Cancer Research Fellow
2003	Robert D. Goldman Award
2004	Fellow, American College of Physicians
2005	Best Doctors in America listing
2007 - 2008	Best Doctors in America listing
2008	Portland Magazine's "Top Docs '08" listing
2008	Castle Connolly Medical Ltd. America's Top Doctors listing
2008	Marquis Who's Who listing
2008	The Global Directory of WHO'S WHO listing
2008	America's Top Oncologists 2008 Edition
2008 – 2009	Cambridge Who's Who Among Executives and Professionals in Healthcare "Honors Edition" listing
2009	Marquis Who's Who in America listing, 63 rd Edition
2009	Castle Connolly Medical Ltd. America's Top Doctors for Cancer, 5 th Edition
2009	Castle Connolly Medical Ltd. America's Top Doctors, 9 th Edition
2009	The Global Directory of WHO'S WHO listing
2009	Guide to America's Top Oncologists, 2009 Edition
2009	OHSU Technology Innovation Award for Pulse Doses of Vitamin D and Analogues as Anticancer Therapy (Technology Licensed to Startup Onco-D Therapeutics)
2009 – 2010	Marquis Who's Who in Medicine and Healthcare, 7 th Edition
2009 – 2010	Best Doctors in America listing
2010	Marquis Who's Who in America listing, 64 th Edition
2010	2010 Man of the Year in Medicine & Healthcare, American Biographical Institute, Inc.
2010	Top 3 OHSU Technology Innovation Award for Pulse Doses of Vitamin D and Analogues as Anticancer Therapy (Licensed to Receptor Therapeutics)
2011	Marquis Who's Who in America listing, 65 th Edition
2011 – 2012	Marquis Who's Who in Science and Engineering listing, 11 th Edition
2011 – 2012	Best Doctors in America listing
2012	Portland's Top Doctors 2012 Portland Monthly listing
2012	Top 1% of Physicians by US News and World Report
2013	Best Doctors in America listing
2013	Top Doctors 2013 Portland Monthly listing
2014	Top Doctors & Nurses 2014 <i>Portland Monthly</i>
2020	OHSU Continuing Professional Development Clinical Star Award
2020	Portland Monthly's Top Doctors

Patents:

US patent 6,521,608: Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders

Australian patent 762481 (32022/99): Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders

Applications filed:

Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof (US patent applications 11/482,111)

Estrogen administration for treating male cognitive dysfunction or improving male cognitive function (US patent application serial no. 60/533,693)
 IRX5 inhibition as treatment for hyperproliferative disorders (US patent application serial no. 60/571,043)
 Transdermal diethylstilbestrol for treating prostate cancer (US patent application serial no. 60/851,255)

Grants and Contracts:Federal (Include Title, Source, PI, Amount, Period, and % Effort)

P30 CA069533 (Druker)	07/01/17–06/30/22	effort: 5%
NIH/NCI	\$15,675,769	
OHSU Knight Cancer Institute, Cancer Center Support Grant		
Role: Deputy Director		
W81XWH-17-2-0018 (Beer)	9/30/17-9/29/22	effort: 10%
US Army Med Rsch Acquisition Act	\$1,535,750	
Clinical Consortium Award - Clinical Research Site		
R01 CA222605 (Winters-Stone)	7/23/18-6/30/23	effort: 4%
NIH/NCI	\$3,354,582	
Preventing Falls and Fragility in Prostate Cancer Survivors: GET FIT Prostate		
R01 CA218093 (Winters-Stone)	4/1/19-3/31/23	effort: 3%
NIH/NCI	\$3,337,174	
EXERCISING TOGETHER: A randomized controlled trial of partnered exercise training on the health of couples coping with cancer		
R01 HL151367 (Shatzel)	6/15/20-5/31/25	effort: 5%
DHHS NIH Natl Heart, Lung, & Blood Institute	\$614,297	
Evaluating the Safety and Efficacy of Targeting the Contact Pathway to Prevent Device Associated Thrombosis		
EA8191 (Beer)	7/1/16-12/31/23	effort: <5%
Knight SWOG	\$240,092	
SWOG Clinical Trial EA8191		
EA8191: Phase III study of local or systemic therapy INTensification Directed by PET in prostate CAncer patients with post-prostatTEctomy biochemical recurrence (INDICATE): ECOG-ACRIN		
S1802 (Beer)	5/7/19-12/31/23	effort: <5%
NIH/NCI	\$240,092	
SWOG Clinical Trial S1802		
Phase III Randomized Trial of Standard Systemic Therapy (SST) vs. Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer		

State and Local (Include Title, Source, PI, Amount, Period, and % Effort)

None

Other Support (Include Title, Source, PI, Amount, Period, and % Effort)

(Beer, site PI)	6/16/14-6/30/24	effort: <5%
Astellas Scientific & Med Affairs	\$515,721	
Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment		

(Beer, site PI)	11/11/16-9/30/22	effort: <5%
Merck Sharp & Dohme Corp	\$522,038	
A Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) previously treated with Chemotherapy (KEYNOTE-199)		
(Beer, site PI)	4/11/18-4/30/23	effort: <5%
Alliance Foundation Trials LLC	\$137,235	
A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer.		
(Beer, site PI)	5/10/18-5/31/23	effort: <5%
Corcept Therapeutics	\$123,565	
Phase 1/2a Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer		
(Beer, site PI)	12/12/18-12/31/22	effort: <5%
Endocyte Inc	\$629,851	
Vision: An International, Prospective, Open-Label, Multicenter, Randomized Phase 3 Study of 177LU-PSMA-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (MCRPC)		
(Beer, site PI)	10/21/19-10/31/22	effort: <5%
Harpoon Therapeutics	\$241,966	
A Phase I open-label, multicenter, dose escalation and dose expansion study of the safety, tolerability, and pharmacokinetics of HPN424 in patients with advance prostate cancer refractory to androgen therapy		
(Beer, site PI)	11/5/19-11/30/22	effort: <5%
Zenith Epigenetics	\$34,353	
Continuation protocol for ZEN003694 in patients experiencing clinical benefit while enrolled in a ZEN003694 protocol		
(Beer, site PI)	2/7/20-2/28/23	effort: 5%
GRAIL Inc	\$2,471,100	
The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice		
(Beer, site PI)	9/25/20-9/30/25	effort: <5%
Bayer HealthCare Pharm Inc	\$65,788	
VAPORHCS/OHSU: A randomized, open-label, multicenter, phase 2b study to evaluate physical function, including balance and daily activity, in participants with castration-resistant prostate cancer treated with darolutamide		
(Beer, site PI)	10/20/20-10/31/25	effort: <5%
Freenome Holdings Inc	\$378,190	
PREEMPT CRC: PREvention Employing a Multiomics Plasma-based Test for Colorectal Cancer		
(Beer, site PI)	6/1/21-6/30/26	effort: <5%
Freenome Holdings Inc	\$144,816	
Project Danube: Multi-Cancer and Comorbidity Blood Sample Collection for Cross-Reactivity Analysis for a Multiomics CRC Screening Test		

(Beer, site PI)	1/1/22-1/31/27	effort: <5%
GRAIL Inc	\$131,626	
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population		
(Beer, site PI)	1/24/22-1/31/27	effort: <5%
Exact Sciences Corporation	\$0	
ASCEND 2: Detecting cancers earlier through elective plasma-based CancerSEEK Testing – Ascertaining Serial Cancer patients to enable new diagnostic II (DETECT-ASCEND 2)		
(Beer, site PI)	7/1/21-6/30/22	effort: <5%
Beta Psi Foundation	\$5,000	
Feasibility of substitution of virtual reality greenspace and volatile organic compound humidification to simulate the forest experience effects on immune system recovery.		

Pending Support (Include Title, Source, PI, Amount, Period, and % Effort)

None

Completed Grants and Contracts (Include Title, Source, PI, Amount, Period, and % Effort)

3M01 RR00334-33S2 (Kohler)	7/1/99-6/30/04	effort: 75%
NIH-NCRR	\$122,500 (annual direct)	
GCRC-Clinical Associate Physician – Tomasz M. Beer, M.D.		
5 R21 CA82504-02 (Beer)	8/1/99-7/31/03	effort: <5%
National Institutes of Health	\$74,532.00 (annual direct)	
Randomized study of pre-prostatectomy pulse calcitriol for the prevention of prostate cancer		
5 R21 CA85585-02 (Beer)	9/30/99-9/29/03	effort: <5%
National Institutes of Health	\$125,000.00 (annual direct)	
Phase II study of pulse calcitriol in patients with rising PSA after definitive treatment for prostate cancer		
1R13 CA93317 (Beer)	6/15/01-6/14/04	effort: <5%
National Institutes of Health	\$12,000 (total direct)	
Oregon Prostate Cancer Conference		
P50 CA89520 (Lange)	3/1/03-4/30/05	effort: <5%
NIH/SPORE Funds	\$45,000 (total direct)	
Phase II study of transdermal estrogen in androgen-independent prostate cancer (AIPC)		
263-MQ-417220 (Beer)	9/14/04-3/31/06	effort: <5%
NIH-NCI	\$24,637 (total)	
Cancer Outcomes with Androgen Deprivation Therapy for Localized and Advanced Prostate Cancer.		
PC040477 (Beer)	10/23/04-4/22/06	effort: 10%
Department of Defense	\$113,088 (total)	
A Novel Vitamin D Target in Human Prostate Cancer		
1R21CA113380-01 (Beer)	3/1/06-2/29/08	effort: 7.5%

NIH-NCI	\$76,000 (annual direct)	
A Novel Vitamin D Target in Human Prostate Cancer		
PC051353 (Beer)	1/1/06-12/31/08	effort: 15%
DOD	\$225,382 (annual direct)	
Clinical Consortium Award – Coordinating Center with option		
DN101-2 (Ryan)	9/11/02-10/30/05	effort: <5%
Novacea, Inc.	\$114,254.17 (total direct)	
A Phase 2/3 Multicenter, Randomized, Double Blind, Study of Docetaxel Plus DN101 or Placebo in Androgen Independent Prostate Cancer (Co-Investigator)		
PF-99-135-01-CCE (Beer)	7/1/99-6/30/03	effort: <5%
American Cancer Society	\$6,666 (annual direct)	
Nuclear receptor targets for prevention and treatment of prostate cancer		
(Beer)	10/1/04-9/30/07	effort: <5%
Kosan Biosciences Inc.	\$74,820 (total)	
A Phase II Study of KOS-862, Administered Intravenously Weekly for 3 Weeks every 4 Weeks, in Patients with Hormone Resistant Prostate Cancer Who Have Progressed Following Initial Therapy for Metastatic Disease (Study Agreement)		
GIA16066 (Beer)	3/2/00-12/31/05	effort: <5%
Aventis Pharmaceuticals Products, Inc.	\$169,188.00 (total direct)	
Phase II study of calcitriol enhanced taxotere in hormone refractory prostate cancer		
20000775-001 (Beer)	5/22/01-7/31/03	effort: <5%
Praecis Pharmaceuticals Inc.	\$141,563 (total direct)	
Phase II Study of Abarelix Depot In Androgen-Independent Prostate Cancer		
(Beer)	12/8/00-6/30/03	effort: <5%
Bristol-Myers Squibb	\$48,000 (total direct)	
Phase II Study of Calcitriol Enhanced Carboplatin in Hormone Refractory Prostate Cancer		
AVI-4126-142-2003 (Beer)	3/18/01-3/31/03	effort: <5%
AVI BioPharma	\$20,554 (total direct)	
A Phase I Study to Evaluate the Localization of AVI-4126 in Solid Tumors		
(Beer)	11/20/00-11/19/02	effort: <5%
AVI BioPharma	\$25,378 (total direct)	
Expression of HCG and other Antigens in the Human Prostate		
GIA# 16024 (Henner)	10/9/98-6/30/02	effort: <5%
Aventis Pharmaceuticals	\$84,956 (total direct)	
Phase II Study of Weekly Docetaxel in Symptomatic Androgen-Independent Prostate Cancer (co-investigator)		
VX98-710-005 (Henner)	11/15/98-8/30/02	effort: <5%
A Phase II Study of the Safety, Efficacy, and Pharmacokinetics of VX-710 in Combination with Mitoxantrone and Prednisone in Patients with Advanced Hormone-Refractory Prostate Cancer (co-investigator)		
98-OEMP-039 (Beer)	4/25/00-4/25/02	effort: <5%

Pharmacia & Upjohn Co.	\$6,027 (total direct)	
A Phase II Evaluation of Intravenous Estramustine Phosphate in Patients with Advanced Prostate Cancer		
STI571B US43 (Beer)	10/31/01-10/30/03	effort: <5%
Novartis Pharmaceuticals Corp.	\$117,190 (total direct)	
Phase II study of Gleevec (STI571, Imatinib mesylate) and Zometa (zoledronic acid) in symptomatic androgen-independent prostate cancer metastatic to the bones		
DN-101(Beer)	3/1/02-2/28/04	effort: <5%
Novacea	\$317,654.94 (total direct)	
A Phase I, Open Label, Single Dose, Dose Escalation Study of a New Formulation of Calcitriol (DN-101) for Safety, Tolerability, and Pharmacokinetics in Patients with Advanced Malignancies		
GIA10077 (Beer)	8/9/00-8/8/04	effort: <5%
Aventis Pharmaceuticals Products, Inc.	\$82,624.00 (total direct)	
Docetaxel combinations with calcitriol in vitro		
(Beer)	2/12/04-2/11/05	effort: <5%
Praecis Pharmaceuticals Inc.	\$3,322 (total)	
Biomarker Discovery in Prostate Cancer		
(Higano)	8/14/03-4/30/05	effort: <5%
Amgen	\$100,000 (total)	
Phase II Study of ARANESP® (DARBEPOETIN ALFA) in Prostate Cancer Patients (co-principal investigator)		
S0207 (Beer)	2002-2005	effort: <5%
Southwest Oncology Group	N/A	
Study of Arsenic Trioxide in Patients with Refractory Germ Cell Malignancies, Phase II		
GIA 16136 (Beer)	10/14/02-10/31/05	effort: <5%
Aventis Pharmaceuticals	\$144,767 (total direct)	
Phase I Dose De-escalation Study of High Dose Pulse Calcitriol, Docetaxel, and Estramustine in Androgen-Independent Prostate Cancer (AIPC)		
DN-105 (Ryan)	3/1/02-10/31/05	effort: <5%
Novacea	\$317,654.94 (total direct)	
A Phase I, Open Label, Single Dose, Dose Escalation Study of a New Formulation of Calcitriol (DN-101) for Safety, Tolerability, and Pharmacokinetics in Patients with Advanced Malignancies		
(Beer)	8/1/04-2/1/06	effort: <5%
BioScience Innovation Fund	\$73,259 (total direct)	
New Cancer Treatment Target		
XRP6976J/2501 (Beer- Site PI)	1/21/03-12/31/05	effort: <5%
Aventis Pharmaceuticals	\$76,526 (total direct)	
A Multicenter, Open-Label, Phase II Trial of Adjuvant Taxotere in Patients at High Risk of Relapse Following Prostatectomy		
(Montgomery)	3/1/03-3/31/06	effort: <5%
Aventis	\$205,000 (total)	
Docetaxel and Diethylstilbestrol in the treatment of Androgen Independent Prostate		

carcinoma: A Phase II trial (co-investigator)

(Beer) 6/16/04-6/15/07 effort: <5%
 Praecis Pharmaceuticals Inc. \$143,075 (total)
 Phase 2 Study of Abarelix in Androgen-Independent Prostate Cancer Progressing after Agonist Therapy

(Beer) 10/1/04-9/30/06 effort: 7.5%
 Kosan Biosciences Inc. \$39,890 (total)
 A Phase II Study of KOS-862, Administered Intravenously Weekly for 3 Weeks every 4 Weeks, in Patients with Hormone Resistant Prostate Cancer Who Have Progressed Following Initial Therapy for Metastatic Disease (Protocol Chair Agreement)

S0306 (Beer) 2003-2007 effort: <5%
 Southwest Oncology Group
 Phase II Study of Irinotecan in Patients with Advanced Transitional Cell Carcinoma of the Urothelium

R21CA098406-02 7/1/03-6/30/07 effort: 15%
 NIH-NCI (Beer) \$150,000 (annual direct)
 Phase II study of acupuncture for the treatment of hot flashes in men receiving hormonal therapy for prostate cancer

S0418 (Beer) 2005 - effort: <5%
 Southwest Oncology Group N/A
 A Phase II Study of SB-715992 in Taxane-Resistant Androgen-Independent Metastatic Prostate Cancer

031.G0008 (Beer) 9/27/00-10/31/07 effort: <5%
 OSI Pharmaceuticals Inc. \$96,000.00 (total direct)
 Phase I/II study of neoadjuvant weekly docetaxel and mitoxantrone prior to prostatectomy in patients with high risk localized prostate cancer

GIA16080 (Beer) 4/4/00-10/31/07 effort: <5%
 sanofi-aventis \$265,050 (total direct)
 Phase I/II study of neoadjuvant weekly docetaxel and mitoxantrone prior to prostatectomy in patients with high risk localized prostate cancer

635-ONC-0509-010 (Beer) 2/1/02-9/30/07 effort: <5%
 Pfizer, Inc. \$75,000 (total direct)
 Randomized study of pre-prostatectomy celecoxib or placebo

(Beer) 9/10/02-12/1/06 effort: <5%
 Novacea, Inc. \$326,615.00 (total direct)
 A Phase 2/3 Multicenter, Randomized, Double Blind, Study of Docetaxel Plus DN101 or Placebo in Androgen Independent Prostate Cancer (Study Chair)

(Beer, Site PI) 6/10/04-6/9/07 effort: <5%
 Dana-Farber/Partners CancerCare, Inc. \$45,000 (total direct)
 A Phase II Study of Docetaxel plus Carboplatin in Hormone Refractory Prostate Cancer Patients Refractory to Prior Docetaxel-based Chemotherapy

NCI 7347 (Beer, site PI) 3/1/07-12/31/09 effort: <5%
 NIH-NCI \$141,000
 Phase I/II trial of epothilone analog BMS-247550 (Ixabepilone), mitoxantrone, and

prednisone in hormone refractory prostate cancer patients previously treated with chemotherapy
(part of Department of Defense Consortium)

ATN-224-005 (Beer, site PI) 4/1/07-3/30/10 effort: <5%
Attenuon, LLC
A phase II study of ATN-224 in patients with biochemically relapsed, hormone naïve prostate cancer
(part of Department of Defense Consortium)

(Beer) 10/25/06-3/1/10 effort: <5%
Berlex \$140,000 (approx. total)
Phase II study of ZK Epothilone (2K-Epo; ZK219477) plus prednisone as first-line chemotherapy in patients with metastatic androgen-independent prostate cancer

(Beer, site PI) 8/10/06-4/30/10 effort: <5%
Beth Israel Deaconess Medical Center, Inc. and Dana-Farber/Partners CancerCare, Inc.
KHAD: An open label phase II study of ketoconazole, hydrocortisone, and dutasteride in asymptomatic hormone refractory prostate cancer
(part of Department of Defense Consortium)

(Beer) 4/27/07-4/30/10 effort: <5%
Sanofi-aventis \$189,170
Phase II Study of the Early Use of Docetaxel in Patients with Biochemical Relapse After Primary Therapy For Prostate Cancer and an Incomplete Response to Androgen Deprivation Therapy
(part of Department of Defense consortium)

1 R01 CA119125-01 (Beer) 5/1/06-3/31/11 effort: <6%
NIH-NCI \$251,861 (annual direct)
Resistance and Response Mechanisms to Prostate Cancer Therapy

5P30 CA69533-09 (Druker) 08/05/05-05/31/11 effort: 5%
NIH/NCI \$736,404 (total direct)
OHSU Cancer Institute
Role: Program Leader

(Beer) 11/30/06-9/30/10 effort: <5%
Cell Therapeutics Inc. \$182,925 (approx. direct)
A Phase II Study of Paclitaxel Poliglumex (PPX) in combination with Transdermal Estradiol for the Treatment of Androgen Independent Prostate Cancer after Docetaxel Chemotherapy

(Beer) 7/14/08-7/31/11 effort: <5%
ImClone \$165,838
Phase II Multicenter, Randomized Study of Erbitux® (Cetuximab) plus Mitoxantrone and Prednisone in Metastatic Androgen Independent Prostate Cancer (AIPC) following Docetaxel-Based Chemotherapy

(Beer, site PI) 10/6/08-10/31/11 effort: <5%
Duke University \$80,000
Prospective Validation of a Microarray-Based Docetaxel Response Signature in Metastatic, Hormone-Refractory Prostate Cancer

SWOG-99045 (Beer) 1/1/99 – 12/31/13 effort: <4%

Southwest Oncology Group	~\$224,855 (total direct)	
Urologic Cancer Outreach Program (UCOP) of the Southwest Oncology Group, OHSU		
(Beer, site PI)	9/8/06-6/30/13	effort: <5%
Novartis Pharmaceuticals	\$39,573	
A Randomized Multicenter Phase II Trial of Patupilone (EPO906) plus Prednisone versus Docetaxel (Taxotere) plus Prednisone in Patients with Metastatic Hormone Refractory Prostate Cancer		
PC081633 (Beer)	4/1/09 – 3/31/14	effort: 25%
DoD-CDMRP	\$999,960 (total direct)	
Clinical Consortium Award- Clinical Research Site		
(Beer, national PI)	3/9/10-2/28/14	effort: <5%
OncoGenex Technologies, Inc.	\$115,977	
A Randomized, Placebo-controlled, Double-blind, Phase III Study Evaluating Clinical Benefit of Adding Custirsen to Docetaxel Retreatment/Prednisone as an Option for Second-line Therapy in Men with Castrate Resistant Prostate Cancer		
(Beer, site PI)	11/30/09-9/30/14	effort: <5%
Medivation, Inc.	\$134,572	
Multinational Phase III Randomized, Double-blind, Placebo-controlled Efficacy & Safety Study of Oral MDV3100 in Patients with Progressive Castration-resistant Prostate Cancer Previously Treated with Docetaxel-based Chemotherapy		
MDX010-21 (Beer, site PI)	3/17/05-2/28/15	effort: <5%
Bristol-Myers Squibb	\$351,473	
A phase I/II open label, dose escalation study of MDX-010 administered every 3 weeks for 4 doses in patients with metastatic hormone refractory prostate cancer (part of Department of Defense Consortium)		
Internal (Beer)	6/4/13-4/14/15	effort: <5%
OHSU	\$14,562	
An Open-label, Phase I, randomized pharmacokinetic study of dietary effects on abiraterone acetate drug levels in patients w/ metastatic castration-resistant prostate cancer (DEAL)		
(Beer, site PI)	3/1/07-6/30/15	effort: <5%
U. of California, San Francisco	\$116,083	
A randomized phase II study of intermittent chemotherapy or intermittent chemotherapy with maintenance GM-CSF in patients with previously untreated metastatic hormone refractory prostate cancer (part of Department of Defense Consortium)		
(Beer, site PI)	8/6/12-8/31/15	effort: <5%
Astellas Pharma	\$23,727	
Multicenter, Single-arm, Open Label Treatment Protocol to Provide Expanded Access to MDV3100 & Monitor Its Safety in Patients w/ Progressive Castration-Resistant Prostate Cancer Previously Treated w/Docetaxel-Based Chemotherapy		
W81XWH-13-1-0314 (Liu)	9/30/13-9/29/15	effort: 0%
US Army Medical Rsch Acquisition Activity \$111,516 (total costs)		
Ketone body metabolic enzyme OXCT1 regulates prostate cancer chemoresistance		
(Beer, national PI)	12/1/10-12/31/15	effort: <5%
Bristol-Myers Squibb	\$197,029	

Randomized, double-blind, phase 3 trial to compare efficacy of Ipilimumab vs placebo in asymptomatic or minimally symptomatic patients w/metastatic chemotherapy-naïve castration resistant prostate cancer

(Beer, site PI) 3/1/12-2/29/16 effort: <5%
Dendreon Corporation \$60,378
An Open-label Multicenter Study of Sipuleucel-T in Teastatic Castrate Resistant Prostate Cancer Patients Previously TGreated with Sipuleucel-T on Dendreon Study P-11

(Beer, site PI) 7/5/07-5/31/16 effort: <5%
Medivation Inc. \$569,771
A Phase 1, Open-Label, Dose-Escalation Safety and Pharmacokinetic Study of MDV3100 in Patients with Castration-Resistant Prostate Cancer (part of Department of Defense Consortium)

P11 (Beer, site PI) 9/27/01-8/31/16 effort: <5%
Dendreon Corporation \$551,795
Autologous PAP-loaded dendritic cell vaccine (APC8015, Provenge) in patients with non-metastatic prostate cancer who experience PSA elevation following radical prostatectomy: a randomized, controlled, double-blind trial

LCCC1231 (Beer) 11/06/13 – 9/29/16 effort: 1%
U. of N. Carolina at Chapel Hill/DoD \$105,508 (total direct)
Development of Pain End Point Models for Use in Prostate Cancer Clinical Trials and Drug Approval
Role: Site Principal Investigator

(Beer, national PI) 8/1/12-9/30/16 effort: <5%
OncoGenex Technologies Inc. \$193,511
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men with Metastatic Castrate Resistant Prostate Cancer

7465sc (Beer, Principal) 1/1/13-12/31/16 effort: 10%
U. of California, San Francisco/AACR \$1,102,541 (total direct)
Targeting Adaptive Pathways in Metastatic Castration Resistant Prostate Cancer

2010-007 (Beer) 4/1/10-5/31/17 effort: 10%
Kuni Foundation \$125,000
Phase II Study of MAOA Inhibitor plus Docetaxel in Patients Currently Receiving and Progressing on Docetaxel Therapy

P30 CA069533 (Druker) 07/20/11 – 06/30/17 effort: 5%
NIH/NCI \$737,232 (total direct)
OHSU Knight Cancer Institute, Cancer Center Support Grant
Role: Deputy Director

W81XWH-14-2-0156 (Beer) 9/30/14-9/29/17 effort: 15%
US Army Medical Rsch Acquisition Activity \$599,224 (total direct)
Clinical Consortium Award - Clinical Research Site

(Beer, site PI) 8/25/09-4/30/18 effort: <5%
Cougar Biotechnology, Inc. \$296,664
Phase III, Randomized, Double-blind, Placebo-controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or mildly Symptomatic Patients with Metastatic Castration-resistant Prostate Cancer

P50 CA097186-11A1 (Nelson) Fred Hutchinson/SPORE/NIH Targeting LSD1 in Prostate Cancer	9/17/13-8/31/18 \$702,779 (direct costs)	effort: 10%
(Beer, national PI) Medivation, Inc. PREVAIL: A Multinational Phase 2, Randomized, DB, Placebo-Controlled Efficacy & Safety Study of Oral MDV3100 in Chemotherapy-Naive Patients w/Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy	12/6/10-10/31/19 \$498,230	effort: <5%
(Beer, site PI) Boehringer Ingelheim Pharma A Phase Ib/II, Multicentre, Open Label, Randomised Study of BI 836845 in Combination with Enzalutamide, vs. Enzalutamide Alone, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Following Disease Progression on Docetaxel.	6/24/16-4/30/20 \$124,453	effort: <5%
10100sc (Beer, Principal) U. of California, San Francisco/AACR The PROMOTE Program: Precision Oncology and Molecular Targeting in Advanced Prostate Cancer Advancing the Promise of the PCF/SU2C/AACR West Coast Prostate Cancer Dream Team	10/01/16-07/04/20 \$1,500,000	effort: <5%
(Beer, site PI) Sotio A randomized, double blind, multicenter, parallel-group, phase III study to evaluate efficacy and safety of DCVAC/Pca versus placebo in men with metastatic castration resistant prostate cancer eligible for 1 st line chemotherapy	11/14/14-10/31/20 \$428,432	effort: <5%

Publications/Creative Work:Peer-reviewed (Original Articles)

- 1) McWilliams JE, Evans AJ, Beer TM, Anderson PE, Cohen JI, Everts EC, Henner WD. Genetic Polymorphisms in Head and Neck Cancer Risk. *Head Neck*. 2000 Sep; 22(6): 609-17.
- 2) Beer TM, Munar M, Henner WD. A Phase I Trial of Pulse Calcitriol in Patients with Refractory Malignancies: Pulse Dosing Permits Substantial Dose Escalation. *Cancer*. 2001 Jun 15; 91(12): 2431-9.
- 3) Beer TM, Pierce WC, Lowe BA, and Henner WD. Phase II Study of Weekly Docetaxel in Symptomatic Androgen-Independent Prostate Cancer. *Annals of Oncology*. 2001 Sep; 12(9): 1273-9.
- 4) Garzotto M and Beer TM. Syndrome of Inappropriate Anti-Diuretic Hormone Secretion: A Rare Complication of Prostate Cancer. *Journal of Urology*. 2001 Oct; 166(4): 1386.
- 5) Henner WD, Evans AJ, Hough KM, E Harris, and Lowe BA, Beer TM, Association of Codon 72 Polymorphism of p53 with Lower Prostate Cancer Risk. *The Prostate*. 2001 Dec; 1;49(4): 263-6.
- 6) Beer TM, Evans AJ, Hough KM, Lowe BA, McWilliams JE, and Henner WD. Polymorphisms of *GSTP1* and Related Genes and Prostate Cancer Risk. *Prostate Cancer and Prostatic Diseases*, 2002; 5(1): 22-7.
- 7) Hayes-Lattin BM, Kovach, PA, Henner WD, and Beer TM, Successful Treatment of Metastatic Hormone-Refractory Prostate Cancer with Malignant Pericardial Tamponade using Docetaxel. *Urology*. 2002 Jan; 59(1): 137.
- 8) Madison DL, Bliziotis M, and Beer TM. Acute Estramustine-Induced Hypocalcemia Unmasking Severe Vitamin D Deficiency. *American Journal of Medicine*. 2002 Jun; 1;112(8): 680-1.
- 9) Lavelle M, Schuff KG, Keller FS, Binkert CA, O'Hara M, Fairfax CA, and Beer TM.

- Unilateral autonomous testicular testosterone production mimicking androgen-independent prostate cancer. *Journal of Urology*. 2002 Sep: 168(3): 1098-9.
- 10) Beer TM, Morris CD, Montalto MA, McMurry M, Nyberg SE, and Henner WD. Simplified Assessment of Compliance with Dietary Calcium Restriction in Patients Treated with High Dose Calcitriol for Advanced Cancer. *Topics in Clinical Nutrition*. 2003: 18(1): 61-70.
 - 11) Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, and Henner WD. Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer. *Journal of Clinical Oncology*. 2003 Jan: 1;21(1): 123-8.
 - 12) Beer TM, Lemmon D, Lowe BA, Henner WD. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. *Cancer*. 2003 Mar: 1;97(5): 1217-24.
 - 13) Rago RP, Einstein Jr AB, Lush III RM, Beer TM, Ko Y, Henner WD, Bublely G, Shepard RC, Chatta G, Unger P, Merica EA, Garg V, Harding MW, and Dalton WS. Safety and efficacy of the MDR inhibitor Incel™ (Bircodar, VX-710) in combination with mitoxantrone and prednisone in hormone refractory prostate cancer. *Cancer Chemotherapy & Pharmacology*. 2003 Apr: 51(4): 297-305.
 - 14) Beer TM, Garzotto M, Eilers, KM, Lemmon D. Phase II Study of Abarelix-Depot in Androgen-Independent Prostate Cancer Progressing on GnRH Agonist Therapy. *Journal of Urology*. 2003 May: 169(5): 1738-41.
 - 15) Beer TM. Preventing Prostate Cancer. Finasteride Shrinks Enlarged Prostates and May Prevent Some Cases of Prostate Cancer. But it's No Panacea. *Health News* 2003 Aug; 9(8):1-2
 - 16) Hoffelt SC, Marshall LM, Garzotto M, Hung A, Holland J, and Beer TM. A Comparison of CT scan to Transrectal Ultrasound-Measured Prostate Volume in Untreated Prostate Cancer. *International Journal of Radiation Oncology Biology Physics*. 2003 Sep: 1;57(1): 29-32.
 - 17) Beer TM. Development of Weekly High-Dose Calcitriol Based Therapy for Prostate Cancer. *Urol Oncol*. Sep-Oct 2003; 21(5):399-405
 - 18) Beer TM, Garzotto M, Henner WD, Eilers KM. Intermittent Chemotherapy in Metastatic Androgen-Independent Prostate Cancer. *Br J Cancer*. 2003 Sep: 15;89(6): 968-70. (PMCID: PMC2376967)
 - 19) Garzotto M, Hudson RG, Peters L, Hsieh YC, Barrera E, Mori M, Beer TM, Klein T. Predictive Modeling for the Presence of Prostate Cancer Using Clinical, Laboratory and Ultrasound Parameters with PSA \leq 10 ng/ml. *Cancer*. 2003 Oct: 1;98(7): 1417-22.
 - 20) Beer TM, Berry W, Wersinger EM, and Bland LB. Weekly docetaxel in the elderly: a comparison of efficacy and toxicity in prostate cancer patients age 70 and older and younger than 70. *Clinical Prostate Cancer*. 2003 Dec: 2(3): 167-72.
 - 21) Panagiotou I, Beer TM, Hsieh YC, Mori M, Peters L, Klein T, and Garzotto M. Predictors of Delayed Therapy After Expectant Management for Localized Prostate Cancer in the Era of Prostate-Specific Antigen. *Oncology*. 2004: 67(3-4): 194-202.
 - 22) Evans AJ, Henner WD, Eilers KM, Montalto MA, Wersinger EM, Andersen PE, Cohen JI, MD, Everts EC, McWilliams JE, Beer TM. Polymorphisms of GSTT1 and Related Genes in Head and Neck Cancer Risk. *Head and Neck*. 2004 Jan: 26(1): 63-70.
 - 23) Beer TM, Garzotto M, Lowe BA, Ellis WJ, Montalto MA, Lange PH, and Higano CS. Phase I Study of Weekly Mitoxantrone and Docetaxel Prior to Prostatectomy in Patients with High Risk Localized Prostate Cancer. *Clinical Cancer Research*. 2004 Feb: 15;10(4): 1306-11.
 - 24) Beer TM. Experimental Use of GnRH Antagonists as Second-Line Hormonal Therapy. *Rev Urol*. 2004; 6 Suppl 7 (Suppl 7):S33-8
 - 25) Beer TM, Garzotto M, Eilers KM, and Henner WD. Quality of life during treatment with Calcitriol Enhanced Docetaxel in Metastatic Androgen-Independent Prostate Cancer. *Cancer*. 2004 Feb: 15;100(4): 758-63.
 - 26) Beer TM, Garzotto M, Eilers KM, Lemmon D, EM Wersinger. Targeting FSH in Androgen-Independent Prostate Cancer: Abarelix for Prostate Cancer Progressing after

- Orchiectomy. *Urology*. 2004 Feb; 63(2): 342-7.
- 27) Beer TM, Garzotto M, Lowe BA, Ellis WJ, Montalto MA, Lange PH, Higano CS. Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. *Clin Cancer Res*. 2004 Feb; 10(4):1306-11
 - 28) El-Geneidi M, Garzotto M, Panagiotou I, Hsieh YC, Mori M, Peters L, Klein T, and Beer TM. Delayed Therapy with Curative Intent in a Contemporary Prostate Cancer Watchful-Waiting Cohort. *BJU International*. 2004 Mar; 93(4): 510-5.
 - 29) Beer TM, Myrthue A. Calcitriol in Cancer Treatment: From the Lab to the Clinic. *Mol Cancer Ther*. 2004 Mar; 3(3):373-81
 - 30) Beer TM, Bubalo JS. Prevention and Management of Prostate Cancer Chemotherapy Complications. *Urol Clin North Am*. 2004 May; 31(2):367-78
 - 31) Tiffany NM, Wersinger EM, Garzotto M, and Beer TM. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. *Urology*. 2004 May; 63(5): 934-9.
 - 32) Fromme EK, Eilers KM, Mori M, Hsieh YC, and Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison to patient-reported symptoms from the QLQ-C30. *Journal of Clinical Oncology*. 2004 Sep; 22(17): 3485-90.
 - 33) Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Multiple Cycles of Intermittent Chemotherapy in Metastatic Androgen-Independent Prostate Cancer. *Br J Cancer*. 2004 Oct; 91(8): 1425-7. (PMCID: PMC2409932)
 - 34) Beer TM, Garzotto M, and Katovic NM. High-Dose Calcitriol and Carboplatin in Metastatic Androgen-Independent Prostate Cancer. *American Journal of Clinical Oncology*. 2004 Oct; 27(5): 535-41.
 - 35) Beer TM, Myrthue A, Garzotto M, O'Hara MF, Chin R, Lowe BA, Montalto MA, Corless CL, and Henner WD. Randomized Study of High-Dose Pulse Calcitriol or Placebo Prior to Radical Prostatectomy. *Cancer Epidemiology Biomarkers and Prevention*. 2004 Dec; 13(12): 2225-32.
 - 36) Beer TM, Tangen C, Bland LB, Thompson IM, and Crawford ED. Prognostic value of anemia in untreated metastatic prostate cancer: a multivariate analysis of SWOG 8894. *Journal of Urology*. 2004 Dec; 172(6 Pt 1): 2213-7. Erratum in: *J Urol*. 2005 Sep; 174(3): 1156.
 - 37) Vetto JT, Beer TM, Fidda N, Ham B, Jimenez-Lee R, and Schmidt W. Fine-needle aspiration diagnosis of plasmacytoma presenting as breast masses in a patient on estrogen therapy for prostate cancer. *Diagnostic Cytopathology*. 2004 Dec; 31(6): 417-9.
 - 38) Beer TM, Myrthue A, Eilers KM. Rationale for the Development and Current Status of Calcitriol in Androgen-Independent Prostate Cancer. *World J Urol*. 2005 Feb; 23(1):28-32.
 - 39) Bland LB, Garzotto M, DeLoughery TD, Ryan CW, Schuff KG, Wersinger EM, Lemmon D, and Beer TM. Phase II Study of Transdermal Estradiol in Androgen-Independent Prostate Carcinoma. *Cancer*. 2005 Feb; 15;103(4): 717-23.
 - 40) Strother JM, Beer TM, Dreicer R. Novel cytotoxic and biological agents for prostate cancer: where will the money be in 2005? *Eur J Cancer*. 2005 Apr; 41(6):954-64
 - 41) Wagner M, Garzotto M, Lemmon D, Eilers KM, and Beer TM. Prostate Specific Antigen Decline After Gonadotropin-releasing Hormone Antagonist Withdrawal in Androgen-Independent Prostate Cancer. *Urology*. 2005 Apr; 65(4): 799.
 - 42) Devi GR, Beer TM, Corless C, Arora V, Reddy MT, Weller D, and Iversen PL. *In vivo* Bioavailability and Pharmacokinetics of a *c-myc* Phosphorodiamidate Morpholino Oligomer, AVI4126, in Solid Tumors, *Clinical Cancer Research*. 2005 May 15; 11(10): 3930-8.
 - 43) Wagner M, Loos J, Weksler N, Gantner M, Corless CL, Barry JM, Beer TM and Garzotto M. Resistance of Prostate Cancer Cell Lines to COX-2 Inhibitor Treatment. *Biochem Biophys Res Commun*. 2005 Jul; 332(3): 800-7.
 - 44) Garzotto M, Beer TM, Hudson RG, Peters L, Hsieh YC, Barrera E, Klein T, Mori M. Improved Detection of Prostate Cancer using Classification and Regression Tree Analysis. *J Clin Oncol*. 2005 Jul; 23(19): 4322-9.

- 45) Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A. Statins and prostate cancer risk: a case-control study, *American Journal of Epidemiology*. 2005 Aug; 15;162(4): 318-25.
- 46) Stephenson RA, Mori M, Hsieh Y-C, Beer TM, and Potosky AL. Treatment of Erectile Dysfunction Following Therapy for Clinically Localized Prostate Cancer: Patient Reported Use and Outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study. *Journal of Urology*. 2005 Aug; 174(2): 646-50; discussion 650.
- 47) Janoff DM, Peterson C, Mongoue-Tchokote S, Peters L, Beer TM, Wersinger EM, Mori M and Garzotto M. Clinical Outcomes of Androgen Deprivation as the Sole Therapy for Localized and Locally Advanced Prostate Cancer, *BJU Int*. 2005 Sep: 96(4): 503-7.
- 48) Beer TM. ASCENT: the Androgen-Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere, *BJU International*. 2005 Sep: 96(4): 508-13.
- 49) Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, and Beer TM. High Dose Pulse Calcitriol, Docetaxel, and Estramustine for Androgen-Independent Prostate Cancer (AIPC): A Phase I/II Study. *Journal of Urology*. 2005 Sep: 174(3): 888-92.
- 50) Beer TM, Javle M, Lam GN, Henner WD, and Trump DL. Pharmacokinetics and Tolerability of a Single Dose of DN-101, a New Formulation of Calcitriol, in Patients with Cancer, *Clinical Cancer Research*. 2005 Nov: 1;11(21): 7794-9.
- 51) Garzotto M, Park Y, Mongoue-Tchokote S, Bledsoe J, Peters L, Blank BH, Austin D, Beer TM, Mori M. Recursive Partitioning for Risk Stratification in Men Undergoing Repeat Prostate Biopsies, *Cancer*. 2005 Nov: 1;104(9): 1911-7.
- 52) Bussiere JR, Beer TM, Neiss MB, and Janowsky JS. Androgen Deprivation Impairs Memory in Older Men, *Behavioral Neuroscience*. 2005 Dec: 119(6): 1429-37.
- 53) Garzotto M, Myrthue A, Higano CS, Beer TM. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. *Urol Oncol*. 2006 May-Jun: 24(3): 254-9.
- 54) Ganzini L, Beer TM, Brouns M, Mori M, Hsieh Y-C. Interest in Physician-Assisted Suicide Among Oregon Cancer Patients, *The Journal of Clinical Ethics*. 2006 Spring: 17(1): 27-38.
- 55) Beer TM, Bland LB, Bussiere JR, Neiss M, Wersinger EM, Garzotto M, Ryan CW, and Janowsky JS. Testosterone loss and estradiol administration modify memory in men, *Journal of Urology*. 2006 Jan: 175(1): 130-5.
- 56) Purnell JQ, Bland LB, Garzotto M, Lemmon D, Wersinger EM, Ryan CW, Brunzell JD, and Beer TM. Effects of transdermal estrogen therapy levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer. *Journal of Lipid Research*. 2006 Feb: 47(2): 349-55.
- 57) Spurgeon S, Hsieh YC, Rivadinera A, Beer TM, Mori M, and Garzotto M. Classification and Regression Tree Analysis for the Prediction of Aggressive Prostate Cancer on Biopsy, *Journal of Urology*. 2006 Mar: 175(3 Pt 1): 918-22.
- 58) Beer TM, Garzotto M, Park B, Mori M, Myrthue A, Janeba N, Sauer D, Eilers K. Effect of calcitriol on Prostate-Specific Antigen *in vitro* and in humans. *Clinical Cancer Research*. 2006 May: 1;12(9): 2812-6.
- 59) Beer TM, Tangen CM, Nichols CR, Margolin KA, Dreicer R, Stephenson WT, Quinn DI, Raghavan D, Crawford ED. Southwest Oncology Group Phase II Study of Arsenic Trioxide in Patients with Refractory Germ Cell Malignancies, *Cancer*. 2006 Jun: 15;106(12): 2624-9.
- 60) Adams G, Mitchell A, Ravichandran R, Beer TM and Garzotto M. Metastatic adenocarcinoma of prostate in a healing sternotomy site, *Urology*. 2006 Jul: 68(1): 204.e13-5.
- 61) Beer TM, Myrthue A. Calcitriol in the treatment of prostate cancer. *Anticancer Res*. Jul-Aug 2006; 26(4A):2647-51
- 62) True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, Beer TM, Gelmann E, Datta M, Mostaghel E, Knudsen B, Lange P, Vessella R, Lin D, Hood L, Nelson PS. A Molecular Correlate to the Gleason Grading System for Prostate Adenocarcinoma, *Proc Natl Acad Sci U S A*. 2006 Jul: 18;103(29): 10991-6. (PMCID: PMC1544162)

- 63) Beer TM, Tangen CM, Bland LB, Hussain M, Goldman BH, Deloughery TG, Crawford ED. The Prognostic Value of Hemoglobin Change After Initiating Androgen-Deprivation Therapy for Newly Diagnosed Metastatic Prostate Cancer: A Multivariate Analysis Of SWOG 8894. *Cancer*. 2006 Aug; 1;107(3): 489-96.
- 64) Ganzini L, Beer TM, Brouns MC Views on Physician-Assisted Suicide Among Family Members of Oregon Cancer Patients. *Journal of Pain and Symptom Management*. 2006 Sep; 32(3): 230-6.
- 65) Ryan CW, Huo D, Demers LM, Beer TM, Lacerna L. Zoledronic Acid Initiated During the First Year of Androgen Deprivation Therapy Increases Bone Mineral Density in Prostate Cancer Patients. *Journal of Urology*. 2006 Sep; 176(3): 972-8; discussion 978.
- 66) Beer TM, Ryan C, Bhat G, Garnick M. Dose-escalated abarelix in Androgen-Independent Prostate Cancer: a Phase I Study. *Anti-Cancer Drugs*. 2006 Oct; 17(9): 1075-9.
- 67) Taylor BC, Wilt TJ, Fink HA, Lambert LC, Marshall LM, Hoffman AR, Beer TM, Bauer DC, Zmuda JM, Orwoll ES. Prevalence, Severity and Health Correlates of Lower Urinary Tract Symptoms among Older Men: The MrOS Study. *Urology*. 2006 Oct; 68(4): 804-9.
- 68) Lycette JL, Luoh SW, Beer TM, and Deloughery T. Acute Bilateral Pulmonary Emboli Occurring While on Adjuvant Aromatase Inhibitor Therapy with Anastrozole: Case Report and Review of the Literature, *Breast Cancer Research and Treatment*. 2006 Oct; 99(3): 249-55.
- 69) Sternberg CS, Krainer M, Oh WK, Bracada S, Bellmunt J, Ozen H, Zlotta A, Beer TM, Oudard S, Rauchenwald M, Skoneczna I, Borner MM, and Fitzpatrick JM. The medical management of prostate cancer: a multidisciplinary team approach, *BJU International*. 2007 Jan; 99(1):22-7.
- 70) Beer TM, Venner PM, Ryan CW, Petrylak DP, Chatta GS, Ruether JD, Chi KN, Curd JG, Arroyo A, Clow FW. High dose calcitriol may reduce thrombosis in cancer patients. *British Journal of Hematology*. 2006 Nov; 135(3): 392-4.
- 71) Lycette JL, Bland LB, Garzotto M, Beer TM. Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities? *Clin Genitourin Cancer*. 2006 Dec; 5(3):198-205
- 72) Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario V, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. *J Clin Oncol*. 2007 Feb; 20;25(6): 669-74.
- 73) Beer TM, Javle M, Ryan CW, Wong A, Lam GN, Henner WD, and Trump DL. Phase I study of Weekly DN-101, a New Formulation of Calcitriol, in Patients with Cancer. *Cancer Chemotherapy and Pharmacology*. 2007 Apr; 59(5): 581-7.
- 74) Graff JN, Mori M, Li H, Garzotto M, Penson D, Potosky A, and Beer TM. Predictors of Overall and Cancer-Free Survival in Patients with Localized Prostate Cancer Treated Initially with Androgen Suppressive Therapy: Results from the Prostate Cancer Outcomes Study. *Journal of Urology*. 2007 Apr; 177(4): 1307-12.
- 75) Spurgeon SEF, Mongoue-Tchokote S, Collins L, Priest R, Hsieh Y-C, Peters LM, Beer TM, Mori M, Garzotto M Assessment of Prostate-Specific Antigen Doubling Time in Prediction of Prostate Cancer on Needle Biopsy, *Urology*. 2007 May; 69(5): 931-5.
- 76) Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E, Sugar EA, Eisenberger MA. Adjuvant Weekly Docetaxel for Patients with High Risk Prostate Cancer after Radical Prostatectomy: a Multi-Institutional Pilot Study, *Journal of Urology*. 2007 May; 177(5): 1777-81.
- 77) Beer TM, Bergenstock M, Birt K, and Higano CS. Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancer. *Clinical GU Cancer*. 2007 Jun; 5(5): 329-33.

- 78) Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT. Lifestyle Factors and Duration of Androgen Deprivation Affect Bone Mineral Density of Patients with Prostate Cancer During First Year of Therapy. *Urology*. 2007 Jul; 70(1): 122-6.
- 79) Kantoff PW, Beer TM, D'Amico AV, Dipaola RS, Eisenberger MA, Hussain MH, Kelly WK, Mathew P, Morris MJ, Ryan CJ, Sandler HM, Thompson IM, Carroll PR. Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference. *J Urol*. 2007 Sep; 178(3 Pt 2):S5-8
- 80) Ryan CJ, Beer TM. Prostate specific antigen only androgen independent prostate cancer: natural history, challenges in management and clinical trial design. *J Urol*. 2007 Sep; 178(3 Pt 2):S25-9
- 81) Ryan CW, Goldman BH, Lara PN Jr, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan CX, Drabkin HA, Crawford ED. Sorafenib with Interferon Alfa-2b as First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group. *J Clin Oncol*. 2007 Aug; 1;25(22): 3296-301.
- 82) Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M, Beer TM. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer. *Cancer*. 2007 Sep; 1: 110(5): 996-1002.
- 83) Lagunova Z, Porojnicu A, Dahlback A, Berg JP, Beer TM and Moan J. Prostate Cancer Survival Is Dependent on Season of Diagnosis. *Prostate*. 2007 Sep; 1;67(12): 1362-70.
- 84) Huang CY, Beer TM, Higano CS, True LD, Vessella R, Lange PH, Garzotto M, Nelson PS. Molecular Alterations in Prostate Carcinomas that Associate with *In Vivo* Exposure to Chemotherapy: Identification of a Cytoprotective Mechanism Involving Growth Differentiation Factor 15. *Clin Cancer Res*. 2007 Oct; 1;13(19): 5825-33.
- 85) Beer TM, Higano CS, Saleh M, Dreicer R, Hudes G, Picus J, Rarick M, Fehrenbacher L, Hannah AL. Phase II Study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. *Invest New Drugs*. 2007 Dec; 25(6): 565-70.
- 86) Basch EM, Somerfield MR, Beer TM, Carducci MA, Higano CS, Hussain MH, Scher HI. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. *J Clin Oncol*. 2007 Nov; 25(33):5513-8
- 87) Beer TM, Ryan CW. The hazards of intermediate endpoints. *Cancer*. 2007 Nov; 110(9):1877-9
- 88) Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Chi KN, Young J, Henner WD. Intermittent Chemotherapy in patients with Metastatic Androgen-Independent Prostate Cancer: Results from ASCENT, a Double-blinded, Randomized Comparison of High-dose Calcitriol Plus Docetaxel with Placebo Plus Docetaxel. *Cancer*. 2008 Jan; 112(2): 326-30.
- 89) Ross RW, Beer TM, Jacobus S, Bublely GJ, Taplin ME, Ryan CW, Huang J, and Oh WK. A Phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. *Cancer*. 2008 Feb; 112(3): 521-26.
- 90) Beer TM, Goldman B, Nichols CR, Petrylak DP, Agarwal M, Ryan CW, Crawford ED, Southwest Oncology Group Phase II Study of Irinotecan in Patients with Advanced Transitional Cell Carcinoma of the Urothelium. *Clin GU Cancer*. 2008 Mar; 6(1): 36-9.
- 91) Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bublely GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. *J Clin Oncol*. 2008 Mar; 26(7): 1148-59. (PMCID: PMC4010133)
- 92) Ciszewski A, Shackleton D, Beer TM. Long-term remission of metastatic small cell carcinoma of the prostate. *Urology*. 2008 Mar; 71(3), 546.
- 93) Myrthue A, Rademacher BL, Pittsenbarger J, Kutyba-Brooks B, Gantner M, Qian DZ, Beer TM. The Iroquois Homeobox Gene 5 is regulated by 1,25-Dihydroxyvitamin D3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate

- cancer cells. *Clin Cancer Res*. 2008 Jun; 14(11): 3562-70.
- 94) Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, Henner WD, Ryan CW, Venner P, Ruether JD, Chi KN. C-Reactive Protein as a Prognostic Marker for Men with Androgen-Independent Prostate Cancer (AIPC): Results from the ASCENT Trial. *Cancer*. 2008 Jun; 112(11): 2377-83.
- 95) Beer TM, Goldman B, Synold TW, Ryan CW, Vasist LS, Van Veldhuizen PJ Jr, Dakhil SR, Lara PN Jr, Drelichman A, Hussain MH, Crawford ED. Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer (AIPC) previously treated with taxanes. *Clin GU Ca*. 2008 Sept; 6(2): 103-9.
- 96) Schnadig ID, Fromme EK, Loprinzi CL, Sloan JA, Mori M, Li H, Beer TM. Patient-Physician Disagreement Regarding Performance Status Is Associated with Worse Survivorship in Patients with Advanced Cancer. *Cancer*. 2008 Oct; 113(8): 2205-14. (PMCID: PMC3580230)
- 97) Chan JS, Beer TM, Quinn DI, Pinski JK, Garzotto M, Sokoloff M, Dehaze DR, Ryan CW. A Phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. *BJU Int*. 2008 Dec; 102(11): 1601-6.
- 98) Schnadig ID, Beer TM. Optimal timing of chemotherapy in androgen independent prostate cancer. *Urol Oncol*. Jan-Feb 2009; 27(1):97-100
- 99) Farhat GN, Taioli E, Cauley JA, Zmuda JM, Orwoll E, Bauer DC, Wilt TJ, Hoffman AR, Beer TM, Shikany JM, Daniels N, Chan J, Fink HA, Barrett-Connor E, Parsons JK, Bunker CH. The Association of Bone Mineral Density with Prostate Cancer Risk in the Osteoporotic Fractures in Men (MrOS) Study. *Ca Epidemiol Biomark Prev*. 2009 Jan; 18(1): 148-54. (PMCID: PMC2651680)
- 100) Qian DZ, Huang CY, O'Brien CA, Coleman IM, Garzotto M, True LD, Higano CS, Vessella R, Lange PH, Nelson PS, Beer TM. Prostate Cancer-Associated Gene Expression Alterations Determined from Needle Biopsies. *Clin Cancer Res*. 2009 May; 15(9): 3135-42. (PMCID: PMC2929837)
- 101) Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. *Science*. 2009 May; 324(5928): 787-90. (PMCID: PMC2981508)
- 102) Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI. Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. *Clin Genitourin Cancer*. 2009 Jan; 7(1):51-7. (PMCID: PMC3394090).
- 103) Rosenberg JE, Ryan CJ, Weinberg VK, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Pagliaro LC, Harzstark AL, Sharib J, Small EJ. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the Department of Defense Prostate Cancer Clinical Trials Consortium. *J Clin Oncol*. 2009 Jun; 27(17): 2772-8. (PMCID: PMC2698016)
- 104) Blanke CD, Beer TM, Todd K, Mori M, Stone M, Lopez C. Phase II Study of Calcitriol-Enhanced Docetaxel in Patients with Previously Untreated Metastatic or Locally Advanced Pancreatic Cancer. *Invest New Drugs*. 2009 Aug; 27(4): 374-8.
- 105) Taplin ME, Regan MM, Ko YJ, Bublely GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. *Clin Cancer Res*. 2009 Nov; 15(22): 7099-105. (PMCID: PMC3644858)
- 106) Qian DZ, Rademacher BLS, Pittsenbarger J, Huang CY, Myrthue A, Higano CS, Garzotto M, Nelson PS, Beer TM. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. *Prostate*. 2010 Mar; 70(4): 433-42.

- (PMCID: PMC2931415)
- 107) Beer TM, Ryan C, Alumkal J, Ryan CW, Sun J, Eilers KM. A Phase II study of Paclitaxel Poliglumex (PPX) in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. *Anti-Cancer Drugs*. 2010 Apr; 21(4): 433-8.
 - 108) Geng H, Rademacher BL, Pittsenbarger J, Huang CY, Harvey CT, Lafortune MC, Myrthue A, Garzotto M, Nelson PS, Beer TM, Qian DZ. ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. *Cancer Res*. 2010 Apr; 70(8): 3239-48. (PMCID: PMC2999007)
 - 109) Garzotto M, Higano CS, O'Brien C, Rademacher BLS, Janeba N, Fazli L, Lange PH, Lieberman S, Beer TM. Phase I/II Study of Preoperative Docetaxel and Mitoxantrone for High-risk Prostate Cancer. *Cancer*. 2010 Apr; 116(7): 1699-708. (PMCID: PMC2846994)
 - 110) O'Brien C, True LD, Higano CS, Rademacher BLS, Garzotto M, Beer TM. Histological changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer. *Am J Clin Pathol*. 2010 Apr; 133(4): 654-61. (PMCID: PMC3047497)
 - 111) Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efsthathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL. Antitumour Activity of MDV3100 in Castration-Resistant Prostate Cancer: a Phase I-2 Study. *Lancet*. 2010 Apr; 375(9724): 1437-46. (PMCID: PMC2948179)
 - 112) Barnett CM, Nielson CM, Shannon J, Chan JM, Shikany JM, Bauer DC, Hoffman AR, Barrett-Connor E, Orwoll E, Beer TM. Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. *Cancer Causes Control*. 2010 Aug; 21(8): 1297-303. (PMCID: PMC2903686)
 - 113) Zhu ML, Horbinski C, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer. *Cancer Res*. 2010 Oct; 70(20): 7992-8002. (PMCID: PMC2978028)
 - 114) Beer TM, Benavides M, Emmons SL, Hayes M, Liu G, Garzotto M, Donovan D, Katovic N, Reeder C, Eilers K. Acupuncture for hot flashes in patients with prostate cancer. *Urology*. 2010 Nov; 76(5): 1182-8. (PMCID: PMC2928879)
 - 115) Barnett CM, Flamiatos JF, Beer TM. Prolonged response to early docetaxel in a patient with biochemical relapse after primary therapy for prostate cancer and incomplete response to androgen suppression therapy. *Anticancer Res*. 2011 Mar; 31(3): 973-4.
 - 116) Ryan CW, Vuky J, Chan JS, Chen Z, Beer TM, Nauman D. A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma. *Invest New Drugs*. 2011 Apr; 29(2): 374-9.
 - 117) Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, Schraml P, Moch H, Cassidy AM, Brewer D, Al-Lazikani B, Workman P, De-Bono J, Kaye SB, Larkin J, Gore ME, Sawyers CL, Nelson P, Beer TM, Geng H, Gao L, Qian DZ, Alumkal JJ, Thomas G, Thomas GV. A HIF-Regulated VHL-PTP1B-Src Signaling Axis Identifies a Therapeutic Target in Renal Cell Carcinoma. *Sci Transl Med*. 2011 Jun; 3(85): 85ra47. (PMCID: PMC3303496)
 - 118) Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the department of defense prostate cancer clinical trials consortium. *Cancer*. 2011 Jun; 117(11): 2419-25.
 - 119) Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF. New therapies for castration-resistant prostate cancer: efficacy and safety. *Eur Urol*. 2011 Aug; 60(2):279-90
 - 120) Beer TM, Bernstein GT, Corman JM, Glode M, Hall SJ, Poll W, Schellhammer PF, Jones LA, Xu Y, Kylastra JW, Frohlich MW. Randomized trial of autologous cellular immunotherapy with Sipuleucel-T in androgen dependent prostate cancer. *Clin Cancer Res*. 2011 Jul; 17(13): 4558-67.

- 121) Barnett CM, Beer TM. Prostate cancer and vitamin D: what does the evidence really suggest? *Urol Clin North Am*. 2011 Aug;38(3) 333-42
- 122) Geng H, Harvey CT, Pittsenbarger J, Liu Q, Beer TM, Xue C, Qian DZ. HDAC4 protein regulates HIF1 α protein lysine acetylation and cancer cell response to hypoxia. *J Biol Chem*. 2011 Nov: 286(44): 38095-102. (PMCID: PMC3207467)
- 123) Prins RC, Rademacher BL, Mongoue-Tchokote S, Alumkal JJ, Graff JN, Eilers KM, Beer TM. C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results. *Urol Oncol*. 2012 Jan: 30(1): 33-7. (PMCID: PMC2894303)
- 124) Fleming MT, Sonpavde G, Kolodziej M, Awasthi S, Hutson TE, Martincic D, Rastogi A, Rousey SR, Weinstein RE, Galsky MD, Berry WR, Wang Y, Boehm KA, Asmar L, Rauch MA, Beer TM. Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer. *Clin Genitourin Cancer*. 2012 Mar: 10(1): 6-14.
- 125) Winters-Stone KM, Lyons KS, Nail LM, Beer TM. The exercising together project: Design and recruitment for a randomized, controlled trial to determine the benefits of partnered strength training for couples coping with prostate cancer. *Contemp Clin Trials*. 2012 Mar: 33(2): 342-50. (PMCID: PMC3268842)
- 126) Li X, Priest RA, Woodward WJ, Siddiqui F, Beer TM, Garzotto MG, Rooney WD, Springer CS Jr. Cell membrane water exchange effects in prostate DCE-MRI. *J Magn Reson*. 2012 May: 218: 77-85. (PMCID: PMC3532863)
- 127) Beer TM, Smith DC, Hussain A, Alonso M, Wang J, Giurescu M, Roth K, Wang Y. Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium. *Br J Cancer*. 2012 Aug: 107(5): 808-13. (PMCID: PMC3425976)
- 128) Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L, Nelson PS. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. *Nat Med*. 2012 Sep: 18(9): 1359-68. (PMCID: PMC3677971)
- 129) Geng H, Liu Q, Xue C, David LL, Beer TM, Thomas GV, Dai MS, Qian DZ. HIF1 α Protein Stability Is Increased by Acetylation at Lysine 709. *J Biol Chem*. 2012 Oct: 287(42): 35496-505. (PMCID: PMC3471753)
- 130) Li X, Priest RA, Woodward WJ, Tagge IJ, Siddiqui F, Huang W, Rooney WD, Beer TM, Garzotto MG, Springer CS Jr. Feasibility of shutter-speed DCE-MRI for improved prostate cancer detection. *Magn Reson Med*. 2013 Jan: 69(1): 171-8. (PMCID: PMC3532861)
- 131) Graff JN, Drake CG, Beer TM. Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research. *Urology*. 2013 Feb: 81(2): 381-3. (PMCID: PMC4868050)
- 132) Sonpavde G, Pond GR, Fougerey R, Choueiri TK, Qu AQ, Vaughn DJ, Niegisch G, Albers P, James ND, Wong YN, KO YJ, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Khan A, Vogelzang NJ, Beer TM, Stadler WM, O'Donnell PH, Sternberg CN, Rosenberg JE, Bellmunt J. Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials. *Eur Urol*. 2013 Apr: 63(4): 717-23. (PMCID: PMC4127896)
- 133) Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. *Ann Oncol*. 2013 Jul: 24(7): 1813-21. (PMCID: PMC3707423)
- 134) Lin J, Zahurak M, Beer TM, Ryan CJ, Wilding G, Mathew P, Morris M, Callahan JA, Gordon G, Reich SD, Carducci MA, Antonarakis ES. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in

- patients with biochemically recurrent hormone-naïve prostate cancer. *Urol Oncol*. 2013 Jul; 31(5):581-88. (PMCID: PMC3227793)
- 135) Liu Q, Harvey CT, Geng H, Xue C, Chen V, Beer TM, Qian DZ. Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism. *Prostate*. 2013 Jul; 73(10): 1028-37. (PMCID: PMC3888097)
- 136) Autio KA, Bennett AV, Jia X, Fruscione M, Beer TM, George DJ, Carducci MA, Logothetis CJ, Kane RC, Sit L, Rogak L, Morris MJ, Scher HI, Basch EM. Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure. *J Oncol Pract*. 2013 Sep; 9(5): 223-9. (PMCID: PMC3994234)
- 137) Graff JN, Beer TM. The role of C-reactive protein in prostate cancer. *Cancer*. 2013 Sep 15; 119(18): 3262-4
- 138) Alumkal JJ, Graff JN, Beer TM. Targeted therapy in prostate cancer: is there hope beyond the androgen receptor? *Oncology (Williston Park)*. 2013 Jul; 27(7):628, 630, 637-8
- 139) Beer TM, Schellhammer PF, Corman JM, Glode LM, Hall SJ, Whitmore JB, Frohlich MW, Penson DF. Quality of Life After Sipuleucel-T Therapy: Results From a Randomized, Double-blind Study in Patients With Androgen-dependent Prostate Cancer. *Urology*. 2013 Aug; 82(2): 410-5.
- 140) Quinn DI, Vaishampayan U, Higano CS, Lin DW, Shore ND, Beer TM. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. *Expert Rev Anticancer Ther*. 2014 Jan;14(1): 51-61
- 141) Barnett CM, Heinrich MC, Lim J, Nelson D, Beadling C, Warrick A, Neff TL, Higano C, Garzotto M, Qian D, Corless CL, Thomas GV, Beer TM. Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer. *Clin Cancer Res*. 2014 Mar; 20(5): 1306-12. (PMCID: PMC3947466)
- 142) Carney PA, Tucker EK, Newby TA, Beer TM. Feasibility, acceptability and findings from a pilot randomized controlled intervention study on the impact of a book designed to inform patients about cancer clinical trials. *J Cancer Educ*. 2014 Mar; 29(1): 181-7. (PMCID: PMC4280016)
- 143) Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G. Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. *Clin Genitourin Cancer*. 2014 Apr; 12(2): 130-7. (PMCID: PMC4142680)
- 144) Graff JN, Puri S, Bifulco CB, Fox BA, Beer TM. Sustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancer. *Cancer Immunol Res*. 2014 May; 2(5): 399-403. (PMCID: PMC4418943)
- 145) Winters-Stone KM, Lyons KS, Bennett JA, Beer TM. Patterns and predictors of symptom incongruence in older couples coping with prostate cancer. *Support Care Cancer*. 2014 May; 22(5): 1341-8. (PMCID: PMC3969757)
- 146) Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJM, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengelov L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicenter, randomized, double-blind, phase 3 trial. *Lancet Oncol*. 2014 Jun; 15(7): 700-12. (PMCID: PMC4418935)
- 147) Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med*. 2014 Jul; 371(5): 424-33. (PMCID: PMC4418931)

- 148) Winters-Stone KM, Beer TM. Review of exercise studies in prostate cancer survivors receiving androgen deprivation therapy calls for an aggressive research agenda to generate high-quality evidence and guidance for exercise as standard of care. *J Clin Oncol*. 2014 Aug 10;32(23):2518-9.
- 149) Winters-Stone KM, Dobek JC, Bennett JA, Maddalozzo GF, Ryan CW, Beer TM. Skeletal response to resistance and impact training in prostate cancer survivors. *Med Sci Sports Exerc*. 2014 Aug; 46(8): 1482-8. (PMID: PMC4101037)
- 150) Shtivelman E, Beer TM, Evans CP. Molecular pathways and targets in prostate cancer. *Oncotarget*. 2014 Sep 15;5(17):7217-59. (PMCID:PMC4202120)
- 151) Gordon RR, Wu M, Huang CY, Harris WP, Sim HG, Lucas JM, Coleman I, Higano CS, Gulati R, True LD, Vessella R, Lange PH, Garzotto M, Beer TM, Nelson PS. Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes. *PLoS One*. 2014 Sep; 9(9): e104271. (PMCID: PMC4157741)
- 152) Cetnar JP, Beer TM. Personalizing prostate cancer therapy: the way forward. *Drug Discov Today*. 2014 Sep; 19(9):1483-7
- 153) Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F. Updated interim efficacy analysis and long-term safety of Abiraterone Acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). *Eur Urol*. 2014 Nov; 66(5): 815-25. (PMCID: PMC4418928)
- 154) Ivanescu C, Phung D, Loriot Y, Saad F, Mansbach H, Beer TM, Tomball B, Holmstrom S. Skeletal-Related Events (SRES) Impact Significantly the Health-Related Quality of Life (HRQOL) of Chemo-Naive Men With Metastatic Castration Resistant Prostate Cancer (MCRPC). *Value Health*. 2014 Nov;17(7):A650-1
- 155) Winters-Stone KM, Dobek JC, Bennett JA, Dieckmann NF, Maddalozzo GF, Ryan CW, Beer TM. Resistance training reduces disability in prostate cancer survivors on androgen deprivation therapy: evidence from a randomized controlled trial. *Arch Phys Med Rehabil*. 2015 Jan; 96(1): 7-14. (PMCID: PMC4433162)
- 156) Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME. A Phase I Study of Everolimus and Docetaxel in Patients with Castration-Resistant Prostate Cancer. *Clin Genitourin Cancer*. 2015 Apr; 13(2): 113-23. (PMCID: PMC4418946)
- 157) Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med*. 2014 Oct 30; 371(18):1755-6
- 158) DeLoughery TG, Beer TM. Bevacizumab and thrombosis: Some answers but questions remain. *Cancer*. 2015 Apr; 121(7): 975-7.
- 159) Alumkal JJ, Slottke R, Schwartzman J, Cherala G, Munar M, Graff JN, Beer TM, Ryan CW, Koop DR, Gibbs A, Gao L, Flamiatos JF, Tucker E, Kleinschmidt R, Mori M. A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. *Invest New Drugs*. 2015 Apr; 33(2): 480-9. (PMCID: PMC4390425)
- 160) Graff JN, Beer TM. Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents. *Drugs Aging*. 2014 Dec; 31(12): 873-82. (PMCID: PMC4418948)
- 161) Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. *Clin Genitourin Cancer*. 2015 Jun; 13(3): e191-8.
- 162) Graff JN, Beer TM. Should docetaxel be administered earlier in prostate cancer therapy? *Expert Rev Anticancer Ther*. 2015; 15(9): 977-9.
- 163) Jiang K, Wang X, Geng H, Beer TM, Qian DZ, Ramstrom O, Yan M. Carbohydrate-

- conjugated fluorescent silica nanoprobe for selective detection of galectin-1 and prostate cancer cells. *Sci Lett J*. 2015;4:132. (PMCID:PMC4827262)
- 164) Liu Q, Geng H, Xue C, Beer TM, Qian DZ. Functional regulation of hypoxia inducible factor-1 α by SET9 lysine methyltransferase. *Biochim Biophys Acta*. 2015 May: 1853(5): 881-91. (PMCID: PMC4380656)
- 165) Devlin N, Herdman M, Pavesi M, Phung D, Naidoo S, Beer TM, Tombal B, Lorient Y, Ivanescu C, Parli T, Balk M, Holmstrom S. Health-Related Quality Of Life (Hrql) Benefits Of Enzalutamide In Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc): An In-Depth Analysis Of Eq-5d Data From The Prevail Trial. *Value Health*. 2015 Nov: 18(7): A475.
- 166) Graff JN, Beer TM, Liu B, Sonpavde G, Taioli E. Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer Patients. *Clin Genitourin Cancer*. 2015 Aug: 13(4): e217-21.
- 167) Higano CS, Beer TM, Taplin ME, Efsthathiou E, Hirmand M, Forer D, Scher HI. Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. *Eur Urol*. 2015 Nov: 68(5): 795-801. (PMCID: PMC5013546)
- 168) Graff JN, Gordon, MJ, Beer TM. Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer. *Expert Opin Pharmacother*. 2015 Apr: 16(5): 749-54.
- 169) Lorient Y, Miller K, Sternberg CN, Fizazi K, De Bono JS, Chowdhury S, Higano CS, Noonberg S, Holmstrom S, Mansbach H, Perabo FG, Phung, Ivanescu C, Skaltsa K, Beer TM, Tombal B. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomized, phase 3 trial. *Lancet Oncol*. 2015 May: 16(5): 509-21.
- 170) Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of COU-AA-302. *Eur Urol*. 2015 Oct: 68(4): 570-7. (PMCID:PMC5056561).
- 171) Graff JN, Beer TM. Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer. *Oncology (Williston Park)*. 2015 Jun: 29(6): 416-23.
- 172) Gillissen S, Omlin A, Attard G, de Bono JS, Efsthathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. *Ann Oncol*. 2015 Aug: 26(8): 1589-604. (PMCID: PMC4511225)
- 173) Winters-Stone KM, Dieckmann N, Maddalozzo GF, Bennett JA, Ryan CW, Beer TM. Resistance Exercise Reduces Body Fat and Insulin During Androgen-Deprivation Therapy for Prostate Cancer. *Oncol Nurs Forum*. 2015 Jul: 42(4): 348-56.
- 174) Beer TM. Building on Last Year's Advances. *Oncology (Williston Park)*. 2015 Jul: 29(7): 504-6.
- 175) Lyons KS, Winters-Stone KM, Bennett JA, Beer TM. The Effects of Partnered Exercise on Physical Intimacy in Couples Coping with Prostate Cancer. *Health Psychol*. 2016 May: 35(5): 509-13. (PMCID: PMC4829498)
- 176) Graff JN, Baciarello G, Armstrong AJ, Higano CS, Iversen P, Flaig TW, Forer D, Parli T, Phung D, Tombal B, Beer TM, Sternberg CN. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from PREVAIL. *Ann Oncol*. 2016 Feb: 27(2): 286-94.

- 177) Graff JN, Thomas GV, Higano CS, Beer TM. Prolonged Response to an IGF-1 Receptor Antibody in a Patient with Metastatic Castration Prostate Cancer with Neuroendocrine Differentiation. *Cureus*. 2015 Dec 22;7(12):e426. (PMCID: PMC4727917)
- 178) Winters-Stone KM, Lyons KS, Dobek J, Dieckmann NF, Bennett JA, Nail L, Beer TM. Benefits of partnered strength training for prostate cancer survivors and spouses: results from a randomized controlled trial of the Exercising Together project. *J Cancer Surviv*. 2016 Aug; 10(4): 633-44.
- 179) Graff JN, Beer TM. Metastatic prostate cancer in 2015: The new and the old that is new again. *Nat Rev Clin Oncol*. 2016 Feb; 13(2): 73-4.
- 180) Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ; Prostate Cancer Clinical Trials Working Group 3. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. *J Clin Oncol*. 2016 Apr 20;34(12):1402-18. (PMCID: PMC4872347)
- 181) Evans CP, Higano CS, Keane T, Andriole G, Saad F, Iversen P, Miller K, Kim CS, Kimura G, Armstrong AJ, Sternberg CN, Lorient Y, de Bono J, Noonberg SB, Mansbach H, Bhattacharya S, Perabo F, Beer TM, Tombal B. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. *Eur Urol*. 2016 Oct;70(4):675-83.
- 182) Kimura G, Yonese J, Fukagai T, Kamba T, Nishimura K, Nozawa M, Mansbach H, Theeuwes A, Beer TM, Tombal B, Ueda T. Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial. *Int J Urol*. 2016 May;23(5):395-403.
- 183) Luo J, Beer TM, Graff JN. Treatment of Nonmetastatic Castration-Resistant Prostate Cancer. *Oncology (Williston Park)*. 2016 Apr;30(4):336-44.
- 184) Coleman DJ, Van Hook K, King CJ, Schwartzman J, Lisac R, Urrutia J, Sehrawat A, Woodward J, Wang NJ, Gulati R, Thomas GV, Beer TM, Gleave M, Korkola JE, Gao L, Heiser LM, Alumkal JJ. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. *Oncotarget*. 2016 Jun;7(26):40690-703. (PMCID: PMC5130036)
- 185) Alumkal JJ, Beer TM. Raising the Bar for Therapeutic Trials in Advanced Prostate Cancer. *J Clin Oncol*. 2016 Sep 1;34(25):2958-60.
- 186) Beer TM, Armstrong AJ, Rathkopf D, Lorient Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B. Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. *Eur Urol*. 2017 Feb;71(2):151-4. (PMCID: PMC5570461)
- 187) Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, Cetnar JP, Ey FS, Bergan RC, Slotke R, Beer TM. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. *Oncotarget*. 2016 Aug;7(33):52810-7. (PMCID: PMC5288150)
- 188) Cameron JL, Jain R, Rais M, White AE, Beer TM, Kievit P, Winters-Stone K, Messaoudi fl, Varlamov O. Perpetuating effects of androgen deficiency on insulin resistance. *Int J Obes (Lond)*. 2016 Dec;40(12):1856-63. (PMCID: PMC5140744)
- 189) Flamiatos JF, Beer TM, Graff JN, Eilers KM, Tian W, Sekhon HS, Garzotto M. Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention: double-blind randomised study of pre-prostatectomy celecoxib or placebo. *BJU Int*. 2017 May;119(5):709-16.
- 190) Zhang Z, Garzotto M, Beer TM, Thuillier P, Lieberman S, Mori M, Stoller WA, Farris PE, Shannon J. Effects of ω -3 Fatty Acids and Catechins on Fatty Acid Synthase in the

- Prostate: A Randomized Controlled Trial. *Nutr Cancer*. 2016 Nov-Dec;68(8):1309-19. (PMCID: PMC5154733)
- 191) Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F, Humanski P, Piulats JM, Gonzalez Mella P, Ng SS, Jaeger D, Parnis FX, Franke FA, Puente J, Carvajal R, Sengelov L, McHenry MB, Varma A, van den Eertwegh AJ, Gerritsen W. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naïve castration-resistant prostate cancer. *J Clin Oncol*. 2017 Jan;35(1):40-7.
- 192) Aggarwal R, Beer TM, Gleave M, Stuart JM, Rettig M, Evans CP, Youngren J, Alumkal JJ, Huang J, Thomas G, Witte O, Small EJ. Targeting adaptive pathways in metastatic treatment-resistant prostate cancer: update on the Stand Up 2 Cancer/Prostate Cancer Foundation-supported West Coast Prostate Cancer Dream Team. *Eur Urol Focus*. 2016 Dec;2(5):469-71.
- 193) McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. *J Immunother Cancer*. 2016 Dec;4:92. (PMCID: PMC5170901).
- 194) Beer TM, Prasad V. Taking Care of Our Friends and Neighbors: DeVita's The Death of Cancer and the Challenge of Letting Go. *JAMA Oncol*. 2017 Jan;3(1):16-17.
- 195) Bergstrom CP, Ruffell B, Ho CM, Higano CS, Ellis WJ, Garzotto M, Beer TM, Graff JN. Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates. *Anticancer Drugs*. 2017 Jan;28(1):120-6. (PMCID:PMC7370800)
- 196) Graff JN, Alumkal JJ, Beer TM. Should Chemotherapy Be Used in Nonmetastatic Prostate Cancer? *JAMA Oncol*. 2017 Jan;3(1):11-12.
- 197) Tao DL, Bailey S, Beer TM, Foss E, Beckett B, Fung A, Foster BR, Guimaraes A, Cetnar JP, Graff JN, Eilers KM, Small EJ, Corless CL, Thomas GV, Alumkal JJ. Molecular Testing in Patients With Castration-Resistant Prostate Cancer and Its Impact on Clinical Decision Making. *JCO Precis Oncol*. 2017; 1:10. (PMCID:PMC6812573)
- 198) Saad F, Ivanescu C, Phung D, Lorient Y, Abhyankar S, Beer TM, Tombal B, Holmstrom S. Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials. *Prostate Cancer Prostatic Dis*. 2017 Mar;20(1):110-6. (PMCID: PMC5332552)
- 199) Bryce AH, Alumkal JJ, Armstrong A, Higano CS, Iversen P, Sternberg CN, Rathkopf D, Lorient Y, de Bono J, Tombal B, Abhyankar S, Lin P, Krivoschik A, Phung D, Beer TM. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. *Prostate Cancer Prostatic Dis*. 2017 Jun;20(2):221-7. (PMCID: PMC5435962)
- 200) Alumkal JJ, Chowdhury S, Lorient Y, Sternberg CN, de Bono JS, Tombal B, Carles J, Flaig TW, Dorff TB, Phung, Forer D, Noonberg SB, Mansbach H, Beer TM, Higano CS. Effect of Visceral Disease Site on Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in the PREVAIL Trial. *Clin Genitourin Cancer*. 2017 Oct;15(5):610-7.
- 201) Winters-Stone KM, Moe E, Graff JN, Dieckmann NF, Stoyles S, Borsch C, Alumkal JJ, Amling CL, Beer TM. Falls and Frailty in Prostate Cancer Survivors: Current, Past and Never Users of Androgen Deprivation Therapy. *J Am Geriatr Soc*. 2017 Jul;65(7):1414-19. (PMCID: PMC5507739)
- 202) Podolak J, Eilers K, Newby T, Slottke R, Tucker E, Olson SB, Lue HW, Youngren J, Aggarwal R, Small EJ, Graff JN, Alumkal JJ, Beer TM, Thomas GV. Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. *Oncotarget*. 2017 Mar;8(42):71447-55. (PMCID: PMC5641061)
- 203) Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E,

- Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard CC, Thomas GV, Tomlins SA, Knudsen KE, Lord CJ, Ryan CJ, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY. Analysis of Circulating Cell-free DNA Identifies Multi-clonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. *Cancer Discov.* 2017 Sep;7(9):999-1005. (PMCID: PMC5581695)
- 204) Armstrong AJ, Halabi S, Healy P, Alumkal JJ, Winters C, Kephart J, Bitting RL, Hobbs C, Soleau CF, Beer TM, Slottke R, Mundy K, Yu EY, George DJ. Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. *Eur J Cancer.* 2017 Aug;81:228-36. (PMCID:PMC6345641)
- 205) Holmes MG, Foss E, Joseph G, Foye A, Beckett B, Motamedi D, Youngren J, Thomas GV, Huang J, Aggarwal R, Alumkal JJ, Beer TM, Small EJ, Link TM. CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. *J Vasc Interv Radiol.* 2017 Aug;28(8):1073-81.
- 206) Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. *Clin Genitourin Cancer.* 2017 Dec;15(6):733-41.
- 207) Devlin N, Herdman M, Pavesi M, Phung, Naidoo S, Beer TM, Tombal B, Loriot Y, Ivanescu C, Parli T, Balk M, Holmstrom S. Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial. *Health Qual Life Outcomes.* 2017 Jun;15(1):130. (PMCID: PMC5481866)
- 208) Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Dos Reis RB, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khaulil RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. *Eur Urol.* 2018 Feb;73(2):178-211.
- 209) Kim CS, Choi YD, Lee SE, Lee HM, Ueda T, Yonese J, Fukagai T, Chiong E, Lau W, Abhyankar S, Theeuwes A, Tombal B, Beer TM, Kimura G. Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer. *Medicine (Baltimore).* 2017 Jul;96(27):e7223. (PMCID: PMC5502144)
- 210) Taplin ME, Armstrong AJ, Lin P, Krivoshik A, Phung, Parli T, Tombal B, Beer TM. Clinical outcomes of chemotherapy naïve men with metastatic castration resistant prostate cancer and low baseline prostate specific antigen treated with enzalutamide vs placebo. *J Urol.* 2017 Dec;198(6):1324-32.
- 211) Pezaro CJ, Omlin A, Mastris K, ANZUP Consumer Advisory Panel, Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, de Bono JS, Efstathiou E, Gravis G, Higano CS, Hussain M, James N, Logothetis CJ, Morgans A, Parker C, Ryan CJ, Saad F, Sartor O, Small EJ, Sternberg CN, Sweeney CJ, Tannock I, Tombal B, Gillessen S. Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. *Ann Oncol.* 2017 Aug;28(8):1692-4.
- 212) Beer TM. Management of castration-resistant, taxane-resistant prostate cancer. *Oncology (Williston Park).* 2017 Aug;31(8):633-6.
- 213) Beer TM, Hotte SJ, Saad F, Alekseev B, Matveev V, Flechon A, Gravis G, Joly F, Chi KN, Malik Z, Blumenstein B, Stewart PS, Jacobs CA, Fizazi K. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in

- patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomized, open-label, international, phase 3 trial. *Lancet Oncol.* 2017 Nov;18(11):1532-42.
- 214) Beer TM, Miller K, Tombal B, Cella D, Phung, Holmstrom S, Ivanescu C, Skaltsa K, Naidoo S. The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies. *Eur J Cancer.* 2017 Dec;87:21-9.
- 215) Beer TM, Prasad V. Is “Do Everything!” Always Appropriate?-Reply. *JAMA Oncol.* 2017 Nov;3(11):1588-9.
- 216) Shatzel JJ, Daughety MM, Olson SR, Beer TM, DeLoughery TG. Management of anticoagulation in patients with prostate cancer receiving enzalutamide. *J Oncol Pract.* 2017 Nov;13(11):720-727.
- 217) Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. *J Natl Cancer Inst.* 2017 Dec;109(12). PMID:PMC6440274
- 218) Carlo MI, Giri VN, Paller CJ, Abida W, Alumkal JJ, Beer TM, Beltran H, George DJ, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Ryan CJ, Schaeffer EM, Stadler WM, Taplin ME, Kauff ND, Vinson J, Antonarakis ES, Cheng HH. Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. *JCO Precis Oncol.* 2018;2018. (PMCID: PMC6370313).
- 219) Sehrawat A, Gao L, Wang Y, Bankhead A 3rd, McWeeney SK, King CJ, Schwartzman J, Urrutia J, Bisson WH, Coleman DJ, Joshi SK, Kim DH, Sampson DA, Weinmann S, Kallakury BVS, Berry DL, Haque R, Van Den Eeden SK, Sharma S, Bearss J, Beer TM, Thomas GV, Heiser LM, Alumkal JJ. LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. *Proc Natl Acad Sci USA.* 2018 May;115(18):E4179-88. (PMCID: PMC5939079)
- 220) Rathkopf DE, Beer TM, Lorient Y, Higano CS, Armstrong AJ, Sternberg CN, de Bono JS, Tombal B, Parli T, Bhattacharya S, Phung, Krivoshik A, Scher HI, Morris MJ. Radiographic progression-free survival as a clinically meaningful end point in metastatic castration-resistant prostate cancer: The PREVAIL randomized clinical trial. *JAMA Oncol.* 2018 May;4(5):694-701. (PMCID: PMC5885186)
- 221) Aggarwal R, Huang J, Alumkal JJ, Zhang L, Fend FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. *J Clin Oncol.* 2018 Aug;36(24):2492-503. (PMCID: PMC6366813).
- 222) Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. *Cell.* 2018 Jul;174(3):758-69. (PMCID: PMC6425931).
- 223) Lu E, Thomas GV, Chen Y, Wyatt AW, Lloyd P, Youngren J, Quigley D, Bergan R, Bailey S, Beer TM, Feng FY, Small EJ, Alumkal JJ. DNA repair gene alterations and PARP inhibitor response in patients with metastatic castration-resistant prostate cancer. *J Natl Compr Canc Netw.* 2018 Aug;16(8):933-7.

- 224) Ferrari AC, Alumkal JJ, Stein MN, Taplin ME, Babb JS, Barnett ES, Gomez-Pinillos A, Liu X, Moore DF, DiPaola RS, Beer TM. Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer. *Clin Cancer Res.* 2019 Jan;25(1):52-63.
- 225) Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. *Cell.* 2018 Oct;175(3):889.
- 226) Armstrong AJ, Lin P, Higano CS, Sternberg CN, Sonpavde G, Tombal B, Templeton AJ, Fizazi K, Phung D, Wong EK, Krivoshik A, Beer TM. Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. *Ann Oncol.* 2018 Nov;29(11):2200-7. (PMCID: PMC6888025).
- 227) Winters-Stone KM, Kenfield SA, Van Blarigan EL, Moe EL, Ramsdill JW, Daniel K, Macaire G, Paich K, Kessler ER, Kucuk O, Gillespie TW, Lyons KS, Beer TM, Broering JM, Carroll PR, Chan JM. Effect of Increasing Levels of Web-Based Behavioral Support on Changes in Physical Activity, Diet and Symptoms in Men with Prostate Cancer: Protocol for a Randomized Controlled Trial. *JMIR Res Protoc.* 2018 Nov; 7(11):e11257. (PMCID: PMC6265599).
- 228) Geng H, Xue C, Mendonca J, Sun XX, Liu Q, Reardon PN, Chen Y, Qian K, Hua V, Chen A, Pan F, Yuan J, Dang S, Beer TM, Dai MS, Machhap SK, Qian DZ. Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy. *Nat Commun.* 2018 Nov; 9(1):4972. (PMCID: PMC6255907).
- 229) Armstrong AJ, Lin P, Higano CS, Iversen P, Sternberg CN, Tombal B, Phung, Parli T, Krivoshik A, Beer TM. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. *Eur Urol Oncol.* 2019 Nov;2(6):677-684.
- 230) Mitri ZI, Parmar S, Johnson B, Kolodzie A, Keck JM, Morris M, Guimaraes AR, Beckett BR, Borate U, Lopez CD, Kemmer KA, Alumkal JJ, Beer TM, Corless CL, Mills GB, Gray JW, Bergan RC. Implementing a comprehensive translational oncology platform: from molecular testing to actionability. *J Transl Med.* 2018 Dec;16(1):358. (PMCID: PMC6295039).
- 231) Layton JL, Lewis B, Ryan C, Beer TM, Sartor O. Recycling Discarded Drugs: Improving Access to Oral Antineoplastic Drugs. *Oncologist.* 2019 Mar;24(3):291-292. (PMCID: PMC6519754).
- 232) Geng H, Xue C, Mendonca J, Sun XX, Liu Q, Reardon PN, Chen Y, Qian K, Hua V, Chen A, Pan F, Yuan J, Dang S, Beer TM, Dai MS, Kachhap SK, Qian DZ. Publisher Correction: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy. *Nat Commun.* 2019 Jan;10(1):164. (PMCID: PMC6325161).
- 233) Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. *Prostate Cancer Prostatic Dis.* 2019 Dec;22(4):531-538. (PMCID: PMC6853839).
- 234) Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave

- ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, Alumkal JJ, Small EJ. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. *Mol Cancer Res.* 2019 Jun;17(6):1235-1240. (PMCID: PMC6548614).
- 235) Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ, West Coast Prostate Cancer Dream Team. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. *Eur Urol.* 2019 Nov;76(5):562-571. (PMCID: PMC6764911).
- 236) Ferrari AC, Alumkal JJ, Stein MN, Taplin ME, Babb JS, Barnett ES, Gomez-Pinillos A, Liu X, Moore DF, DiPaola RS, Beer TM. Correction: Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer. *Clin Cancer Res.* 2019 Apr;25(8):2672.
- 237) Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, Ryan CJ, Taplin ME, Whang YE, Vinson J, Cheng HH, Giri VN; PCCTC Germline Genetics Working Group. Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. *Clin Genitourin Cancer.* 2019 Aug;17(4):275-282.e1. (PMCID: PMC6662206).
- 238) Kapoor R, Deek MP, McIntyre R, Raman N, Kummerlowe M, Chen I, Gaver M, Wang H, Denneke S, Lotan T, Paller C, Markowski M, Carducci M, Eisenberger M, Beer TM, Song DY, DeWeese TL, Hearn JW, Greco S, DeVille C, Desai NB, Heath EI, Liauw S, Spratt DE, Hung AY, Antonarakis ES, Tran PT. A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). *BMC Cancer.* 2019 Jun 13;19(1):572. (PMCID: PMC6567492).
- 239) Kopp RP, Beer TM. Combining options in metastatic prostate cancer. *Nat Rev Urol.* 2019 Oct;16(10):569-570.
- 240) Gillesen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. *Ann Oncol.* 2019 Dec;30(12):e3.
- 241) Armstrong AJ, Al-Adhami M, Lin P, Parli T, Sugg J, Steinberg J, Tombal B, Sternberg CN, de Bono J, Scher HI, Beer TM. Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials. *JAMA Oncol.* 2020 Feb; 6(2):217-25. (PMCID: PMC6990871).
- 242) Gillesen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report

- of the Advanced Prostate Cancer Consensus Conference 2019 *Eur Urol.* 2020 Apr;77(4):508-547.
- 243) Lin DW, Shih MC, Aronson W, Basler J, Beer TM, Brophy M, Cooperberg M, Garzotto M, Kelly WK, Lee K, McGuire V, Wang Y, Lu Y, Markle V, Nseyo U, Ringer R, Savage SJ, Sinnott P, Uchio E, Yang CC, Montgomery RB. Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study. *Eur Urol.* 2020 May;77(5):563-572.
- 244) Chen WS, Feng EL, Aggarwal R, Foye A, Beer TM, Alumkal JJ, Gleave M, Chi KN, Reiter RE, Rettig MB, Evans CP, Small EJ, Sharifi N, Zhao SG. Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. *Prostate Cancer Prostatic Dis.* 2020 Jun;23(2):316-323.
- 245) Alumkal JJ, Sun D, Lu E, Beer TM, Thomas GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatabaei S, Bailey S, Turina CB, Quigley DA, Guan X, Foye A, Youngren JF, Urrutia J, Huang J, Weinstein AS, Friedl V, Rettig M, Reiter RE, Spratt DE, Gleave M, Evans CP, Stuart JM, Chen Y, Feng FY, Small EJ, Witte ON, Xia Z. Transcriptional Profiling Identifies an Androgen Receptor Activity-Low, Stemness Program Associated With Enzalutamide Resistance. *Proc Natl Acad Sci U S A.* 2020 Jun 2;117(22):12315-12323. (PMCID: PMC7275746).
- 246) Graff JN, Beer TM, Alumkal JJ, Slottke RE, Redmond WL, Thomas GV, Thompson RF, Wood MA, Koguchi Y, Chen Y, Latour E, Bergan RC, Drake CG, Moran AE. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone. *J Immunother Cancer.* 2020 Jul;8(2): e000642. (PMCID: PMC7333874).
- 247) Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, Zhang L, Alshalalfa M, Laura Chang S, Houlahan KE, Shiah YJ, Beer TM, Thomas G, Chi KN, Gleave M, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Yvonne Kim M, Fong L, Spratt DE, Morgan TM, Bose R, Huang FW, Li H, Chesner L, Shenoy T, Goodarzi H, Asangani IA, Sandhu S, Lang JM, Mahajan NP, Lara PN, Evans CP, Febbo P, Batzoglou S, Knudsen KE, He HH, Huang J, Zwart W, Costello JF, Luo J, Tomlins SA, Wyatt AW, Dehm SM, Ashworth A, Gilbert LA, Boutros PC, Farh K, Chinnaiyan AM, Maher CA, Small EJ, Quigley DA, Feng FY. The DNA methylation landscape of advanced prostate cancer. *Nat Genet.* 2020 Aug; 52(8):778-789. (PMCID: PMC7454228).
- 248) Graff JN, Stein MN, Surana R, Al Rabadi L, Liu E, Fong L, Bailey S, Latour E, Newby TA, Moran AE, Beer TM. Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy. *Front Oncol.* 2020 Aug 7; 10:1381. (PMCID: PMC7426513).
- 249) Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, Parli T, Rosbrook B, van Os S, Beer TM. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. *Eur Urol.* 2020 Sep;78(3):347-357.
- 250) Guan X, Sun D, Lu E, Urrutia JA, Reiter RE, Rettig M, Evans CP, Lara P Jr, Gleave M, Beer TM, Thomas GV, Huang J, Aggarwal RR, Quigley DA, Foye A, Chen WS, Youngren J, Weinstein AS, Stuart JM, Feng FY, Small EJ, Xia Z, Alumkal JJ. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. *Clin Cancer Res.* 2020 Sep;26(17): 4616-4624. (PMCID: PMC7484240).
- 251) Schmid S, Omlin A, Higano C, Sweeney C, Martinez Chanza N, Mehra N, Kuppen MCP, Beltran H, Conteduca V, Vargas Pivato de Almeida D, Cotait Maluf F, Oh WK, Tsao CK, Sartor O, Ledet E, Di Lorenzo G, Yip SM, Chi KN, Bianchini D, De Giorgi U, Hansen AR, Beer TM, Lavaud P, Morales-Barrera R, Tucci M, Castro E, Karalis K, Bergman AM, Le ML, Zürrer-Härdi U, Pezaro C, Suzuki H, Zivi A, Klingbiel D, Schär S, Gillissen S. Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer

- With and Without DNA Repair Gene Aberrations. *JAMA Netw Open*. 2020 Oct 1; 3(10): e2021692. (PMCID: PMC7593810).
- 252) Beer TM. Novel blood-based early cancer detection: diagnostics in development. *Am J Manag Care*. 2020 Nov; 26(14 Suppl): S292-S299.
- 253) Kwon DH, Zhang L, Quigley DA, Foye A, Chen WS, Wong CK, Feng FY, Bailey A, Huang J, Stuart JM, Friedl V, Weinstein AS, Beer TM, Alumkal JJ, Rettig M, Gleave M, Lara PN Jr, Thomas GV, Li P, Lui A, Small EJ, Aggarwal RR. Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. *Urol Oncol*. 2020 Dec; 38(12):931. e9-931.e16.
- 254) Fizazi K, Drake CG, Beer TM, Kwon ED, Scher HI, Gerritsen WR, Bossi A, den Eertwegh AJMV, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Danielli R, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, McHenry MB, Chen A, Logothetis C, CA184-043 Investigators. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. *Eur Urol*. 2020 Dec; 78(6):822-830.
- 255) Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M, Evans CP, Lara P, Chi KN, Reiter RE, Alumkal JJ, Ashworth A, Aggarwal R, Small EJ, Daugherty PS, Ribas A, Oh DY, Shon JC, Feng FY. Autoantibody Landscape in Patients with Advanced Prostate Cancer. *Clin Cancer Res*. 2020 Dec 1; 26(23): 6204-6214. (PMCID: PMC7710628).
- 256) Szymaniak BM, Facchini LA, Giri VN, Antonarakis ES, Beer TM, Carlo MI, Danila DC, Dhawan M, George D, Graff JN, Gupta S, Heath E, Higano CS, Liu G, Molina AM, Paller CJ, Patnaik A, Petrylak DP, Reichert Z, Rettig MB, Ryan CJ, Taplin ME, Vinson J, Whang YE, Morgans AK, Cheng HH, McKay RR. Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. *JCO Oncol Pract*. 2020 Dec; 16(12):811-819. (PMCID: PMC7735040).
- 257) Chan JM, Van Blarigan EL, Langlais CS, Zhao S, Ramsdill JW, Daniel K, Macaire G, Wang E, Paich K, Kessler ER, Beer TM, Lyons KS, Broering JM, Carroll PR, Kenfield SA, Winters-Stone KM. Feasibility and Acceptability of a Remotely Delivered, Web-Based Behavioral Intervention for Men With Prostate Cancer: Four-Arm Randomized Controlled Pilot Trial. *J MED Internet Res*. 2020 Dec 31; 22(12):e19238. (PMCID: PMC7808895).
- 258) Finelli A, Beer TM, Chowdhury S, Evans CP, Fizazi K, Higano CS, Kim J, Martin L, Saad F, Saarela O. Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer: A Secondary Post Hoc Analysis of the PREVAIL Randomized Clinical Trial. *JAMA Netw Open*. 2021 Jun 1;4(6):e2112426. (PMCID: PMC8207237)
- 259) Nadauld LD, McDonnell CH 3rd, Beer TM, Liu MC, Klein EA, Hudnut A, Whittington RA, Taylor B, Oxnard GR, Lipson J, Lopatin M, Shaknovich R, Chung KC, Fung ET, Schrag D, Marinac CR. The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. *Cancers (Basel)*. 2021 Jul 13;13(14):3501. (PMCID: PMC8304888)
- 260) Winters-Stone KM, Lyons KS, Dieckmann NF, Lee CS, Mitri Z, Beer TM. Study protocol for the Exercising Together© trial: a randomized, controlled trial of partnered exercise for couples coping with cancer. *Trials*. 2021 Aug 30;22(1):579. (PMCID: PMC8404361)
- 261) Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ, Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med*. 2021 Sep 16;385(12):1091-1103. (PMCID: PMC8446332)
- 262) Schmidt AL, Tucker MD, Bakouny Z, Labaki C, Hsu CY, Shyr Y, Armstrong AJ, Beer TM,

- Bijjula RR, Bilen MA, Connell CF, Dawsey SJ, Faller B, Gao X, Gartrell BA, Gill D, Gulati S, Halabi S, Hwang C, Joshi M, Khaki AR, Menon H, Morris MJ, Puc M, Russell KB, Shah NJ, Sharifi N, Shaya J, Schweizer MT, Steinharter J, Wulff-Burchfield EM, Xu W, Zhu J, Mishra S, Grivas P, Rini BI, Warner JL, Zhang T, Choueiri TK, Gupta S, McKay RR. Association Between Androgen Deprivation Therapy and Mortality Among Patients with Prostate Cancer and COVID-19. *JAMA Netw Open*. 2021 Nov 1;4(11):e2134330 (PMCID: PMC8590166)
- 263) Winters-Stone KM, Li F, Horak F, Dieckmann N, Hung A, Amling C, Beer TM. Protocol for GET FIT Prostate: A Randomized, Controlled Trial of Group Exercise Training for Fall Prevention and Functional Improvements During and After Treatment for Prostate Cancer. *Trials*. 2021 Nov 6;22(1):775. (PMCID: PMC8571824)
- 264) Geng H, Ko HK, Pittsenbarger J, Harvey CT, Xue C, Liu Q, Wiens S, Kachhap SK, Beer TM, Qian DZ. HIF1 and ID1 Interplay Confers Adaptive Survival to HIF1 α -Inhibition. *Front Cell Dev Biol*. 2021 Nov 8;9:724059 (PMCID: PMC8606652)
- 265) Tombal B, Stenzl A, Cella D, Loriot Y, Armstrong AJ, Fizazi K, Beer T, Sternberg CN, Hussain M, Ivanescu C, Ganguli A, Ramaswamy K, Saad F. The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials. *Cancers (Basel)*. 2021 Nov 23;13(23):5872. (PMCID: PMC8657254)
- 266) Beer TM. Examining developments in multicancer early detection: highlights of new clinical data from recent conferences. *Am J Manag Care*. 2021 Dec;27(19 Suppl):S347-S355.
- 267) Autio KA, Antonarakis ES, Mayer TM, Shevrin DH, Stein MN, Vaishampayan UN, Morris MJ, Slovin SF, Heath EI, Tagawa ST, Rathkopf DE, Milowsky MI, Harrison MR, Beer TM, Balar AV, Armstrong AJ, George DJ, Paller CJ, Apollo A, Danila DC, Graff JN, Nordquist L, Dayan Cohn ES, Tse K, Schreiber NA, Heller G, Scher HI. Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. *Eur Urol Open Sci*. 2021 Nov 17;34:70-78. (PMCID: PMC8655386)
- 268) Winters-Stone KM, Lyons KS, Beer TM, Skiba MB, Hung A. A pilot feasibility study of Exercising Together[®] During Radiation Therapy for Prostate Cancer: A Dyadic Approach for Patients and Spouses. *Pilot Feasibility Stud*. 2021 Dec 8;7(1):216. (PMCID: PMC8653603)
- 269) Vogl UM, Beer TM, Davis ID, Shore ND, Sweeney CJ, Ost P, Attard G, Bossi A, de Bono J, Drake CG, Efsthathiou E, Fanti S, Fizazi K, Halabi S, James N, Mottet N, Padhani AR, Roach M, Rubin M, Sartor O, Small E, Smith MR, Soule H, Sydes MR, Tombal B, Omlin A, Gillessen S. Lack of Consensus Identifies Important Areas for Future Clinical Research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 Findings. *Eur J Cancer*. 2022 Jan;160:24-60.
- 270) Langlais CS, Chen YH, Van Blarigan EL, Kenfield SA, Kessler ER, Daniel K, Ramsdill JW, Beer TM, Graff RE, Paich K, Chan JM, Winters-Stone KM. Quality of Life of Prostate Cancer Survivors Participating in a Remotely Delivered Web-Based Behavioral Intervention Pilot Randomized Trial. *Integr Cancer Ther*. 2022 Jan-Dec;21:15347354211063500. (PMCID: PMC9016550)
- 271) Vogelzang NJ, Beer TM, Gerritsen W, Oudard S, Wiechno P, Kukielka-Budny B, Samal V, Hajek J, Feyerabend S, Khoo V, Stenzl A, Csöszi T, Filipovic Z, Goncalves F, Prokhorov A, Cheung E, Hussain A, Sousa N, Bahl A, Hussain S, Fricke H, Kadlecova P, Scheiner T, Korolkiewicz RP, Bartunkova J, Spisek R; VIABLE Investigators. Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. *JAMA Oncol*. 2022 Feb 10;e217298. (PMCID: 35142815)
- 272) Tombal BF, Freedland SJ, Armstrong AJ, Beer TM, Stenzl A, Sternberg CN, Hussain M, Ganguli A, Ramaswamy K, Bhadauria H, Ivanescu C, Turnbull J, Holmstrom S, Saad F. Impact of Enzalutamide on Patient-Reported Fatigue in Patients with Prostate Cancer:

- Data from the Pivotal Clinical Trials. *Prostate Cancer Prostatic Dis.* 2022 Feb;25(2):288-295. (PMCID: PMC9184276)
- 273) Winters-Stone KM, Boisvert C, Li F, Lyons KS, Beer TM, Mitri Z, Meyers G, Eckstrom E, Campbell KL. Delivering exercise medicine to cancer survivors: has COVID-19 shifted the landscape for how and who can be reached with supervised group exercise? *Randomized Controlled Trial. Support Care Center.* 2022 Mar;30(3):1903-1906. (PMCID: PMC8571667)
- 274) Klein EA, Beer TM, Seiden M. Multicancer Early Detection. *Clin Chem Lab Med.* 2022 Feb;60(5):e119-e120.
- 275) Post CM, Kahn JM, Turina CB, Beer TM, Hung AY. Short-term ADT and Dose-escalated IMRT in Patients With Intermediate-risk Prostate Cancer: Benefit or Caution? *Am J Clin Oncol.* 2022 May 1;45(5):190-195.
- 276) Feng Z, Curti BD, Quinn DI, Strother JM, Chen Z, Agnor R, Beer TM, Ryan CW. A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma. *Clin Genitourin Cancer.* 2022 May 5;S1558-7673(22)00094-5. [online ahead of print]
- 277) Klein EA, Beer TM, Seiden M. The Promise of Multicancer Early Detection. Comment on Pons-Belda et al. Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? *The Grail Paradigm. Diagnostics* 2021, 11, 2171. *Diagnostics (Basel).* 2022 May; 12(5):1243. (PMCID: PMC9141107)
- 278) Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke Onyeaunam N, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Pablo Sade J, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. *Eur Urol.* 2022 Jul; 82(1):6-11. (PMCID: PMC8849852)
- 279) Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke ON, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [*Eur Urol* 82 (1): 6-11]. *Eur Urol* 2022 Jul;82(1)e18-e19. (PMCID: PMC9012951)
- 280) Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, de Bono JS, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP,

- Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt DE, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. *Eur Urol.* 2022 Jul;82(1): 115-141.
- 281) Joshua AM, Armstrong, A, Crumbaker M, Scher HI, de Bono J, Tombal B, Hussain M, Sternberg CN, Gillessen S, Carles J, Fizazi K, Lin P, Duggan W, Sugg J, Russell D, Beer TM. Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. *Eur J Cancer.* 2022 Jul;170:285-295.
- 282) Roalf DR, Berlow YA, Lebow MR, Salat DH, Beer TM, Janowsky JS. Androgen deprivation results in white matter loss as shown by diffusion tensor imaging. (submitted)
- 283) Garzotto M, Mongoue-Tchokote S, Collins L, Priest R, Spurgeon S, Peters LM, Beer TM, Mori M. Nomogram For The Prediction Of Gleason ≥ 7 Prostate Cancer in Men With a PSA of ≤ 10 ng/ml. (in preparation)
- 284) Luk BV, Nail LM, Perrin NA, Beer TM, Tolle SW, Lasarev M, Hall K, Kenworthy-Heinige T, Fromme EK. Do printed symptom reports influence clinical management? A longitudinal controlled trial of patient-reported outcomes in patients receiving chemotherapy. (in preparation)

Abstracts

- 1) Mawe GM, Beer TM, and Gershon MD. Cytochrome Oxidase Histochemistry: a Tool for the Study of the Ontogeny of Enteric Neuronal Activity. FASEB Summer Conference, Saxton River, Vermont; 1985.
- 2) Beer TM and Henner WD. Pulse Dosing Allows Substantial Dose Escalation of Calcitriol: a Phase I Clinical Trial in Advanced Malignancies. *Proceedings of the AACR 40: 84, 1999.*
- 3) A Einstein Jr, R Lush, R Rago, Y-j Ko, G Bublely, WD Henner, T Beer, G Chatta, R Shepard, P Unger, EA Merica, E Ette, MW Harding, and WS Dalton. A Phase II Study of Safety, Pharmacokinetics and Efficacy in Incel (biricodar, VX-710) in Combination with Mitoxantrone (M) and Prednisone (P) in Hormone Refractory Prostate Cancer (HRPC). Abstract #531, *Proceedings of the 1999 AACR · NCI · EORTC International Conference, Clinical Cancer Research, Vol. 5 (Supplement), 1999.*
- 4) Einstein A Jr, Lush R, Rago R, Ko Y-j, Bublely G, Henner WD, Beer TM, Chatta G, Shepard R, Unger P, Merica EA, Ette E, Harding MW, and Dalton WS. A Phase II Study of Safety, Pharmacokinetics and Efficacy in Incel (Biricodar, VX-710) in Combination with Mitoxantrone (M) and Prednisone (P) in Hormone Refractory Prostate Cancer (HRPC). *CaPCure Annual Scientific Retreat, October 1999, Lake Tahoe, NV.*
- 5) Beer TM, Evans AJ, Lowe BA, and Henner WD. Glutathione S-Transferase Pi Polymorphism hGSTP*B and the Risk of Prostate Cancer. *Proceedings of the AACR 41: 359, 2000.*
- 6) Henner WD, Evans AJ, Hough KM, Beer TM, and Lowe BA. The Pro/Pro genotype at position 72 in p53 is protective against the development of adenocarcinoma of the prostate. *Proceedings of the AACR 41: 596, 2000.*
- 7) TM Beer, WC Pierce, BA Lowe, and WD Henner. Phase II Study of Weekly Docetaxel (Taxotere®) in Hormone Refractory Metastatic Prostate Cancer (HRPC). *Proc Am Soc Clin Onc 19:348a, 2000.*
- 8) RP Rago, AB Einstein Jr, RM Lush III, Y Ko, TM Beer, G Chatta, RC Shepard, P Unger, EA Merica, E Ette, MW Harding, and WS Dalton. A Phase II Study of Safety, Pharmacokinetics and Efficacy in Incel (Biricodar, VX-710) in Combination with Mitoxantrone (M) and Prednisone (P) in Hormone Refractory Prostate Cancer (HRPC). *Proc Am Soc Clin Onc 19: 180a, 2000.*
- 9) TM Beer, KM Hough, M Garzotto, WC Pierce, BA Lowe, and WD Henner. Treatment of Androgen-Independent Prostate Cancer with Weekly High-Dose Calcitriol and

- Docetaxel. Proc Am Soc Clin Onc 20: abstract 2369, 2001.
- 10) Wagner M, Weksler N, Loos J, Beer TM, Barry JM, Garzotto M. Cox-2 expression and effects of selective inhibition in prostate cancer cell lines. Annual Northwest Urological Society Meeting. December 8, 2001.
 - 11) Wagner M, Weksler N, Loos J, Beer TM, Barry JM, Garzotto M. Cox-2 expression and effects of selective inhibition in prostate cancer cell lines. American Urological Assn Meeting, Abstract #542, 167:135, 2002.
 - 12) Beer TM, Garzotto M, O'Hara MF, Lowe BA, Montalto MA, Corless CL, and Henner WD. Randomized study of high-dose pulse calcitriol or placebo prior to prostatectomy. Proc Am Assoc Cancer Res 43:388, 2002.
 - 13) Evans AJ, Henner WD, Eilers KM, Montalto MA, Andersen PE, Cohen JI, Everts EC, McWilliams JE, and Beer TM. Polymorphisms of GSTT1 and Related Genes in Head and Neck Cancer Risk. Proc Am Assoc Cancer Res 43:406, 2002.
 - 14) Beer TM, Hough KM, Garzotto M, Lowe BA, and Henner WD. Androgen-independent prostate cancer (AIPC) treatment with weekly high-dose calcitriol and docetaxel. Proc Am Soc Clin Onc 21:177a, 2002.
 - 15) Lowe BA, Henner WD, Lemmon D, Urankar R, and Beer TM. Long term administration of high dose weekly oral calcitriol in patients with a rising PSA after definitive treatment for prostate cancer (PC): a phase II study. Proc Am Soc Clin Onc 21:158b, 2002.
 - 16) Garzotto M, Beer TM, Lowe BA, Ellis WJ, Lange PA, Montalto MA, and Higano CS. Neoadjuvant weekly docetaxel and mitoxantrone in patients with high risk localized prostate cancer: a phase I trial. Proc Am Soc Clin Onc 21:155b, 2002.
 - 17) Beer TM, Eilers KM, Garzotto M, Lowe BA, and Henner WD. Calcitriol and Docetaxel Treatment for Metastatic Androgen-Independent Prostate Cancer, Cancer Investigation 21 (Suppl. 1):61-62, 2002.
 - 18) Beer TM, El-Geneidi M, Panagiotou I, Peters L, Hsieh Y-C, Mori M, and Garzotto M, Delayed curative therapy in patients who initially choose watchful waiting in the PSA era. J Urol 169(4 Suppl):492, 2003 (Abstract 1844)
 - 19) Beer TM, Garzotto M, Lowe BA, Ellis WJ, Lange PA, Montalto MA, and Higano CS. Weekly docetaxel and mitoxantrone prior to prostatectomy in patients with high risk localized prostate cancer. J Urol 169(4 Suppl):444, 2003 (abstract 1662)
 - 20) Garzotto M, Panagiotou I, Hsieh Y-C, Mori M, Peters L, Klein T and Beer TM. Predictors of Delayed Prostate Cancer-Directed Intervention in Watchful Waiting Patients in the PSA Era. J Urol 169(4 Suppl):460, 2003 (abstract 1724)
 - 21) Myrthue A, Hsieh Y-C, Mori M, O'Hara MF, Chin R, Yates J, Garzotto M, and Beer TM. DNA Microarray: pooling of RNA versus pooling of gene expression data in the analysis of human prostate cancer specimens. Proc Am Assoc Cancer Res 44:804, 2003.
 - 22) Hoffelt SC, Marshall LM, Garzotto M, Hung A, Holland J, Beer TM. A Comparison of CT scan to Transrectal Ultrasound-Measured Prostate Volume in Untreated Prostate Cancer. American Radium Society 2003
 - 23) Beer TM, Javle M, Whitehouse MJ, and Trump DL. Phase I Study and Pharmacokinetic (PK) Evaluation Of DN-101, a New Formulation of Calcitriol. Proc Am Soc Clin Onc 22:231, 2003.
 - 24) Berry W and Beer TM. Efficacy and toxicity of weekly docetaxel in the elderly, a pooled comparison of outcome in men with androgen independent prostate cancer (AIPC) \geq 70 vs $<$ 70 years of age. Proc Am Soc Clin Onc 22:745, 2003.
 - 25) Tiffany NM, Wersinger EM, Garzotto M, and Beer TM. Androgen-independent prostate cancer (AIPC) treatment with zoledronic acid and imatinib mesylate (STI-571). Proc Am Soc Clin Onc 22:421, 2003.
 - 26) Wersinger EM, Garzotto M, Henner WD, Eilers KM, and Beer TM. Intermittent Chemotherapy in Metastatic Androgen-Independent Prostate Cancer. Proc Am Soc Clin Onc 22:394, 2003.
 - 27) Eilers KM, Garzotto M, Henner WD, and Beer TM. Palliative activity of weekly high-dose calcitriol and docetaxel in androgen-independent prostate cancer (AIPC). Proc Am Soc Clin Onc 22:412, 2003.

- 28) Garzotto M, Beer TM, Peters L, Klein T, Hsieh Y-C, and Mori M. Improved Detection of Prostate Cancer using Classification and Regression Tree (CART) Analyses. *Proc Am Soc Clin Onc* 22:398, 2003.
- 29) Beer TM, Eilers KM, Garzotto M, Lowe BA, and Henner WD. Androgen-Independent Prostate Cancer (AIPC) Treatment with Weekly High-Dose Calcitriol (C) and Docetaxel (D). North Central Section of the AUA, 2003.
- 30) Myrthue A, Hsieh Y-C, Mori M, O'Hara MF, Chin R, Yates J, Garzotto M, and Beer TM. DNA Microarray: Pooling of RNA Versus Pooling of Gene Expression Data in the Analysis of Human Prostate Cancer Specimens. Western Section of the AUA, 2003
- 31) Bland LB, Tangen C, Crawford ED, and Beer TM. Anemia Is An Independent Adverse Prognostic Factor in Untreated Metastatic Prostate Cancer: An Analysis of SWOG 8894. Western Section of the AUA, 2003.
- 32) Garzotto M, Lowe BA, Ellis WJ, Lange PA, Montalto MA, and Higano CS, and Beer TM. Neoadjuvant Docetaxel and Mitoxantrone Prior to Prostatectomy in Patients with High-Risk Localized Prostate Cancer. Western Section of the AUA, 2003.
- 33) Beer TM, Javle M, Henner WD, and Trump DL. Pharmacokinetics (PK) and Tolerability of DN-101, a new formulation of calcitriol, in patients with cancer. AACR 2004.
- 34) Beer TM, Bland LB, Garzotto M, Ryan CW, Janowsky JS. Effect of High Dose Estrogen May Enhance Memory in Men with Prostate Cancer. *Proc Am Soc Clin Onc* 23:417, 2004.
- 35) Purnell JQ, Bland LB, Garzotto M, Lemmon D, Ryan CW, Beer TM. Transdermal Estrogen Therapy Improves Cholesterol Levels and Lipid Profiles in Men with Prostate Cancer. *Proc Am Soc Clin Onc* 23:734, 2004.
- 36) Bland LB, Tangen CM, Thompson IM, Crawford ED, Beer TM. Prognostic Value of Anemia in Untreated Metastatic Prostate Cancer: A Multivariate Analysis of SWOG 8894. *Proc Am Soc Clin Onc* 23:399, 2004.
- 37) Fromme EK, Eilers KM, Mori M, Hsieh Y-C, Beer TM. How Good is Physician Reporting of Chemotherapy Adverse Effects? A Comparison to Patient-Reported Symptoms From the QLQ-C30. *Proc Am Soc Clin Onc* 23:730, 2004.
- 38) Garzotto M, Mongoue-Tchokote S, Bledsoe J, Parra RO, Peters L, Park Y, Beer TM, Mori M. Predictors of Prostate Cancer in men Undergoing Serial Prostate Biopsies: Results from 371 Patients. *Proc Am Soc Clin Onc* 23:402, 2004.
- 39) Janoff D, Mongoue-Tchokote S, Peterson C, Parra RO, Peters L, Park Y, Beer TM, Mori M, Garzotto M. Outcomes of Androgen Deprivation as Sole Therapy for Localized Prostate Cancer. *Proc Am Soc Clin Onc* 23:412, 2004.
- 40) Brouns M, Beer TM, Ganzini L. Interest In Physician-Assisted Suicide (PAS) Among Oregon Cancer Patients. *Proc Am Soc Clin Onc* 23:743, 2004.
- 41) Spurgeon S, Riavadeneira A, Peters LM, Hsieh Y-C, Beer TM, Mori M, Garzotto M. Prediction of Aggressive Prostate Cancer on Biopsy Using Classification and Regression Tree Analysis (CART). *Proc Am Soc Clin Onc* 23:435, 2004.
- 42) Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, Beer TM. High-Dose Calcitriol, Docetaxel, and Estramustine in Androgen-Independent Prostate Cancer (AIPC): A Phase I/II Study. *Proc Am Soc Clin Onc* 23:424, 2004.
- 43) Higano CS, Beer TM, Garzotto M, Ryan CW, Pitzel M, Works CR, Hall SP. Need for Awareness and Monitoring of Ocular Toxicities (OT) Due to weekly Docetaxel Administration: Experience During a Trial of Neoadjuvant Docetaxel (D) and Mitoxantrone (M) for Patients with High-Risk Prostate Cancer (PC). *Proc Am Soc Clin Onc* 23:399, 2004.
- 44) Rosenbaum E, Kibel A, Roth BJ, Wilding G, Dreicer R, Chatta G, Petrylak D, Dipaola RS, Beer TM, Eisenberger MA. Adjuvant weekly docetaxel for high-risk prostate cancer patients after radical prostatectomy: Preliminary data of a multicenter pilot trial. *Proc Am Soc Clin Onc* 23:417, 2004.
- 45) Nelson PS, Huang A, True LD, Garzotto M, Wersinger EM, O'Brien CA, Ryan CW, Ellis WJ, Lange PH, Higano CS, Beer TM. Molecular Correlates of Prostate Cancer Response and Resistance to Neoadjuvant Mitoxantrone and Docetaxel. *InterProstate*

- SPORE Meeting, Jan: 26, 2005.
- 46) Sweeney C, Dobrolecki L, Beer T, Battiato L, Vinson J, Hickey R. Serum proteomic profiling can distinguish androgen sensitive prostate cancer patients from those with androgen resistant disease. *Proc Prost Ca Symp* 1:135, 2005
 - 47) Garzotto M, Collins L, Park Y, Mongoue-Tchokote S, Bledsoe J, Peters L, Blank BH, Beer TM, Mori M. PSA doubling time for the prediction of aggressive prostate cancer on repeat biopsy. *Proc Multidisciplinary Prostate Cancer Symposium* 1:64, 2005
 - 48) Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT. Early association between duration of androgen deprivation, life-style factors and bone mineral density in patients with prostate cancer: An analysis during the first 12 months of therapy. *Proc Prost Ca Symp* 1:108, 2005
 - 49) Beer TM, Hayes M, Donovan D, Emmons S, Katovic NM, Benavides M, Ryan CW, Liu G. Acupuncture for hot flashes in prostate cancer patients. *Proc Prost Ca Symp* 1:111, 2005
 - 50) Beer TM, Garzotto M, Lowe BA, Ryan CW, Rarick MU, Ellis WJ, Lange PH, Takayama T, Wersinger EM, Higano CS. Weekly docetaxel and mitoxantrone prior to prostatectomy in patients with high risk localized prostate cancer: Results form 54 patients. *Proc Prost Ca Symp* 1:118, 2005
 - 51) Montgomery B, Lin D, Ryan C, Garzotto M, Beer TM. Diethylstilbestrol and docetaxel; a phase II study in patients with metastatic, androgen independent prostate cancer. *Proc Prost Ca Symp* 1:176, 2005
 - 52) Beer TM, Bland LB, Garzotto M, Purnell JQ, Ryan CW, Deloughery TG, Wersinger EM, Lemmon D. Transdermal estradiol in androgen-independent prostate cancer (AIPC). *Proc Prost Ca Symp* 1:181, 2005
 - 53) Kibel AS, Picus J, Cookson MS, Roth B, Jarrard DF, Wilding G, Klein EA, Dreicer R, Nelson JB, Chatta G, Benson MC, Petrylack DP, DiPaola R, Beer TM, Diamond J, Partin AW, Eisenberger MA. Adjuvant weekly docetaxel for high-risk prostate cancer patients after radical prostatectomy. *J Urol* 173(4):222, 2005
 - 54) Ryan CW, Dezheng H, Stallings JW, Davis RL, Beer TM, McWhorter LT. Early association between duration of androgen deprivation, life-style factors and bone mineral density in patients with prostate cancer: an analysis during the first 12 months of therapy. *J Urol* 173(4):222, 2005
 - 55) Garzotto M, Collins L, Priest R, Spurgeon S, Hsieh YC, Beer TM, Mori M. Nomogram for the prediction of high-grade prostate cancer on ultrasound-guided needle biopsy. *Proc Am Soc Clin Onc* 23 (16S):408s, 2005
 - 56) Spurgeon S, Garzotto M, Collins L, Priest R, Hsieh YC, Peters L, Beer TM, Mori M. Utility of PSA doubling time (PSADT) in the detection of prostate cancer in men with a serum PSA < 10 ng/ml. *Proc Am Soc Clin Onc* 23 (16S):408s, 2005
 - 57) Montgomery B, Lin D, Ryan C, Garzotto M, Beer T. Diethylstilbestrol and docetaxel: a phase II study in patients with metastatic, androgen independent prostate cancer. *Proc Am Soc Clin Onc* 23 (16S):408s, 2005
 - 58) O'Brien CA, Garzotto M, Higano CS, Wersinger EM, Kaimaktchiev V, Corles CL, Lange PH, Ryan CW, True LD, Beer TM. Predictors of early relapse in high risk prostate cancer patients treated with neoadjuvant mitoxantrone and docetaxel. *Proc Am Soc Clin Onc* 23 (16S):408s, 2005
 - 59) Rosenbaum E, Kibel A, Roth B, Wilding G, Dreicer R, Chatta G, Petrylak D, Dipaula RS, Beer TM, Eisenberger M. A pilot multicenter phase II study of adjuvant docetaxel for high risk prostate cancer patients after radical prostatectomy: preliminary data. *Proc Am Soc Clin Onc* 23 (16S):408s, 2005
 - 60) Hayes M, Katovic NM, Donovan D, Emmons S, Benavides M, Montalto M, Ryan CW, Liu G, Beer TM. Acupuncture for hot flashes in prostate cancer patients. *Proc Am Soc Clin Onc* 23 (16S):408s, 2005
 - 61) Beer TM, Ryan CW, Venner PM, Petylak DP, Chatta G, Ruether JD, Henner WD, Chi KN, Cruickshank S. Interim results from ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-

- independent prostate cancer (AIPC). Proc Am Soc Clin Onc 23 (16S):408s, 2005
- 62) Beer TM, Ryan CW, Venner P, Petrylak D, Chatta G, Ruether J, Chi K, Arroyo A, Clow F. ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC). Proc Euro Cancer Conf 2005.
- 63) Beer TM, Higano CS. Darbepoetin administered every 4 weeks for anemia in advanced prostate cancer patients. Proc Prost Ca Symp 2006.
- 64) Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic acid (ZA) initiated during the first year of androgen deprivation therapy (ADT) increases bone mineral density (BMD) and suppresses bone turnover markers in prostate cancer patients. Proc Prost Ca Symp 2006.
- 65) Beer TM, Ryan CW, Venner P, Petrylak DP, Chatta G, Ruether JD, Chi KN. Intermittent chemotherapy in metastatic androgen-independent prostate cancer (AIPC): Initial results from ASCENT. Proc Prost Ca Symp 2006.
- 66) Chan JS, Beer TM, Quinn DI, Garzotto M, Sokoloff M, Ryan CW. Phase II study of DN-101 (high dose calcitriol), mitoxantrone, and prednisone in androgen-independent prostate cancer (AIPC). Proc Prost Ca Symp 2006.
- 67) Venner PM, Ryan CW, Petrylak DP, Chatta G, Ruether JD, Chi KN, Curd J, Beer TM. Reduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: hypothesis for a new class of anticoagulants. Proc Prost Ca Symp 2006.
- 68) Montgomery B, Lin DW, Ryan CW, Garzotto M, Beer TM. Diethylstilbestrol and docetaxel: A phase II study in patients with metastatic, androgen-independent prostate cancer. Proc Prost Ca Symp 2006.
- 69) Graff J, Mori M, Li H, Garzotto M, Penson D, Potosky AL, Beer TM. Predictors of overall (OS) and cancer-specific survival (CSS) in patients with clinically localized prostate cancer treated with primary androgen deprivation therapy: Results from PCOS. Proc Prost Ca Symp 2006.
- 70) O'Brien CA, True LD, Higano CS, Garzotto M, Takayama T, Ellis WJ, Lange PH, Katovic NM, Ryan CW, Beer TM. Histologic patterns in radical prostatectomy (RP) specimens of high-risk prostate cancer patients treated with neoadjuvant chemotherapy are predictive of nodal metastases. Proc Prost Ca Symp 2006
- 71) Venner PM, Ryan C, Petrylak DP, Chatta GS, Ruether J, Chi KN, Curd J, Beer TM. Reduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: hypothesis for a new class of anticoagulants. Proc Am Soc Clin Onc 24 (18S): 218s, 2006
- 72) Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta G, Ruether J, Chi KN, Arroyo A, Clow FW. Intermittent chemotherapy in metastatic androgen-independent prostate cancer (AIPC): Initial results from ASCENT. Proc Am Soc Clin Onc 24 (18S): 221s, 2006
- 73) Ryan CW, Goldman BH, Lara PN, Beer TM, Drabkin HA, Crawford E. Sorafenib plus interferon- α 2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. Proc Am Soc Clin Onc 24 (18S): 223s, 2006
- 74) Graff J, Mori M, Li H, Garzotto M, Penson D, Potosky A, Beer TM. Predictors of overall and cancer-specific survival in patients with clinically localized prostate cancer (PC) treated with primary androgen deprivation therapy (PADT): Results from the Prostate Cancer Outcomes Study. Proc Am Soc Clin Onc 24 (18S): 244s, 2006
- 75) Chan JS, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether J, Chi KN, Young J, Shen C, Beer TM. Skeletal related events (SREs) in metastatic androgen independent prostate cancer (AIPC) treated with docetaxel-based chemotherapy: Results from ASCENT. Proc Am Soc Clin Onc 24 (18S): 245s, 2006
- 76) Garzotto M, Mongoue-Tchokote S, Shannon J, Peters L, Sokoloff MH, Beer TM. Effect of obesity on PSA density (PSAD): A new clinical predictor of prostate cancer. Proc Am Soc Clin Onc 24 (18S): 245s, 2006
- 77) Montgomery B, Lin D, Ryan C, Garzotto M, Beer TM. Diethylstilbestrol and docetaxel: A

- phase II study in patients with metastatic androgen independent prostate cancer. Proc Am Soc Clin Onc 24 (18S): 248s, 2006
- 78) O'Brien CA, Mongoue-Tchokote S, Collins L, Spurgeon S, Peters L, Beer TM, Mori M, Garzotto M. Assessment of PSA and digital rectal examination (DRE) for the detection of Gleason ≥ 7 prostate cancer in a referral population. Proc Am Soc Clin Onc 24 (18S): 249s, 2006
 - 79) Oh WK, Manola J, Ross RW, Berkowitz A, Ryan CW, Eilers KM, Beer TM. A phase II trial of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy: Preliminary results. 639s Proc Am Soc Clin Onc 24 (18S): 639s, 2006
 - 80) Beer TM, Lalani AS, Lee S, Eilers KM, Curd JG, Henner WD, Ryan CW, Venner PM, Ruether JD, Chi KN. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer (AIPC): Results from the ASCENT trial. Proc Prost Ca Symp: 181, 2007
 - 81) Oh WK, Jacobus S, Ross R, Inman M, Taplin M, Ryan C, Eilers K, Beer T. A phase II trial of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy. Proc Prost Ca Symp: 190, 2007
 - 82) Rogosin S, Mongoue-Tchkote S, Beer TM, Mori M, Collins L, Garzotto M. PSA density as a predictor of aggressive prostate cancer on repeat prostate biopsy. Proc Prost Ca Symp: 74, 2007
 - 83) Rosenberg JE, Weinberg VK, Beer T, Beekman KW, Mathew P, Hutcheon D, Small EJ. NCI 7347: Phase I/II trial of epothilone analog BMS-247550 (ixabepilone), mitoxantrone, and prednisone in hormone refractory prostate cancer patients previously treated with chemotherapy. Proc Prost Ca Symp: 204, 2007
 - 84) Scher HI, Halabi S, Tannock I, Morris M, Higano C, Beer T, Sternberg C, Eisenberger M, Martin A, Maha H. The prostate cancer clinical trials working group (PCCTWG) consensus for phase II trials in metastatic castration-resistant prostate cancer. Proc Prost Ca Symp: 182, 2007
 - 85) Zurita AJ, Shore N, Kozloff M, Ryan CW, Beer TM, Maneval EC, Chen I, Logothetis C. Phase I study of sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone refractory prostate cancer (mHRPC). Proc Prost Ca Symp: 186, 2007
 - 86) Zurita AJ, Shore ND, Kozloff MF, Ryan CW, Beer TM, Chow Maneval E, Chen I, Logothetis CJ. A phase I/II study of sunitinib in combination with docetaxel (dcx) and prednisone (pdn) in patients with metastatic castrate-resistant prostate cancer (mCRPC). Proc ECCO 14 Conf: 1043, 2007
 - 87) Rogosin S, Collins L, Mongoue-Tchokote S, Blank BH, Beer TM, Mori M, Garzotto M. PSA density as a predictor of aggressive prostate cancer on repeat prostate biopsy. Proc Am Soc Clin Onc: 25 (18S): 236s, 2007
 - 88) Beer TM, Bernstein GT, Corman JM, Glode ML, Hall S, Poll WL, Schellhammer PF, Xu Y, Yu L, Frohlich MW. Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC). Proc Am Soc Clin Onc: 25 (18S): 249s, 2007
 - 89) Graff J, Lalani AS, Lee S, Curd JG, Henner WD, Ryan CW, Venner PM, Ruether JD, Chi KN, Beer TM. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer (AIPC): Results from the ASCENT trial. Proc Am Soc Clin Onc: 25 (18S): 253s, 2007
 - 90) Goldman BH, Lara Jr PN, Beer TM, Mack PC, Drabkin HA, Holland WS, Crawford E, Ryan CW. Clinical and molecular factors predictive of outcome with first-line sorafenib-based therapy in advanced renal carcinoma (RCC): An analysis of SWOG 0412. Proc Am Soc Clin Onc: 25 (18S): 261s, 2007
 - 91) Zurita AJ, Shore ND, Kozloff MF, Ryan CW, Beer TM, Maneval EC, Chen I, Logothetis CJ. Distinct patterns of PSA modulation by single-agent sunitinib before combination with docetaxel and prednisone in patients with metastatic castrate-resistant prostate

- cancer (CRPCa). Proc Am Soc Clin Onc: 25 (18S): 268s, 2007
- 92) Schnadig ID, Fromme EK, Loprinzi CL, Sloan JA, Mori M, Li H, Beer TM, Perrin N. Prognostic significance of patient-physician disagreement about performance status in patients with advanced cancer. Proc Am Soc Clin Onc: 25 (18S): 498s, 2007
 - 93) Lopez CD, Beer T, Todd K, Blanke CD. A phase II trial of high-dose calcitriol and docetaxel in patients with untreated, incurable pancreatic adenocarcinoma. Proc Am Soc Clin Onc: 25 (18S): 641s, 2007
 - 94) Garzotto M, Janeba N, Eilers KM, Sekhon H, Beer TM. Pre-prostatectomy study of the effect of celecoxib versus placebo on androgen receptor (AR) expression in prostate cancer. Proc Am Soc Clin Onc: 25 (18S): 652s, 2007
 - 95) Chan JS, Vuky J, Besaw LA, Beer TM, Ryan CW. A phase II study of mammalian target of rapamycin (mTOR) inhibitor RAD001 plus imatinib mesylate (IM) in patients with previously treated advanced renal carcinoma (RCC). Proc Am Soc Clin Onc: 25 (18S): 657s, 2007
 - 96) Weinberg VK, Beekman K, Hutcheon D, Beer T, Rosenberg JE, Small EJ. NCI 7347: Phase 1/2 Trial of Epothilone Analog BMS-247550 (Ixabepilone), Mitoxantrone, and Prednisone in Hormone Refractory Prostate Cancer Patients Previously Treated with Chemotherapy: Results of a DOD Prostate Cancer Therapy Consortium Trial. Proc IMPaCT: 70(S36-1), Sept 2007
 - 97) Zurita AJ, Shore ND, Kozloff MF, Ryan CW, Maneval EC, Chen I, Logothetis CJ, Beer TM. Phase 1 Study of Sunitinib in Combination with Docetaxel and Prednisone in Metastatic Castrate-resistant Prostate Cancer (CRPC). Proc IMPaCT: 71(S36-4), Sept 2007
 - 98) Krause MA, Beer TM, Janowsky JS. The Brain Basis of Memory Loss with Androgen Deprivation Therapy: Methods Development and Preliminary Findings. Proc IMPaCT: 101(P2-10), Sept 2007
 - 99) Higano C, Lange PH, True L, Beer TM, Garzotto M, Huang CY, Nelson PS, Vessella R. Targeting Mechanisms of Resistance to Taxane-based Chemotherapy. Proc IMPaCT: 174(P13-2), Sept 2007
 - 100) Harzstark AL, Weinberg VK, Sharib J, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Ryan CJ, Small EJ, Rosenberg JE. Second-line combination chemotherapy: A phase I trial of ixabepilone, mitoxantrone, and prednisone in patients with metastatic hormone refractory prostate cancer (HRPC) previously treated with chemotherapy. Proc GU Ca Symp: 178, Abstract #166, Feb 2008
 - 101) Ryan CW, Curti BD, Pattee KJ, Besaw L, Beer TM, Fisher B. A dose-escalation phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC). Proc GU Ca Symp: 273, Abstract #361, Feb 2008
 - 102) Farha GN, Taioli E, Cauley JA, Zmuda JM, Orwoll E, Bauer DC, Wilt TJ, Hoffman AR, Beer TM, Shikany JM, Daniels N, Chan J, Fink HA, Barrett-Connor E, Parsons JK, Bunker CH. The Association of Bone Mineral Density with Prostate Cancer Risk: the Osteoporotic Fractures in Men (MrOS) Study. Proc AACR: 3849, Apr 2008
 - 103) Scher HI, Beer T, Higano CS, Danila DC, Shelkey J, Hirmand M, Hung D, Morris MJ, Larson SM, Sawyers CL. Phase I/II study of the androgen receptor antagonist MDV3100 in castration-resistant prostate cancer. Proc AACR: LB-203, Apr 2008
 - 104) Beer TM, Slovin SF, Higano CS, Tejwani S, Dorff TB, Stankevich E, Lowy I. Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC). Proc Am Soc Clin Onc: 26(15S): 251s, Jun 2008
 - 105) Scher HI, Beer TM, Higano CS, Danila DC, Montgomery B, Shelkey J, Hirmand M, Hung D, Sawyers C. Phase I/II study of MDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC). Proc Am Soc Clin Onc: 26(15S): 251s, Jun 2008
 - 106) Taplin M, Ko Y, Regan MM, Beer TM, Carducci MA, Mathew P, Bublely G, Oh WK, Kantoff PW, Balk SP. Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC). Proc Am Soc Clin Onc: 26(15S): 266s, Jun 2008

- 107) Graff J, Smith DC, Neerukonda L, Alonso M, Jones GR, Beer TM. Phase II study of sagopilone (ZK-EPO) plus prednisone as first-line chemotherapy in patients with metastatic androgen-independent prostate cancer (AIPC). *Proc Am Soc Clin Onc*: 26(15S): 284s, Jun 2008
- 108) Harzstark AL, Weinberg VK, Sharib J, Smith DC, Hussain MH, Beer TM, Ryan CW, Mathew P, Ryan CJ, Small EJ, Rosenberg JE. Second-line combination chemotherapy: A phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic hormone-refractory prostate cancer (HRPC) refractory to docetaxel-based therapy. *Proc Am Soc Clin Onc*: 26(15S): 287s, (Suppl abstract5069) Jun 2008
- 109) Fromme E, Nail L, Tolle S, Perrin N, Kenworthy-Heinige T, Beer TM. Using tablet computers to collect clinical and research data: Ease-of-use analysis. *Proc Am Soc Clin Onc*: 26(15S): 732s, Jun 2008
- 110) Beer TM, Smith DC, Hussain A, Alonso M, Neerukonda L, Hauke R, Giurescu M, Wang Y. Phase II study of first-line sagopilone combined with prednisone in patients with metastatic androgen-independent prostate cancer. *Proc Euro Soc Med Onc*: 438, Sept 2008
- 111) Scher H, Beer T, Higano C, Logothetis C, Shelkey J, Hung D, Hirmand M, Larson S, Fleisher M, Sawyers C. Phase I-II study of MDV3100 in castration resistant prostate cancer. The Prostate Cancer Clinical Trials Consortium. *Proc EORTC-NCI-AACR Symp*: 160, 2008
- 112) Scher HI, Beer TM, Higano CS, Logothetis C, Anand A, Hirmand M, Hung D, Larson S, Fleisher M, Sawyers C. Phase I-II study of MDV3100 in castration-resistant prostate cancer (CRPC). *Proc 2009 GU Ca Symp*: 151, Feb 2009
- 113) Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Smith DC, Mathew P, Beer TM, Liu G, Small EJ. A phase II study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castrate-resistant prostate cancer (CRPC) refractory to docetaxel-based therapy. *Proc 2009 GU Ca Symp*: 160, Feb 2009
- 114) Basch EM, Burke L, Kane R, Carducci M, Beer TM, George D, Fruscione M, Sit L, Morris M, Scher HI. Prevalence and severity of pain in men with metastatic prostate cancer. *Proc 2009 GU Ca Symp*: 205, Feb 2009
- 115) Li X, Priest RA, Siddiqui F, Beer TM, Garzotto MG, Woodward WJ, Rooney WD, Springer CS. Systematic DCE-MRI Parameter Errors Caused by Disproportionate Transverse Relaxation (T2*) Quenching of Tissue Compartmental Water Proton Signals. *Proc ISMRM 2009 An Mtg*: 6836, Apr 2009
- 116) Graff JN, Rademacher BLS, Qian DZ, Beer TM. C-reactive protein-induced docetaxel resistance in prostate cancer. *Proc 100th Ann Mtg AACR*: Abstr 3876, Apr 2009
- 117) Wu M, Huang CY, Sim HG, Higano CS, True LD, Vessella R, Lange PH, Garzotto M, Beer TM, Nelson PS. Chemotherapy-induced monoamine oxidase A expression in prostate carcinoma associates with clinical outcome and functions as a cytoprotective resistance enzyme through HIF1 pathway. *Proc 100th Ann Mtg AACR*: Abstr 5524, Apr 2009
- 118) Scher HI, Beer T, Higano C, Efstathiou E, Anand A, Hirmand M, Hung D, Larson S, Fleisher M, Sawyers C. Clinical study of MDV3100 in progressive castration-resistant prostate cancer (CRPC). *Proc 2009 AUA Ann Mtg*: 181: 230: Abstr 641, Apr 2009
- 119) Scher HI, Beer TM, Higano CS, Taplin M, Efstathiou E, Anand A, Hung D, Hirmand M, Fleisher M. Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC). *Proc 2009 ASCO Ann Mtg*: 27(15S): Abstr 5011, May 2009
- 120) Small E, Harzstark A, Weinberg VK, Smith DC, Mathew P, Beer T, Liu G, Sharib J, Rosenberg J. Ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer refractory to docetaxel-based therapy: A phase II study of the DOD Prostate Cancer Clinical Trials Consortium. *Proc 2009 ASCO Ann Mtg*: 27(15S): Abstr 5058, May 2009
- 121) Beer TM, Smith DC, Hussain A, Alonso M, Wang J, Giurescu M, Wang Y. Phase II study of first-line sagopilone combined with prednisone in patients with metastatic castration-resistant prostate cancer (CRPC). *Proc 2009 ASCO Ann Mtg*: 27(15S): Abstr 5059, May

- 2009
- 122) Rademacher BL, Garzotto M, Higano CS, O'Brien CA, Janeba N, Fazli L, Lange PH, Lieberman S, Beer TM. Five-year relapse-free survival and predictors of relapse following preoperative docetaxel and mitoxantrone for high-risk localized prostate cancer. Proc 2009 ASCO Ann Mtg: 27(15S): Abstr 5121, May 2009
 - 123) Lin J, Beer TM, Ryan CJ, Mathew P, Wilding G, Morris M, Callahan JA, Gordon G, Reich S, Carducci MA. A randomized, phase II study of ATN-224 in patients with biochemically relapsed, hormone-naive prostate cancer: A DOD/PCF Prostate Cancer Clinical Trials Consortium trial. Proc 2009 ASCO Ann Mtg: 27(15S): Abstr 5135, May 2009
 - 124) Slovin SF, Beer TM, Higano CS, Tejwani S, Hamid O, Picus J, Harzstark A, Scher HI, Lan Z, Lowy I. Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC). Proc 2009 ASCO Ann Mtg: 27(15S): Abstr 5138, May 2009
 - 125) Higano C, Alumkal J, Ryan CJ, Yu EY, Beer TM, Chandrawansa K, Katz T, Youssoufian H, Schwartz J. A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody (MAb), against the insulin-like growth factor-1 receptor (IGF-IR), as monotherapy in patients with metastatic, asymptomatic castration-resistant prostate cancer (CRPC). Proc 2009 ASCO Ann Mtg: 27(15S): Abstr 5142, May 2009
 - 126) Prins R, Rademacher BL, Mongoue-Tchokote S, Eilers KM, Beer TM. C-reactive protein as adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results. Proc 2009 ASCO Ann Mtg: 27(15S): Abstr 5168, May 2009
 - 127) Vinson J, Mathew P, Beer TM, Carducci MA, Oh W, Small E, Wilding G, Higano C, Hussain M, Scher HI. Prostate cancer clinical trials consortium: A multicenter mechanism for the rapid design, development, and implementation of early phase clinical trials. Proc 2009 ASCO Ann Mtg: 27(15S): Abstr e16065, May 2009
 - 128) Ryan CW, Vuky J, Chan JS, Beer TM, Rothkopf M. Phase II study of everolimus (E) with imatinib (IM) in patients with previously-treated renal carcinoma (RCC). Proc 2009 ASCO Ann Mtg: 27(15S): Abstr e16075, May 2009
 - 129) Hayes M, Reeder C, Beer TM. Acupuncture for hot flashes for prostate cancer patients. Proc 2009 ASCO Ann Mtg: 27(15S): Abstr e16125, May 2009
 - 130) Basch EM, Sit L, Fruscione M, Burke L, Kane R, George D, Carducci MA, Matthew P, Beer TM, Scher HI. Pain and analgesic use in men with metastatic prostate cancer. Proc 2009 ASCO Ann Mtg: 27(15S): Abstr e20515, May 2009
 - 131) Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro L, Beer T, Liu G, Mathew P, Lin AM, Fong L, Small EJ. Ixabepilone, Mitoxantrone, and Prednisone for Metastatic Castrate Resistant Prostate Cancer (CRPC) After Docetaxel-Based Therapy - A Phase 2 Study of the Department of Defense Prostate Cancer Clinical Trials Consortium. Proc 16th Ann PCF Sci Retreat: Abstr 34, Sept 2009
 - 132) Scher H, Beer T, Higano C, Danila D, Montgomery B, Shelkey J, Hirmand M, Hung D, Anand A, Fleisher M, Sawyers C. Antitumor activity of MDV3100 in a phase 1-2 trial in castration resistant prostate cancer conducted by the Prostate Cancer Clinical Trials Consortium. Proc 16th Ann PCF Sci Retreat: Abstr 92, Sept 2009
 - 133) Vinson J, Morris M, Beer T, Carducci M, Corn P, DiPaola R, George D, Heath E, Higano C, Hussain M, Kantoff P, Small E, Stadler W, Wilding G, Slovin S, Rathkopf D, Warren M, Scher HI. The Prostate Cancer Clinical Trials Consortium (PCCTC): A collaborative multicenter prostate cancer research model. Proc 16th Ann PCF Sci Retreat: Abstr 93, Sept 2009
 - 134) Young LA, Lebow MR, Roalf DR, Beer TM, Janowsky JS. Prefrontal activity does not reflect androgen deprivation induced memory impairment. Proc Neuroscience 2009, Oct 2009 (submitted)
 - 135) Small EJ, Beer TM, Weinberg VK, Higano CS, Alumkal JJ, Yu EY, Nordquist LT, Rosenberg JE, Sun J, Lin AM. Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the Department of Defense Prostate Cancer Clinical Trials Consortium. Proc 2010 GU Ca Symp: 74: Abstr 41, Mar 2010

- 136) Scher HI, Anand A, Beer TM, Higano CS, Danila DC, Hirmand M, Larson SM, Sawyers CL, Fleisher M, Heller G. Circulating tumor cells (CTC) and prostate-specific antigen (PSA) as response indicator biomarkers in patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100: Toward the development of a biomarker basket. Proc 2010 GU Ca Symp: 107: Abstr 173, Mar 2010
- 137) Higano CS, Alumkal JJ, Ryan CJ, Yu EY, Beer TM, Fox FE, Dontabhaktuni A, Youssoufian H, Schwartz JD. A phase II study of cixutumumab (IMC-A12), a monoclonal antibody (MAb) against the insulin-like growth factor 1 receptor (IGF-IR), monotherapy in metastatic castration-resistant prostate cancer (mCRPC): Feasibility of every 3-week dosing and updated results of every 2-week dosing. Proc 2010 GU Ca Symp: 111: Abstr 189, Mar 2010
- 138) Scher HI, Beer TM, Higano CS, Logothetis C, Taplin ME, Efstathiou E, Hirmand M. Antitumor activity of MDV3100 in a phase 1-2 study of advanced prostate cancer. Proc 2010 Amer Urol Assoc Ann Mtg: 183(4):e227, Abstr 580, Apr 2010
- 139) Hall SJ, Schellhammer PF, Higano CS, Corman JM, Beer TM, Small EJ, Pantuck AJ, Kassabian VS, Stewart FP, Sims RB. Integrated safety results for four randomized, double-blind, placebo-controlled studies of sipuleucel-T. Proc 2010 Amer Urol Assoc Ann Mtg: 183(4): e263, Abstr 674, Apr 2010
- 140) Geng H, Beer T, Nelson P, Qian D. A novel role for ID1 in prostate cancer chemotherapy. Proc 101st Ann Mtg AACR: Abstr 5775, Apr 2010
- 141) Tagge I, Priest RA, Beer TM, Garzotto MG, Woodward WJ, Huang W, Springer CS, Li X. Population-Generalized vs. Individual-Specific AIF in Human Prostate DCE-MRI Pharmacokinetic Analysis. Proc ISMRM-ESMRMB Joint Ann Mtg: 18: Abstr 2738, May 2010
- 142) Priest RA, Li X, Tagge IJ, Woodward WJ, Beer TM, Springer CS, Garzotto MG. Multi-Slice Parametric Mapping in Prostate DCE-MRI. Proc ISMRM-ESMRMB Joint Ann Mtg: 18: Abstr 2809, May 2010
- 143) Garzotto M, Hung A, Beer TM, Farris PE. Phase I/II study of preoperative intensity-modulated radiation therapy (IMRT) and docetaxel for high-risk prostate cancer: A platform for radiosensitizer development. Proc 2010 ASCO Ann Mtg: 28(15S): 43s; Abstr TPS250, May 2010
- 144) Ryan CW, Curti BD, Quinn DI, Strother JM, Chen Z, Roberson E, Beer TM, Nauman D. A phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC). Proc 2010 ASCO Ann Mtg: 28(15S): 348s; Abstr 4528[^], May 2010
- 145) Anand A, Scher HI, Beer TM, Higano CS, Danila DC, Taplin M, Efstathiou E, Hirmand M, Sawyers CL, Heller G. Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100. Proc 2010 ASCO Ann Mtg: 28(15S): 353s; Abstr 4546, May 2010
- 146) Beer TM, Rademacher BL, Geng H, Pittsenbarger J, Garzotto M, Nelson P, Higano CS, Qian DZ. Effect of ID1 expression change following chemotherapy on chemotherapy sensitivity. Proc 2010 ASCO Ann Mtg: 28(15S): 353s; Abstr 4548, May 2010
- 147) Fleming MT, Kolodziej MA, Awasthi S, Hutson TE, Martincic D, Sonpavde G, Wang Y, Boehm KA, Asmar L, Beer TM. Results of a randomized phase II study of mitoxantrone versus mitoxantrone with cetuximab in metastatic castrate-resistant prostate cancer (CRPC) previously treated with docetaxel-based chemotherapy. Proc 2010 ASCO Ann Mtg: 28(15S): 355s; Abstr 4555, May 2010
- 148) Small EJ, Beer TM, Weinberg VK, Higano CS, Nordquist LT, Rosenberg JE, Alumkal JJ, Yu EY, Sun J, Lin AM. Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium. Proc 2010 ASCO Ann Mtg: 28(15S): 387s; Abstr 4684, May 2010
- 149) Frohlich MW, Hall SJ, Schellhammer PF, Higano CS, Corman JM, Beer T, Small EJ, Pantuck A, Kassabian VS, Sims RB. Integrated safety results from 4 randomized, double-blind, placebo-controlled studies of sipuleucel-T. Proc 35th ESMO Congress:

- 21(8): viii275, Abstr 880P, Oct 2010
- 150) Hirmand M, Scher HI, Beer T, Higano CS, Taplin M, Efstathiou E. Circulating tumor cells (CTC) and prostate-specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100. Proc 35th ESMO Congress: 21(8): viii277, Abstr 884P, Oct 2010
- 151) Anand A, Scher HI, Danila DC, Beer TM, Higano CS, Taplin ME, Efstathiou E, Hirmand M, Sawyers CL, Heller G. Circulating tumor cells (CTC) and prostate-specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve (CN) patients (pts) with progressive castration resistant prostate cancer (CRPC) treated with MDV3100. Proc ASCO-NCI-EORTC Ann Mtg Mol Markers Ca: Abstr 39, Oct 2010
- 152) Harzstark AL, Beer TM, Weinberg VK, Higano CS, Nordquist LT, Rosenberg JE, Alumkal JJ, Yu EY, Mi J, Small EJ. Intermittent chemotherapy (IC) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium. Proc 2011 GU Ca Symp: 29: 7s, Abstr 133, Feb 2011
- 153) Higano CS, Beer TM, Taplin M, Efstathiou E, Anand A, Hirmand M, Fleisher M, Scher HI. Antitumor activity of MDV3100 in pre- and post-docetaxel advanced prostate cancer: Long-term follow-up of a phase I/II study. Proc 2011 GU Ca Symp: 29: 7s, Abstr 134, Feb 2011
- 154) Ferrari AC, Stein MN, Alumkal JJ, Gomez-Pinillos A, Catamero DD, Mayer TM, Collins F, Beer TM, DiPaola RS. A phase I/II randomized study of panobinostat and bicalutamide in castration-resistant prostate cancer (CRPC) patients progressing on second-line hormone therapy. Proc 2011 GU Ca Symp: 29: 7s, Abstr 156, Feb 2011
- 155) Scher HI, Beer TM, Carducci M, Corn P, DiPaola R, George D, Harzstark A, Heath E, Higano C, Hussain M, Morris MJ, Slovin SF, Stadler W, Taplin ME, Wilding G. The Prostate Cancer Clinical Trials Consortium: A Collaborative Multicenter Prostate Cancer Research Model. Proc 2011 Innovative Minds Prost Ca Today (IMPACT) Conf: Abstr P4-3, Mar 2011
- 156) Janowsky J, Beer T. Markers and time course of neurodegenerative risk with androgen deprivation therapy. Proc 2011 Innovative Minds Prost Ca Today (IMPACT) Conf: Abstr P17-3, Mar 2011
- 157) Beer T. MAOA inhibition during docetaxel therapy: A strategy to block tumor adaptation to docetaxel. Proc 2011 Innovative Minds Prost Ca Today (IMPACT) Conf: Abstr P19-33, Mar 2011
- 158) Small E, Lin AM, Beer TM, Weinberg VK, Higano CS, Nordquist L, Rosenberg JE, Alumkal J, Yu EY, Mi J, Harzstark AL. Intermittent Chemotherapy (ICH) for Metastatic Castration-Resistant Prostate Cancer (MCRPC): Results of a Prospective Randomized Phase 2 Trial of The DoD Prostate Cancer Clinical Trials Consortium. Proc 2011 Innovative Minds Prost Ca Today (IMPACT) Conf: Abstr P19-56, Mar 2011
- 159) Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small E. Ixabepilone, Mitoxantrone, and Prednisone for Metastatic Castrate-Resistant Prostate Cancer (CRPC) after Docetaxel-Based Therapy – A Phase II Study of the Department of Defense Prostate Cancer Clinical Trials Consortium. Proc 2011 Innovative Minds Prost Ca Today (IMPACT) Conf: Abstr P19-57, Mar 2011
- 160) Li X, Priest RA, Woodward WJ, Tagge IJ, Siddiqui F, Beer TM, Garzotto MG, Huang W, Rooney WD, Springer CS. Implications of Mean Intracellular Water Lifetime for Prostate DCE-MRI Modeling. Proc 2011 ISMRM Ann Mtg: Abstr 3197, May 2011
- 161) Higano C, Beer T, Yu E, Taplin ME, Efstathiou E, Anand A, Hirmand M, Fleisher M, Scher H. Phase 1-2 study of MDV3100 in pre- and post-docetaxel advanced prostate cancer: Long-term efficacy results. Proc 2011 AUA Ann Mtg: 185(4S): e262, Abstr 647, May 2011
- 162) Flamiatos J, Beer T, Janeba N, Eilers K, Tian W, Garzotto M. Cox-2 inhibition for prostate cancer chemoprevention: Randomized pre-prostatectomy trial of celecoxib versus placebo. Proc 2011 AUA Ann Mtg: 185(4S): e401, Abstr 996, May 2011

- 163) Beer TM, Logothetis C, Sharma P, Gerritsen WR, Ezzeddine R, Fairchild JP, Gagnier P, Chin KM, Cuillerot J. Randomized, double-blind, phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naïve castration-resistant prostate cancer (CRPC). Proc 2011 ASCO Ann Mtg: 29(15S): 27s, Abstr TPS182, Jun 2011
- 164) Beer TM, Schellhammer PF, Corman JM, Glode LM, Hall S, Xu Y, Frohlich MW, Penson DF. Quality-of-life assessment in a randomized, double-blind study of sipuleucel-T in men with androgen-dependent prostate cancer. Proc 2011 ASCO Ann Mtg: 29(15S): 325s, Abstr 4648, Jun 2011
- 165) Garzotto M, Hung A, Beer TM, Alumkal JJ, Graff JN, Farris PE, Flamiatos JF, Mongoue-Tchokote S, Carter SN. Phase I/II study of neoadjuvant docetaxel plus intensity-modulated radiotherapy (IMRT) prior to surgery for high-risk prostate cancer. Proc 2011 ASCO Ann Mtg: 29(15S): 329s, Abstr 4662, Jun 2011
- 166) Berry WR, Fleming MT, Beer TM, Kolodziej MA, Awasthi S, Hutson TE, Martincic D, Wang Y, Asmar L, Sonpavde G. Association of rash with improved outcomes by the addition of cetuximab (C) to second-line mitoxantrone plus prednisone (MP) for progressive mCRPC after docetaxel-based chemotherapy. Proc 2011 ASCO Ann Mtg: online, Abstr e15040, Jun 2011
- 167) Slovin SF, Hamid O, Tejwani S, Higano CS, Harzstark A, Alumkal JJ, Scher HI, Chin KM, Gagnier P, McHenry MB, Beer TM. Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study. Proc 2012 GU Ca Symp: suppl 5, Abstr 25, Feb 2012
- 168) Small EJ, Weinberg VK, Ryan CJ, Higano CS, Lin AM, Maruca Y, Alumkal JJ, Yu EY, Rosenberg JE, Beer TM. A prospective randomized phase II trial evaluating maintenance GM-CSF in an intermittent chemotherapy (chemo) regimen for metastatic castration-resistant prostate cancer (mCRPC): A DoD prostate cancer clinical trials consortium trial. Proc 2012 GU Ca Symp: suppl 5, Abstr 35, Feb 2012
- 169) Tadros NN, Farris PE, Shannon J, Beer TM, Garzotto M. The safety of prostate biopsy procedures in the research setting: A 10-year multicenter experience. Proc 2012 GU Ca Symp: suppl 5, Abstr 87, Feb 2012
- 170) Liu Q, Geng H, Xue C, Beer T, Qian DZ. Malate dehydrogenase 2 confers resistance to docetaxel chemotherapy in prostate cancer through JNK pathway. Proc 103rd Ann Mtg AACR: Abstr 982, Apr 2012
- 171) Li X, Priest RA, Woodward WJ, Tagge IJ, Siddiqui F, Huang W, Rooney WD, Beer TM, Garzotto MG, Springer CS. Feasibility of Assaying Prostate Cancer Disease Burden with Shutter-Speed DCE-MRI. Proc 2012 ISMRM Ann Mtg: Abstr 236, May 2012
- 172) Li X, Priest RA, Woodward WJ, Siddiqui F, Rooney WD, Beer TM, Garzotto MG, Springer CS. Prostate Cancer Shutter-Speed DCE-MRI. Proc 2012 ISMRM Ann Mtg: Abstr 3300, May 2012
- 173) Beer TM, Logothetis C, Sharma P, Bossi A, McHenry B, Fairchild JP, Gagnier P, Chin KM, Cuillerot JM, Fizazi K, Gerritsen WR. CA184-095: A randomized, double-blind, phase III trial to compare the efficacy of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naïve castration-resistant prostate cancer (CRPC). Proc 2012 ASCO Ann Mtg: suppl, Abstr TPS4691, Jun 2012
- 174) Pond GR, Sonpavde G, Choueiri TK, Qu AQ, Vaughn DJ, Fougerey R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Galsky MD, Petrylak DP, Beer TM, Stadler WM, O'Donnell PH, Sternberg CN, Rosenberg JE, Molins JB. Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy. Proc 2012 ASCO Ann Mtg: suppl, Abstr 4522, Jun 2012
- 175) Maughan B, Boucher KM, Agarwal N, Choueiri TK, Qu AQ, Vogelzang NJ, Fougerey R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Beer TM, Sternberg CN, Rosenberg JE, Molins JB, Sonpavde G. Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC). Proc 2012 ASCO Ann Mtg: suppl, Abstr 4525, Jun 2012

- 176) Rathkopf DE, Smith MR, De Bono JS, Logothetis C, Shore ND, De Souza PL, Fizazi K, Mulders P, Mainwaring PN, Hainsworth JD, Beer TM, North SA, Fradet Y, Griffin TW, Park YC, Kheoh TS, Small EJ, Scher HI, Molina A, Ryan CJ. Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy. Proc 2013 GU Ca Symp: suppl 6, Abstr 5, Feb 2013
- 177) Barnett CM, Heinrich MC, Nelson DA, Lim JY, Beadling C, Warrick A, Neff T, Thomas G, Garzotto M, Higano CS, Beer TM, Qian DZ. Genomic analysis of prostate cancer. Proc 2013 GU Ca Symp: suppl 6, Abstr 80, Feb 2013
- 178) Beer TM, Glode LM, Lance R, Greengold R, Sims RB, Wang Y, Sheikh NA, Corman JM. P10-1 open-label, multicenter study of sipuleucel-T in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) previously treated with sipuleucel-T: Evaluation of antigen-presenting cell (APC) activation. Proc 2013 GU Ca Symp: suppl 6, Abstr 147, Feb 2013
- 179) Rathkopf DE, Smith MR, De Bono JS, Logothetis C, Shore N, De Souza PL, Fizazi K, Mulders P, Mainwaring PN, Hainsworth JD, Beer TM, North SA, Fradet Y, Griffin TW, Park YC, Kheoh TS, Small EJ, Scher HI, Molina A, Ryan CJ. Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302). Proc 2013 ASCO Ann Mtg: 31(suppl), Abstr 5009, Jun 2013
- 180) Alumkal JJ, Slottke R, Mori M, Schwartzman J, Graff JN, Beer TM, Ryan CW, Koop DR, Cherala G, Munar M, Flamiatos JF, Gao L, Tucker E. Sulforaphane treatment in men with recurrent prostate cancer. Proc 2013 ASCO Ann Mtg: 31(suppl), Abstr 5017, Jun 2013
- 181) Beer TM, Glode LM, Lance RS, Greengold RH, dela Rosa CP, Sims RB, Wang Y, Sheikh NA, Corman JM. Open-label, multicenter study of sipuleucel-T in men with metastatic castrate-resistant prostate cancer (mCRPC) previously treated with sipuleucel-T: Evaluation of antigen presenting cell (APC) activation and ELISPOT data. Proc 2013 ASCO Ann Mtg: 31(suppl), Abstr 5053^A, Jun 2013
- 182) Beer TM, Logothetis C, Sharma P, Loriot Y, Fizazi K, Bossi A, Kwon ED, McHenry B, Gagnier P, Gerritsen WR. CA184-095: A randomized, double-blind, phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC). Proc 2013 ASCO Ann Mtg: 31(suppl), Abstr TPS5093, Jun 2013
- 183) Beer TM, Blumenstein BA, Fizazi K, Hotte SJ, Jacobs C, Stewart PS. Design of the AFFINITY study: A randomized phase III study of a novel clusterin inhibitor, custirsen, plus cabazitaxel/prednisone (CbzP) versus CbzP alone as second-line chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). Proc 2013 ASCO Ann Mtg: 31(suppl), Abstr TPS5103, Jun 2013
- 184) Drake CG, Kwon ED, Fizazi K, Bossi A, van den Eertwegh AJM, Logothetis C, Scher HI, Beer TM, McHenry B, Liu D, Gerritsen WR. Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC). Proc 2014 GU Ca Symp: suppl 4, Abstr 2, Feb 2014
- 185) Yu EY, Saad F, Londhe A, Shore ND, Van Poppel H, Rathkopf DE, Smith MR, Logothetis C, De Souza PL, Fizazi K, Mulders PFA, Mainwaring PN, Hainsworth JD, Beer TM, North SA, Small EJ, Scher HI, Griffin TW, Yu MK, Ryan CJ. Association of alkaline phosphatase (ALP) with clinical outcomes in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. Proc 2014 GU Ca Symp: suppl 4, Abstr 27, Feb 2014
- 186) Beer TM, Logothetis C, Gerritsen WR, Kwon ED, Scher HI, Bossi A, van den Eertwegh AJM, Drake CG, McHenry B, Liu D, Fizazi K. Characterization of immune-related adverse events (irAEs) in a phase 3 trial of ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel mCRPC. Proc 2014 GU Ca Symp: suppl 4, Abstr 52, Feb 2014

- 187) Small EJ, Youngren J, Beer TM, Ryan CJ, Thomas G, Pourmand N, Reiter RE, Alumkal JJ, Stuart JM, Evans CP, Gleave ME, Chi KN, Toschi A, Foye A, Lara P, Witte O. The molecular and pathway characterization of patients with metastatic castration resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). Proc 2014 GU Ca Symp: suppl 4, Abstr 79, Feb 2014
- 188) Beer TM, Hotte SJ, De Bono JS, Beuzeboc P, Gabrail NY, Cain D, Jacobs C, Fizazi K. Pain palliation as an oncology label indication: Lessons learned in custirsen phase III development. Proc 2014 GU Ca Symp: suppl 4, Abstr 222, Feb 2014
- 189) Beer TM, Armstrong AJ, Sternberg CN, Higano CS, Iversen P, Loria Y, Rathkopf DE, Bhattacharya S, Carles J, De Bono JS, Evans CP, Joshua AM, Kim CS, Kimura G, Mainwaring PN, Mansbach HH, Miller K, Noonberg SB, Venner PM, Tombal B. Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study. Proc 2014 GU Ca Symp: suppl 4, Abstr LBA1[^], Feb 2014
- 190) Liu Q, Geng H, Xue C, Beer TM, Qian DZ. Regulation of HIF1a by Set9 lysine methyltransferase. Proc AACR Ann Mtg: Abstr 458, April 2014
- 191) Alumkal JJ, Heiser L, Beer TM, Small EJ, Baertsch R, Stuart J, King C, Korkola J, Cetnar J, Graff JN, Thomas G, Ryan CW, Toschi A, Youngren J, Tucker E, Eilers K. Identifying enzalutamide resistance mechanisms in men with castration-resistant prostate cancer. Proc ASCO; J Clin Oncol 32:5s (supple; Abstr TPS5104), May 2014
- 192) Small EJ, Youngren J, Thomas G, Olson S, Toschi A, Foye A, Alumkal JJ, Rettig M, Gleave ME, Evans CP, Stuart J, Ryan CJ, Reiter RE, Chi KN, Lara P, Beer TM. Androgen receptor (AR) amplification in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). Proc ASCO; J Clin Oncol 32:5s (supple; Abstr 5020), May 2014
- 193) Morris MJ, Loria Y, Beer TM, Higano CS, Armstrong AJ, Sternberg CN, De Bono JS, Tombal BF, Noonberg SB, Mansbach HH, Bhattacharya S, Perabo F, Phung D, Rathkopf DE. Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo. Proc ASCO; J Clin Oncol 32:5s (supple; Abstr 5054), May 2014
- 194) Bivol A, Baertsch R, Sokolov A, Paull E, Newton Y, Goldstein TC, Foye A, Pourmand N, Youngren J, Parulkar R, Lopez A, de Vere White R, Alumkal JJ, Toschi A, Beer TM, Evans CP, Gleave ME, Witte O, Small EJ, Stuart JM. Pathway-based signature analysis of RNA-seq data to reveal new targetable avenues for metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). Proc ASCO; J Clin Oncol 32:5s (supple; Abstr 11078), May 2014
- 195) Thomas G, Youngren J, Ryan CJ, Beer TM, Gleave ME, Evans CP, Stuart J, Rettig M, Toschi A, Foye A, Alumkal JJ, Corless CL, Neff T, Baertsch R, Huang J, Chi KN, Lam KS, Goldstein TC, Witte O, Small EJ. Molecular profiling of metastatic castration-resistant prostate cancer (mCRPC): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). Proc ASCO; J Clin Oncol 32:5s (supple; Abstr 5088), May 2014
- 196) Armstrong AJ, Tombal B, Sternberg CN, Higano CS, Rathkopf DE, Loria Y, Saad F, Joshua AM, De Bono JS, Venner PM, Carles J, Mainwaring PN, Evans CP, Noonberg SB, Mansbach HH, Bhattacharya S, Perabo F, Phung D, Beer TM. Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC). Proc ASCO; J Clin Oncol 32:5s (supple; Abstr 5007), May 2014
- 197) Small EJ, Youngren J, Alumkal J, Evan C, Ryan CJ, Lara P, Beer T, Witte O, Baertsch R, Stuart J. Neuroendocrine prostate cancer (NEPC) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or

- enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDDT). Proc ESMO: Abstr 760PD, Sept 2014
- 198) Loriot Y, Miller K, Sternberg CN, Fizazi K, De Bono JS, Chowdhury S, Higano C, Noonberg S, Holmstrom S, Mansbach H, Perabo FG, Phung D, Ivanescu C, Skaltsa K, Beer T, Tombal B. Impact of enzalutamide on skeletal related events (SREs), pain and quality of life (QoL) in the PREVAIL trial. Proc ESMO: Abstr 762PD, Sept 2014
- 199) Fizazi K, Drake C, Kwon E, Bossi A, Van den Eertwegh AJ, Scher HI, Beer T, McHenry M, Liu D, Gerritsen WR, Logothetis C. Updated overall survival (OS) from the phase 3 trial, CA184-043: Ipilimumab (Ipi) vs placebo (Pbo) in patients with post-docetaxel metastatic castration-resistant prostate cancer (mCRPC). Proc ESMO: Abstr 763PD, Sept 2014
- 200) Higano C, Alumkal J, Chowdhury S, Loriot Y, Sternberg CN, De Bono JS, Tombal B, Carles J, Perabo FG, Forer D, Noonberg S, Mansbach H, Beer T. Response rates and outcomes with enzalutamide for patients with metastatic castration resistant prostate cancer and visceral disease in the PREVAIL trial. Proc ESMO: Abstr 767P, Sept 2014
- 201) Frohlich MW, Hall SJ, Schellhammer PF, Higano CS, Corman JM, Beer T, Small EJ, Pantuck A, Kassabian VS, Sims RB. Integrated safety results from 4 randomized, double-blind, placebo-controlled studies of sipuleucel-T. Proc ESMO: Abstr 880P, Sept 2014
- 202) Hirmand M, Scher HI, Beer T, Higano CS, Taplin M, Efstathiou E. Circulating tumor cells (CTC) and prostate-specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100. Proc ESCO: Abstr 884P, Sept 2014
- 203) King C, Coleman D, Lisac R, Schwartzman J, Wang N, Gleave M, Thomas G, Beer T, Van Hook K, Korkola J, Gao L, Heiser L, Alumkal JJ. Integrative Genomic Analysis to Identify Emergent Enzalutamide Resistance Mechanisms in Castration-Resistant Prostate Cancer. Prostate Cancer Foundation (PCF) Annual Scientific Retreat, Abstr 006, October 2014.
- 204) Ivanescu C, Phung D, Loriot Y, Saad F, Mansbach H, Beer TM, Tombal B, Holmstrom S. Skeletal-related events (SRES) impact significantly the health-related quality of life (HRQOL) of chemo-naïve men with metastatic castration resistant prostate cancer (MCRPC). Proc ISPOR 17th Ann Euro Congress: Poster PCN206, Nov 2014
- 205) Sternberg CN, Higano CS, Alumkal J, Chowdhury S, Loriot Y, De Bono JS, Tombal B, Carles J, Perabo F, Forer D, Noonberg SB, Mansbach H, Beer TM. Response rates and outcomes with enzalutamide for patients with metastatic castration-resistant prostate cancer and visceral disease in the PREVAIL trial. PROSCA 2015 Global Congress, Feb 2015
- 206) Graff JN, Baciarello G, Armstrong AJ, Higano CS, Iversen P, Forer D, Mansbach HH, Phung D, Tombal BF, Beer TM, Sternberg CN. Clinical outcomes and safety in men \geq 75 and $<$ 75 years with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide in the phase 3 PREVAIL trial. GU Ca Symp: Abstr 200, Feb 2015
- 207) Kimura G, Yonese J, Fukagai T, Kamba T, Nishimura K, Nozawa M, Mansbach H, Phung D, Beer TM, Tombal BF, Ueda T. Subgroup analyses of Japanese patients from the PREVAIL trial of enzalutamide (ENZA) in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer (mCRPC). GU Ca Symp: Abstr 265, Feb 2015
- 208) Woodward J, King C, Coleman D, Lisac R, Schwartzman J, Wang N, Gleave M, Gray J, Thomas G, Beer TM, Van Hook K, Baertsch R, Goldstein T, Stuart J, Gao L, Urrutia J, Heiser L, Alumkal JJ. Integrative genomic analysis to identify emergent enzalutamide resistance mechanisms in castration-resistant prostate cancer. Ann Mtg AACR: Abstr 731, April 2015
- 209) Scher HI, Morris MJ, Stadler WM, Higano CS, Halabi S, Smith MR, Basch EM, Fizazi K, Ryan CJ, Antonarakis ES, Corn PG, Liu G, De Bono JS, Schwartz LH, Beer TM, Kelly WK, Hussain M, Sartor AO, Kantoff PW, Armstrong AJ. The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC).

- Proc ASCO: Abstr 5000, May 2015
- 210) Small EJ, Huang J, Youngren J, Sokolov A, Aggarwal RR, Thomas G, True LD, Zhang L, Foye A, Alumkal JJ, Ryan CJ, Rettig M, Evans CP, Gleave ME, Baertsch R, Stuart J, Reiter RE, Lara P, Chi KN, Beer TM. Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDDT). Oral Session at Proc ASCO: Abstr 5003, May 2015
- 211) Beer T, Armstrong AJ, Sternberg CN, Higano CS, Rathkopf DE, Loriot Y, Saad F, Joshua AM, De Bono JS, Venner PM, Carles J, Mainwaring PN, Evans CP, Parli T, Mansbach HH, Bhattacharya S, Van Os S, Phung D, Tombal BF. Enzalutamide (ENZA) in men with chemotherapy-Naïve metastatic castration-resistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL study. Proc ASCO: Abstr 5036, May 2015
- 212) Ferrari AC, Alumkal JJ, Stein MN, Mayer TM, Torneten S, Babb J, Taplin ME, DiPaola RS, Beer TM. LBH589 (LBH) and bicalutamide (Bic) in castration-resistant prostate cancer (CRPC) patients (pts) progressing on second line anti-androgen (AA): NYU-08479/PCCTC. Proc ASCO: Abstr 5050, May 2015
- 213) Aggarwal RR, Thomas G, Youngren J, Foye A, Olson S, Paris P, Beer TM, Ryan CJ, Witte O, Evans CP, Gleave ME, Stuart J, Alumkal JJ, Toschi A, Zona N, Reiter RE, Lara P, Chi KN, Small EJ. Androgen receptor (AR) amplification in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) and enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDDT). Proc ASCO: Abstr 5068, May 2015
- 214) Vogelzang NJ, Beer TM, Bartunkova J, Kuklik R, Miller K, Oh WK, Oudard S, Pandha HS, Sartor AO, Spisek R, Borgstein NG, Gerritsen WR. Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer. Proc ASCO: Abstr TPS5070, May 2015
- 215) Devlin N, Herdman M, Pavesi M, Phung D, Naidoo S, Beer TM, Tombal B, Loriot Y, Ivanescu C, Parli T, Balk M, Holmstrom S. Health-Related Quality of Life (HRQOL) Benefits of Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (MCRPC): An In-depth Analysis of EQ-5D Data from the PREVAIL Trial. ISPOR 18th Ann European Congress: Abstr PCN252, Nov 2015
- 216) Kim W, Ryan CJ, Zhang L, Youngren J, Wilton J, Alumkal JJ, Beer TM, Baertsch R, Stuart J, Chi KN, Gleave M, Rettig M, Reiter RE, Lara P, Evans CP, Small EJ. Dehydroepiandrosterone in metastatic castration-resistant prostate cancer: Preliminary results from the SU2C-PCF West Coast Dream Team (WCDDT). J Clin Oncol: 34 (suppl 2S): Abstr 179, Jan 2016
- 217) Morris MJ, Beer TM, Loriot Y, Higano CS, Armstrong AJ, Sternberg CN, De Bono JS, Tombal BF, Parli T, Bhattacharya S, Krivoschik AP, Phung D, Rathkopf DE. Correlation between radiographic progression-free survival (rPFS) and overall survival (OS): Results from PREVAIL. J Clin Oncol: 34 (suppl 2S): Abstr 182, Jan 2016
- 218) Aggarwal RR, Youngren J, Sokolov A, Huang J, Thomas G, Foye A, Alumkal JJ, Ryan CJ, Beer TM, Evans CP, Gleave M, Rettig M, Small EJ. Persistence of androgen receptor (AR) expression in patients (pts) with small cell prostate cancer (SCPC): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDDT). J Clin Oncol: 34 (suppl 2S): Abstr 288, Jan 2016
- 219) Moe EL, Borsch C, Garg B, Dobek JC, Doggett R, Graff JN, Beer TM, Winters-Stone KM. Falls and frailty in prostate cancer survivors on androgen deprivation therapy. Proc Ca Survivorship Symp. J Clin Oncol: 34 (suppl 3S): Abstr 134, Jan 2016
- 220) Tadros N, Ferris P, Shannon J, Beer T, Garzotto M. Safety Profile Assessment of Mandatory Research Biopsies of the Prostate: A Ten Year Multi-Center Experience. Proc AUA Ann Mtg: Abstr S&T-11, May 2016
- 221) Lin D, Garzotto M, Aronson W, Basler J, Beer T, Brophy M, Kelly K, Lee K, Lu Y, Markle V,

- McGuire V, Nseyo U, Ringer R, Savage S, Shih MC, Sinnott P, Uchio E, Wang Y, Yang C, Montgomery B. VA CSP#553 Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma: A Phase III Randomized Study. Proc AUA Ann Mtg: Abstr 740, May 2016
- 222) Beer TM, Ivanescu C, Skaltsa K, Naidoo S, Phung D, Tombal B. Relationship between health-related quality of life (HRQOL) and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients with no prior chemotherapy: Results from PREVAIL study. Proc ISPOR 21st Ann Inter'l Mtg: Abstr 61995, May, 2016
- 223) Coleman DJ, Van Hook K, King CJ, Schwartzman J, Lisac R, Urrutia J, Sehrawat A, Woodward J, Wang NJ, Gulati R, Thomas GV, Beer TM, Gleave ME, Korkola JE, Gao L, Heiser LM, Alumkal JJ. Androgen content and BET bromodomain proteins influence enzalutamide agonism of mutant F876L androgen receptor. J Clin Oncol: 34 (suppl): Abstr e16538, Jun 2016
- 224) Kim W, Ryan CJ, Zhang L, Youngren J, Wilton J, Alumkal JJ, Beer TM, Baertsch R, Stuart J, Chi KN, Gleave M, Rettig M, Reiter RE, Lara P, Evans CP, Small EJ. Dehydroepiandrosterone (DHEA) in metastatic castration-resistant prostate cancer (mCRPC): Preliminary results from the SU2C/PCF/AACR West Coast Dream Team (WCDDT). J Clin Oncol: 34 (suppl): Abstr e16598, Jun 2016
- 225) Small EJ, Aggarwal RR, Huang J, Sokolov A, Zhang L, Alumkal JJ, Youngren J, Ryan CJ, Foye A, Reiter RE, Evans CP, Gleave M, Witte O, Stuart J, Goldstein TC, Thomas GV, True LD, Beltran H, Rubin MA, Beer TM. Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDDT). J Clin Oncol: 34 (suppl): Abstr 5019, Jun 2016
- 226) Aggarwal RR, Youngren J, Sokolov A, Huang J, Thomas GV, True LD, Foye A, Alumkal JJ, Ryan CJ, Beer TM, Evans CP, Gleave M, Rettig M, Stuart JM, Lara P, Goldstein TC, Zhang L, Reiter RE, Chi KN, Small EJ. Persistence of AR signaling in small cell neuroendocrine prostate cancer (SCNC) and intermediate atypical carcinoma (IAC): Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDDT). J Clin Oncol: 34 (suppl): Abstr 5045, Jun 2016
- 227) Fizazi K, Hotte S, Saad F, Alekseev B, Matveev V, Flechon A, Gravis G, Joly F, Chi K, Malik Z, Stewart P, Jacobs C, Beer T. Final overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castration-resistant prostate cancer (mCRPC). Proc ESMO: Abstr LBA9_PR, Oct 2016
- 228) Graff J, Alumkal J, Drake C, Thomas G, Redmond W, Farhad M, Slottke R, Beer T. First evidence of significant clinical activity of PD-1 inhibitors in metastatic, castration resistant prostate cancer (mCRPC). Proc ESMO: Abstr 7190, Oct 2016
- 229) Bryce A, Alumkal J, Armstrong A, Higano C, Iversen P, Sternberg C, Rathkopf D, Loriot Y, de Bono J, Tombal B, Abhyankar S, Lin P, Krivoshik A, Phung D, Beer T. A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study. Proc ESMO: Abstr 760P, Oct 2016
- 230) Beer TM, Corman J, Lance RS, Campogan D, Vu T, Haynes H, Chang NN, Sheikh NA, Curti BD. Boosting long-term immune responses to sipuleucel-T (sip-T) by retreatment of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol: 35 (suppl 6S): Abstr 196, Feb 2017
- 231) Armstrong AJ, Lin P, Higano CS, Sternberg CN, Sonpavde G, Tombal BF, Templeton AJ, Fizazi K, Phung D, Wong EK, Krivoshik A, Beer TM. Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) from the phase III PREVAIL clinical trial. J Clin Oncol: 35 (suppl 6S): Abstr 138, Feb 2017
- 232) Sehrawat A, Gao L, Tayou J, Bankhead A, Heiser LM, King CJ, Wang Y, Schwartzman J, Urrutia J, Coleman DJ, Weinmann S, Kallakury BV, Berry DL, Haque R, Van Den Eeden SK, Beer TM, Thomas GV, McWeeney S and Alumkal JJ. LSD1 promotes

- castration-resistant prostate cancer cell survival independently of the androgen receptor and of histone demethylation. *Proc AACR Cancer Res*: 77(13suppl): Abstr 2406, Apr 2017
- 233) Armstrong AJ, Lin P, Higano CS, Sternberg CN, Sonpavde G, Tombal BF, Templeton AJ, Fizazi K, Phung D, Wong EK, Krivoschik A, Beer, TM. Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) from the phase 3 PREVAIL clinical trial. *J Clin Oncol*: 35 (suppl): Abstr 5022, June 2017
- 234) Lambie NM, Graff JN, Beer TM. Efficacy of sequencing of cytotoxic and endocrine therapies in veterans with metastatic castration-resistant prostate cancer (mCRPC). *J Clin Oncol*: 35 (suppl): Abstr e16501, June 2017
- 235) Armstrong AJ, Lin P, Higano CS, Iversen P, Sternberg CN, Tombal B, Phung D, Parli T, Krivoschik A, Beer TM. Prognostic associations of prostate-specific antigen (PSA) decline with survival, radiographic response and progression in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide. *Proc ESMO*: Abstr 787PD, Sep 2017
- 236) Kim W, Small EJ, Aggarwal RR, Den RB, Lehrer J, Zhang L, Youngren J, Goldstein TC, Alumkal JJ, Gleave M, Rettig M, Evans CP, Beer TM, Reiter RE, Huang J, Thomas GV, Davicion E, Ryan CJ, Eidelberg DS, Feng FY. Luminal and basal subtyping of metastatic castration-resistant prostate cancer (mCRPC) and its clinical implications. *J Clin Oncol*: 36 (suppl 6S): Abstr 197, Feb 2018
- 237) Beer TM, Chowdhury S, Saad F, Shore ND, Higano CS, Iversen P, Fizazi K, Miller K, Heidenreich A, Choung KS, Phung D, Barrus JK, Nikolayeva N, Krivoschik A, Waksman J, Tombal BF. Hepatic effects assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials. *J Clin Oncol*: 36 (suppl): Abstr 199, Feb 2018
- 238) Aggarwal RR, Zhang L, Beer TM, Youngren J, Stromlund A, Bell A, Foye A, Playdle D, Alumkal JJ, Reiter RE, Gleave M, Evans CP, Thomas GV, Huang J, True LD, Rettig M, Lara P, Chi KN, Small EJ. Serum neuroendocrine (NE) markers and clinical characteristics of treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) in men with metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team. *J Clin Oncol*: 36 (suppl 6S): Abstr 278, Feb 2018
- 239) Graff JN, Beer TM, Alumkal JJ, Kreitner D, Petreaca D, Thomas GV, Cheng HH. c15-148: Phase I/II trial of concurrent chemohormonal therapy using enzalutamide and cabazitaxel in patients with metastatic castration resistant prostate cancer (mCRPC). *J Clin Oncol*: 36 (suppl): Abstr TPS5097, June 2018
- 240) Graff JN, Alumkal JJ, Thompson RF, Moran A, Thomas GV, Wood MA, Drake CG, Slottke R, Beer TM. Pembrolizumab (Pembro) plus enzalutamide (Enz) in metastatic castration resistant prostate cancer (mCRPC): Extended follow up. *J Clin Oncol*: 36 (suppl): Abstr 5047, June 2018
- 241) Aggarwal RR, Lloyd P, Huang J, Beer TM, Zhang L, Thomas GV, True LD, Alumkal JJ, Friedl V, Weinstein A, Reiter RE, Rettig M, Lara P, Gleave M, Foye A, Playdle D, Feng FY, Chi KN, Stuart J, Small EJ. DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team. *J Clin Oncol*: 36 (suppl): Abstr 5039, June 2018
- 242) Autio KA, Antonarakis ES, Mayer TM, Vaishampayan UN, Shevrin DH, Harrison MR, Tagawa ST, Milowsky MI, Graff JN, Beer TM, Balar AV, Stein M, Heath EI., Armstrong AJ, Paller CJ, Nordquist LT, Dayan ES, Tse K, Heller G, Scher HI. Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP+D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP). *J Clin Oncol*: 36 (suppl): Abstr 5016, June 2018
- 243) Mitri ZI, Parmar S, Johnson B, Kolodzie AK, Keck J, Morris M, Guimaraes A, Beckett B,

- Borate U, Lopez CD, Kemmer KA, Alumkal JJ, Beer TM, Corless CL, Mills GB, Bergan RC. Implementing a comprehensive translational oncology platform: From molecular testing to actionability. *J Clin Oncol*: 36 (suppl): Abstr e14521, June 2018
- 244) Chen WS, Aggarwal RR, Zhang L, Zhao S, Beer TM, Quigley DA, Foye A, Playdle D, Lloyd P, Rettig M, Gleave M, Evans CP, Lara P, Kothari V, Chi KN, Reiter RE, Maher C, Feng FY, Small EJ, Alumkal JJ. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. *GU Ca Symp*: Abstr 146, Feb 2019
- 245) Armstrong AJ, Al-Adhami M, Lin P, Parli T, Sugg J, Steinbert JL, Tombal BF, Sternbert CN, De Bono JS, Scher HI, Beer TM. The clinical impact of bone scan (BS) flare with enzalutamide (ENZA) in men with metastatic castration-resistant prostate cancer (mCRPC). *GU Ca Symp*: Abstr 183, Feb 2019
- 246) Tombal BF, Armstrong AJ, Barrus JK, Beer TM, Chowdhury S, Evans CP, Heidenreich A, Higano CS, Kamba Tomomi, Lin P, Nikolayeva N, Sugg J, Steinberg JL, Taplin ME, Saad F. Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials. *GU Ca Symp*: Abstr 237, Feb 2019
- 247) Armstrong AJ, Tombal B, Saad F, Parli T, Phung D, Beer TM. Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): long-term overall survival and safety analyses of the phase 3 PREVAIL study. *Eur Assoc Urol*: Abstr 64, March 2019
- 248) Autio K, Antonarakis ES, Baser R, Stein MN, Shevrin DH, Vaishampayan UN, Mayer TA, Morris MJ, Slovin SF, Heath EI, Tagawa ST, Rathkopf DE, Milowsky MI, Harrison MR, Beer TM, Balar AV, Armstrong AJ, Paller CJ, Basch EM, Scher HI. Evaluation of the patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) with abiraterone acetate plus prednisone (AAP), degarelix (D), or the combination in men with biochemically recurrent prostate cancer (BCRPC). *2019 ASCO Annual Meeting Abstracts*: Abstr 5080, May 2019
- 249) Guan X, Sun DC, Lu E, Urrutia JA, Reiter RE, Rettig M, Evans CP, Lara P, Gleave M, Beer TM, Thomas GE, Huang J, Xia Z, Alumkal JJ. Copy number analysis to identify tumor suppressor genes associated with enzalutamide (Enza) resistance and poor prognosis in metastatic castration-resistant prostate cancer (mCRPC) patients. *2019 ASCO Annual Meeting Abstracts*: Abstr 5011, May 2019
- 250) Small EJ, Aggarwal RR, Friedl V, Weinstein A, Thomas GV, True LD, Foye A, Beer TM, Rettig M, Gleave M, Evans CP, Alumkal JJ, Reiter RE, Lara P, Chi KN, Feng FY, Bailey A, Stuart J, Huang J. Intermediate atypical carcinoma (IAC): A discrete subtype of metastatic castration-resistant prostate cancer (mCRPC) suggesting that treatment-associated small cell/neuroendocrine prostate cancer (t-SCNC) may evolve from mCRPC adenocarcinoma (adeno)—Results from the SU2C/PCF/AACR West Coast. *Prostate Cancer Dream Team (WCDDT)*. *2020 GU Ca Symp*: Abstr 158, Feb 2020
- 251) Graff JN, Cheng HH, Vuky J, Alumkal JJ, Kreitner D, Petreaca D, Grivas P, Schweizer MT, Higano CS, Chen Y, Yu EY, Beer TM. Phase II study of cabazitaxel (CAB) plus enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC). *2020 GU Ca Symp*: Abstr 86, Feb 2020
- 252) Kwon D, Zhang L, Foye A, Chen WS, Feng FY, Bailey A, Huang J, Quigley DA, Stuart J, Friedl V, Weinstein A, Beer TM, Alumkal JJ, Rettig M, Gleave M, Lara P, Li P, Lui A, Small EJ, Aggarwal RR. ADRB2 expression in progressive metastatic castration-resistant prostate cancer. *2020 GU Ca Symp*: Abstr 145, Feb 2020
- 253) Nadauld L, McDonnell CH III, Liu MC, Klein E, Beer TM, Schrag D, Hudnut AG, Whittington R, Taylor B, Tierney J, Marinac C, Lipson J, Lopatin M, Chung KC, Fung E, Hartman AR, Oxnard GR. The Pathfinder Study: Assessment of the implementation of an investigational multi-cancer early detection test into clinical practice. *AACR Annual Mtg. 2020: Astr CT291*, Apr 2020. DOI: 10.1158/1538-7445 published Aug 2020
- 254) Beer TM, Shore ND, Morgans AK, Winters-Stone KM, Wefel JS, Ortiz JA, Reeves JA, George DJ. DaroACT: Darolutamide and enzalutamide effects on physical and

- neurocognitive function and daily activity in patients with castration-resistant prostate cancer (CRPC). 2020 ASCO Virtual Annual Meeting Abstracts: Abstr TPS5587, May 2020
- 255) Bendell JC, Fong L, Stein MN, Beer TM, Ross A, Gao X, Weitzman A, Austin R, Ganti Vaishnavi, Law CL, Lemon B, Wesche H, De Bono JS, Cannon S. First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC). 2020 ASCO Virtual Annual Meeting Abstracts: Abstr 5552, May 2020
- 256) Small EJ, Zhao S, Chen WS Li H, Foye A, Sjöström M, Hua JJ, Aggarwal RR, Alumkal JJ, Beer TM, Gleave M, Rettig M, Witte O, Lara P, Chinnaiyan A, Maher C, Quigley DA, Feng FY. The comprehensive methylation landscape of metastatic castration-resistant prostate cancer (mCRPC) identifies new phenotypic subtypes: Results from the West Coast Prostate Cancer Dream Team (WCDT). 2020 ASCO Virtual Annual Meeting Abstracts: Abstr 5507, May 2020
- 257) Beer TM. Advanced Prostate Cancer: Putting Survival Into Perspective (Discussant). 2020 ASCO Virtual Annual Meeting Abstracts: Abstr 5514; 5515; 5516, May 2020
- 258) Beer TM, Shore ND, Morgans AK, Winters-Stone K, Wefel JS, Ortiz JA, Reeves JA, George DJ. DaroACT: Darolutamide and enzalutamide effects on physical and neurocognitive function and daily activity in patients with castration-resistant prostate cancer (CRPC). 2020 ASCO Virtual Scientific Program. Abstr TPS5587, May 2020
- 259) Boisvert C, Stoyles S, Mitri Z, Beer TM, Winters-Stone K. Retention and Adherence Rates in Cancer Survivors and Partners to Virtual Exercise Delivery During COVID-19. Poster Session, American College of Sports Medicine Northwest Virtual 2021 Meeting. Feb 2021
- 260) Lumbad O, Boisvert C, Daniel K, Stoyles S, Winters-Stone K. Adherence to Prescribed Exercise Dose in Cancer Survivors and their Partners. Poster Session, American College of Sports Medicine Northwest Virtual 2021 Meeting. Feb 2021
- 261) Beer TM, Saad F, Sternberg CN, Hussain MHA, Ganguli A, Bhadauria HS, Oh M, Skaltsa K, Tombal B. Network Meta-Analysis (NMA) Comparing the Efficacy of Enzalutamide Versus Apalutamide, Darolutamide, and Bicalutamide for Treatment of Nonmetastatic (nm) Castration-Resistant Prostate Cancer (CRPC). 2021 Virtual GU Ca Symp: Abstr 101, Feb 2021
- 262) Sjöström M, Zhao S, Small EJ, Ning YH, Maurice-Dror C, Foye A, Hua, JJT Li H, Beer TM, Evans CP, Rettig M, Chi KM, Alumkal JJ, Aggarwal RR, Ashworth A, Levy S, He HH, Wyatt AW, Quigley DA, Feng FY. 5-Hydroxymethylcytosine as a Liquid Biopsy Biomarker in mCRPC. 2021 Virtual GU Ca Symp: Abstr 148, Feb 2021
- 263) Beer TM, McDonnell CH, Nadauld L, Liu MC, Klein EA, Reid RL, Chung K, Lopatin M, Fung ET, Schrag D. A prespecified interim analysis of the PATHFINDER study: Performance of a multicancer early detection test in support of clinical implementation. *J Clin Oncol*: 39 (suppl 15): Abstr 3070, 2021
- 264) Beer TM, McDonnell CH, Nadauld L, Liu MC, Klein EA, Reid RL, Marinac C, Karen Chung K, Lopatin M, Fung ET, Schrag D. Interim results of PATHFINDER, a clinical use study using a methylation-based multi-cancer early detection test. *J Clin Oncol*: 39 (suppl 15): Abstr 3010, 2021
- 265) Wu CY, Tibbitts D, Beattie Z, Dodge HH, Beer TM, Marks D, Shannon J, Kaye J, Winters-Stone KM. Continuous unobtrusive assessment of meaningful change in older adults with cancer: The Pacific Aging & Cancer Study Collaborative—PACS collaborative. *J Clin Oncol*: 39 (suppl 15): Abstr 1569, 2021
- 266) De Bono JS, Fong L, Beer TM, Gao X, Geynisman DM, Burris III HA, Strauss JF, Courtney KD, Quinn DI, VanderWeele DJ, Yaron Y, Law CL, Stein MN. Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC). *J Clin Oncol*: 39 (suppl 15): Abstr 5013, 2021
- 267) Morris MJ, De Bono JS, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Pérez-Contreras WJ,

- Desilvio M, Kpamegan EE, Gericke G, Messmann RA, Krause BJ, Sartor AO. Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). *J Clin Oncol*: 39 (suppl 15): Abstr LBA4, 2021
- 285) Winters-Stone KM, Li F, Horak FB, Dieckmann N, Hung A, Amling CL, Beer TM. A randomized, controlled trial of group exercise training for fall prevention and functional improvements during and after treatment for prostate cancer. *J Clin Oncol*: 40 (suppl 6): Abstr TPS193-TPS193, 2022
- 286) Winters-Stone KM, Stoyles S, Amling CL, Hung A, Dieckmann N, Li F, Horak FB, Tibbitts D, Beer TM. Characteristics of prostate cancer survivors exposed to ADT and enrolled in a fall prevention exercise trial: Comparison of men with confirmed fall history to men with fall risk factors. *L Clin Oncol*: 40 (suppl 6:) Abstr 81, 2022
- 268) Sokolova A, Gulati R, Cheng HH, Beer TM, Graff JN, Amador M, Toulouse A, Taylor K, Bailey S, Smith S, Tabatabaei S, Sinit R, Slotke R, Vuky J, Yezefski T, Grivas P, Yu EY, Schweizer MT. Trial in progress: Durvalumab and olaparib for the treatment of prostate cancer in men predicted to have a high neoantigen load. *J Clin Oncol*: 40: (suppl 6): Abstr TPS202, 2022
- 269) Kouchkovsky ID, Zhang L, Huang J, Trepka K, Chou J, Foye A, Shui D, Wong C, Fried F, Weinstein A, Hope TA, Quigley DA, Stuart J, Beer TM, Reiter RE, Gleave ME, Evans CP, Feng FY, Small EJ, Aggarwal RR. Clinical and molecular features of low prostate-specific membrane antigen (PSMA) expression in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). *J Clin Oncol*: 40 (suppl 6): Abstr 167, 2022

V. SERVICE

Membership in Professional Societies:

1992	American College of Physicians
1992	Oregon Medical Association
1992	Medical Society of Metropolitan Portland
1996	American Society of Clinical Oncology
1996	American Society of Hematology (Associate)
1998	American Association for Cancer Research
1999	Southwest Oncology Group
	Member GU Committee
	Principal Investigator – OHSU UCOP
2003	American Urological Association (Affiliate)
2008	Radiation Therapy Oncology Group (RTOG)
2012	Oregon Society of Medical Oncology (OSMO)

Granting Agency Review Work:

Grant reviewer for:

Cancer Research UK
 ASCO Young Investigator Grant
 National Cancer Institute of Canada
 National Science Foundation
 Doris Duke Foundation Distinguished Clinical Scientist Grant, 2006
 American Association for the Advancement of Science (AAAS), University of Kansas Medical Center Research Institute's (KUMC RI) Clinical Pilot Research Fund Grant Program, 2009

Study section member for:

Congressional Directed Medical Research Program (DoD), 2008

Editorial and Ad Hoc Review Activities:

Editorial Board Member:

2005 - Reviews on Recent Clinical Trials
 2006 - Anti-Cancer Drugs
 2006 - Clinical GU Cancer
 2007 - Libertas Academica
 2009 - HCPLive.com Oncology Advisory Board
 2009 - Oncology & Biotech News
 2009 - Contemporary Oncology
 2010 - Clinical Medicine Insights: Urology
 2010 - Clinical Genitourinary Cancer
 2014 - ONCOLOGY
 2015 - Oncology in Clinical Practice

Reviewer:

Anti-Cancer Drugs
 British Journal of Cancer
 Cancer Chemotherapy and Pharmacology
 Clinical Cancer Research
 Clinical Pharmacology and Therapeutics
 Clinical Prostate Cancer
 Drugs and Aging
 Expert Opinion on Pharmacotherapy
 European Journal of Clinical Nutrition
 Journal of the American Medical Association
 Journal of Clinical Oncology
 Journal of the National Cancer Institute
 Journal of Urology
 Lancet Oncology
 Molecular Cancer Therapeutics
 Nature Clinical Practice Urology
 Oncology (Karger)
 Prostate Cancer and Prostatic Diseases
 Urology

Advisory Board Member:

Oncology Net Guide
 Michael J. Hennessy & Associates Oncology Publications
 Contemporary Oncology
 Medscape Hematology/Oncology

Committees:International/National

2000 - GU Committee, Southwest Oncology Group
 2003- 2007 Geriatric Oncology Consortium, Scientific Advisory Board
 2004 - 2006 American Society of Clinical Oncology, Annual Meeting Program
 Committee
 2006 - 2009 American Society of Clinical Oncology, Cancer Education
 Committee
 2006 – 2007 American Urological Association, Annual Meeting Abstract Review
 Committee
 2007 - National Inter-SPORE Immunotherapy Working Group
 2008 - 2008 Congressionally Directed Medical Research Programs, Scientific Peer
 Review Panel
 2010 Co-Chair, 2010 Inaugural NCI-PCF Metastatic Prostate Cancer
 Treatment Sciences Meeting
 2010-2011 Prostate Cancer Foundation (PCF) Research Awards, Review Committee

2010-2013 American Society of Clinical Oncology's Scientific Program Committee
 2011 Genitourinary Track Leader, 2011 ASCO Annual Meeting
 Scientific Program Committee
 2012- Executive Committee, Pacific NW SPORE
 2015 International Advisory Group (IAG)
 2015 Tisch Cancer Institute External Advisory Board

Regional

2004 - Oregon Partnership for Cancer Control, State Cancer Plan
 Development Committee
 2004 - 2010 American Cancer Society, Harvey Baker Memorial Committee

Institutional

2000 - Member, OCC Leadership Council
 2000 - 2001 Co-Chair, Program Committee, 1st Annual OHSU Prostate Cancer
 Conference
 2001 - 2002 Member, Search Committee for Director of the Advanced Imaging
 Research Center
 2003 - 2005 Member, Search Committee for Associate Director of the OHSU
 Cancer Institute
 2003 Chair, Program Committee, 3rd Annual OHSU/UW/ACS Prostate
 Cancer Conference
 2003 - Member, OCI Senior Leadership Council
 2004 - 2005 Member, OCI Clinical Advisory Council
 2004 - Member, OCI Executive Council
 2005 Chair, Program Committee, 5th Annual OHSU/UW/ACS Prostate
 Cancer Conference
 2005 - Medical Director, Oncology Service Line
 2006 - 2009 Member, School of Medicine Promotion and Tenure Committee
 2006 Member, Graduate Faculty of the School of Medicine of the OHSU
 2006 - Member, Research Pharmacy Task Force
 2006 - 2007 Member, Search Committee for Chief of Urology
 2007 Member, OCTRI K13 Multidisciplinary Advisory Committee
 2007 Chair, Program Committee, 7th Annual OHSU/UW Prostate
 Cancer Conference
 2008 - 2009 Chair, Search Committee for Chief of Urology
 2008 Member, Cancer Institute's RFA for Pilot Projects and Career
 Development
 Scientific Review Committee
 2008 Member, Oncology Executive Advisory Board Committee
 2008 Member, Advanced Imaging Research Center (AIRC) Institutional
 Advisory Board (IAD)
 2009 Member, OCTRI Internal Advisory Board Committee
 2009 Chair, Program Committee, 9th Annual OHSU/UW Prostate
 Cancer Conference
 2010 Chair, Program Committee, 10th Annual OHSU/UW Prostate
 Cancer Conference
 2010 - 2013 Member, Search Committee for Chair of the Department of Dermatology
 2011 Chair, Program Committee, 11th Annual OHSU/UW Prostate
 Cancer Conference
 2012 Chair, Program Committee, 12th Annual OHSU/UW Prostate
 Cancer Conference
 2013 Chair, Program Committee, 13th Annual OHSU/UW Prostate
 Cancer Conference
 2014 Chair, Program Committee, 14th Annual OHSU/UW Prostate

2015 Cancer Conference
Chair, Program Committee, 15th Annual OHSU/UW Prostate
Cancer Conference

Departmental

1999 – 2000 Fellowship Committee, Division of Hematology and Medical Oncology

Community Service:

2001 - 2002 Section Medical Editor, *Understanding Advanced Prostate Cancer*, an interactive educational software program

2001 - 2008 Media Consultant, ABC News

2008 Reviewer, *Treating Prostate Cancer – A Guide for Men with Localized Prostate Cancer* (Pub. No.: 08-EHC010-2A, July 2008), Agency for Healthcare Research and Quality (AHRQ) consumer's guide

2008 Reviewer, *Treatments for Clinically Localized Prostate Cancer* (Pub. No.: 08-EHC010-3, July 2008), Agency for Healthcare Research and Quality (AHRQ) clinician's guide

2009 Faculty Member, *Expert Guidance in Defining and Treating Hormone-Refractory Prostate Cancer*, a web-based educational tool

2013 Participant, Development of the 2013 Update in Medical Oncology self-evaluation module for the Maintenance of Certification (MOC) program, American Board of Internal Medicine (ABIM)

Clinical Responsibilities (since last promotion):

Clinical responsibilities include 1¾ days of clinic per week. The practice is fully focused on prostate cancer. In addition, clinical responsibilities include 1 month of attending on the inpatient oncology service and 1 month of attending on the oncology consult service (both OHSU and VA simultaneously)

VI. TEACHING (OHSU Educator's Portfolio):

Overview of your Role as an Educator:

Through my many teaching roles including (1) direct mentor in research, (2) clinical mentor in the outpatient practice, (3) lecturer to a broad range of audiences, (4) author of many educational publications, and (5) leader of educational programs, I reach a broad range of learners including: high school students, college students, medical students, residents, fellows, junior faculty, general practitioners, practicing oncologists, patients, and the general public.

Scholarship of Teaching:

Curriculum Development

Developed Curriculum for the Annual Prostate Cancer Conference in 2001, 2003, 2005, 2007, and 2009

Assisted in the development of the Division Oncology curriculum.

Oversee and approve curricula for many regional oncology conferences on behalf of the American Society of Clinical Oncology Cancer Education Committee

Coordinate and set the curricular expectations for the GU Oncology Tumor Board and Prostate Cancer Journal Club/Research conference, both of which meet weekly

Oversaw national annual meeting program for the ASCO annual meeting while a member of the program committee

Cancer, Active Surveillance, Hypofractionated Radiation Therapy. *Scientific American Bulletins: Prostate Disorders*, 23-8, Spring 2015.

Educational Publications

Peer-reviewed Editorial and Review Articles

- 1) Beer TM and Raghavan D. Chemotherapy for Hormone-Refractory Prostate Cancer: Beauty is in the Eye of the Beholder. *The Prostate*. 2000 Oct: 1;45(2): 184-93. Review.
- 2) Beer TM, El-Geneidi, and Eilers KM. Docetaxel in the Treatment of Prostate Cancer. *Expert Review of Anticancer Therapy*, 2003 Jun: 3(3): 261-8. Review.
- 3) Culkin D and Beer TM. Advanced Penile Carcinoma. *Journal of Urology*. 2003 Aug;170(2 Pt 1):359-65. Review.
- 4) Beer TM. Development of Weekly High-Dose Calcitriol Based Therapy For Prostate Cancer. *Urologic Oncology*. 2003 Sep-Oct: 21(5): 399-405. Review.
- 5) Beer TM and Myrthue A. Calcitriol in Cancer Treatment: From the Lab to the Clinic. *Molecular Cancer Therapeutics*. 2004 Mar: 3(3): 373-81. Review.
- 6) Beer TM and Bubalo JS. Prevention and management of prostate cancer chemotherapy complications. *Urologic Clinics of North America*. 2004 May: 31(2): 367-78. Review.
- 7) Strother J, Beer TM and Dreicer R. Novel Cytotoxic and Biological Agents for Prostate Cancer – Where will the Money be in 2005? *European Journal of Cancer*. 2005 Apr: 41(6): 954-64. Review.
- 8) Beer TM and Myrthue A. Calcitriol in the Treatment of Prostate Cancer. *Anticancer Research*. 2006 Jul-Aug: 26(4A): 2647-51. Review.
- 9) Lycette JL, Bland LB, Garzotto M, and Beer TM. Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities? *Clin Genitourin Cancer*. 2006 Dec: 5(3): 198-205. Review.
- 10) Sternberg CS, Krainer M, Oh WK, Bracada S, Bellmunt J, Ozen H, Zlotta A, Beer TM, Oudard S, Rauchenwald M, Skoneczna I, Borner MM, and Fitzpatrick JM. The medical management of prostate cancer: a multidisciplinary team approach, *BJU International*. 2007 Jan: 99(1):22-7. Review.
- 11) Ryan CJ, Beer TM. Prostate specific antigen only androgen-independent prostate cancer: natural history, challenges in management, and clinical trial design, *J Urol*. 2007 Sept: 178(3 Pt 2):S25-9. Review.
- 12) Kantoff PW, Beer TM, D'Amico AV, Dipaola RS, Eisenberger MA, Hussain MH, Kelly WK, Mathew P, Morris MJ, Ryan CJ, Sandler HM, Thompson IM, Carroll PR. Innovations and Challenges in Prostate Cancer: Summary Statement for the 6th Cambridge Conference, *J Urol*. 2007 Sep: 178(3 Pt 2): S5-8; quiz S4.
- 13) Basch EM, Somerfield MR, Beer TM, Carducci MA, Higano CS, Hussain MH, Scher HI. American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Non-hormonal Therapy for Men with Metastatic Hormone-refractory (Castration-resistant) Prostate Cancer, *J Clin Oncol*. 2007 Nov: 20;25(33): 5313-5318. Review.
- 14) Beer TM, Ryan CW. The hazards of intermediate endpoints, *Cancer*. 2007 Nov: 1;110(9):1877-1879.
- 15) Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI. Department of Defense Prostate Cancer Clinical Trials Consortium: A New Instrument for Prostate Cancer Clinical Research. *Clin Genitourin Cancer*. 2009 Jan: 7(1): 51-7. (PMCID: PMC3394090)
- 16) Schnadig ID, Beer TM. Optimal timing of chemotherapy in androgen independent prostate cancer. *Urol Oncol*. 2009 Jan-Feb: 27(1): 97-100.
- 17) Beer TM. Editorial comment on “A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation”. *J Urol*. 2009 Mar: 181(3): 1113.
- 18) Barnett CM, Beer TM. Prostate cancer and vitamin D: what does the evidence really suggest? *Urol Clin North Am*. 2011 Aug: 38(3): 333-42.
- 19) Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF. New therapies for castration-resistant prostate cancer: efficacy and safety. *Eur Urol*. 2011 Aug: 60(2): 279-90. Review.

- 20) Graff JN, Beer TM. Toward predictors of survival in castration-resistant prostate cancer. *Cancer*. 2011 Sep: 117(17): 3882-4.
- 21) Alumkal JJ, Graff JN, Beer TM. Targeted therapy in prostate cancer: is there hope beyond the androgen receptor? *Oncology (Williston Park)*. 2013 Jul: 27(7): 628, 630, 637-8.
- 22) Graff JN, Beer TM. The role of C-reactive protein in prostate cancer. *Cancer*. 2013 Sep: 15;119(18): 3262-4.
- 23) Quinn DI, Vaishampayan U, Higano CS, Lin DW, Shore ND, Beer TM. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. *Expert Rev Anticancer Ther*. 2014 Jan: 14(1): 51-61. Review.
- 24) Winters-Stone KM, Beer TM. Review of exercise studies in prostate cancer survivors receiving androgen deprivation therapy calls for an aggressive research agenda to generate high-quality evidence and guidance for exercise as standard of care. *J Clin Oncol*. 2014 Aug: 10;32(23): 2518-9. Review.
- 25) Shtivelman E, Beer TM, Evans CP. Molecular pathways and targets in prostate cancer. *Oncotarget*. 2014 Sep: 15;5(17): 7217-59. (PMCID: PMC4202120)
- 26) Cetnar JP, Beer TM. Personalizing prostate cancer therapy: the way forward. *Drug Discov Today*. 2014 Sep: 19(9): 1483-7. Review.

Non-peer-reviewed

Books

- 1) Beer TM, Axmaker LW. Cancer Clinical Trials: A commonsense guide to experimental cancer therapies and clinical trials. New York: DiaMedica Publishing, 2012.

Chapters

- 1) Panagiotou I, Beer TM. (2003) Salvage chemotherapy and emerging drugs in germ cell tumors. In Raghavan D (Ed.), *American Cancer Society Atlas of Germ Cell Tumors* (pp. 182-98).
- 2) Beer TM, Myrthue A. (2007) Vitamin D Analogs and Their Role in Prostate Cancer. In Dawson NA, Kelly WK (Eds.), *Prostate Cancer Translational and Emerging Therapies* (pp. 257-79). New York: Informa Healthcare USA, Inc.
- 3) Jensen AR, Szmulewitz RZ, Beer TM, Posadas EM. Calcitriol and Vitamin D Analogs, submitted.
- 4) Barnett CM, Beer TM. (2011) Vitamin D and Prostate Cancer. In Trump DL, Johnson CS (Eds.), *Vitamin D and Cancer* (pp. 221-249). New York: Springer Science+Business Media LLC.
- 5) Barnett CM, Beer TM. (2011) Prostate Cancer and Vitamin D: What Does the Evidence Really Suggest?. In Donley S, Moyad MA (Eds.), *Complementary and Alternative Medicine in Urology* (pp. 333-342). Philadelphia, PA: Elsevier Inc.

Electronic Publications

- 1) Beer TM and Garzotto M. When you hear hoofbeats, don't forget zebras: SIADH associated with prostate cancer. Guest Editorial, *Urohealth*, http://www.urohealth.org/editorials/display_editorial.asp?EDITORIAL_ID=157&EDITORIAL_CAT=PRO, 2002.
- 2) Beer TM. Prostate Cancer: Improving Screening, Treatment, and Prognosis. *Medscape* <http://www.medscape.com/viewarticle/436143>, 2002.
- 3) Beer TM. Progress in Prostate Cancer: An Update. *Medscape* <http://www.medscape.com/viewarticle/481669>, 2004.
- 4) Beer TM. Prostate Cancer at the 2004 Annual Meeting of the American Society for Clinical Oncology (ASCO) http://professional.cancerconsultants.com/conference_asco_2004.aspx?id=30936, 2004.
- 5) Beer TM. Management of Metastatic Prostate Cancer in a Nonelderly Patient With Comorbid Medical Conditions

- <http://clinicaloptions.com/onco/challenges/prostatecases/#beer>, 2005.
- 6) Beer TM. Treatment of a Patient With Metastatic Prostate Cancer and no Other Comorbidities <http://clinicaloptions.com/onco/challenges/prostatecases/#beer2>, 2005.
 - 7) Beer TM. Prostate Cancer: Risk Factors, Prognostic Indicators, and Treatment Advances, Medscape CME, <http://www.medscape.com/viewprogram/4210> , 2005.
 - 8) Beer TM. Should oncologists recommend hormone therapy plus abiraterone for patients with nonmetastatic prostate cancer? HemOnc Today, <https://goo.gl/eLyCMT> Sept 2017.

Reviews

- 1) Beer TM, Pierce WC, Lowe BA, and Henner WD. Docetaxel Weekly Administration in Symptomatic Androgen-Independent Prostate Cancer. Cancer Conference Highlights. 2000; 4(12):2-5.
- 2) Beer TM and Bubalo JS, Complications of chemotherapy for prostate cancer. Seminars in Urologic Oncology, 2001 Aug; 19(3): 222-230.
- 3) Beer TM, Hough KM, Garzotto M, Lowe BA, and Henner WD. Weekly High Dose Calcitriol and Docetaxel in Advanced Prostate Cancer. Seminars in Oncology. 2001 Aug; 28(4 Suppl 15):49-55.
- 4) Hayes-Lattin BM, Maziarz RT, and Beer TM, Allogeneic stem cell transplantation in renal-cell carcinoma. Current Oncology Reports. 2001 Sep; 3(5): 433-7.
- 5) Beer TM, Pierce WC, Lowe BA, and Henner WD. Weekly Docetaxel Treatment of Symptomatic Androgen-Independent Prostate Cancer. Advances in Prostate Cancer 2002: (6): 8-10.
- 6) Beer TM and Bubalo JS. Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer. Current Urology Reports, 2002 Jun; 3(3): 232-8.
- 7) Beer TM, Montalto MA, Lowe BA, and Garzotto M. High-Risk Localized Prostate Cancer Treated with Neoadjuvant Docetaxel and Mitoxantrone. Case Studies in Prostate Cancer. 2002: 1(2): 2-7.
- 8) Hayes-Lattin BM, Kovach, PA, Henner WD, and Beer TM. Successful Treatment of Metastatic Hormone-Refractory Prostate Cancer with Malignant Pericardial Tamponade using Docetaxel. Review Series Oncology. 2003: (2): 10-11.
- 9) Henner WD and Beer TM. A New Formulation of Calcitriol (DN-101) for High-Dose Pulse Administration in the Therapy of Prostate Cancer, Reviews in Urology, 2003: 5 Suppl 3: S38-44. (PMCID: PMC1502349)
- 10) Beer TM. Preventing prostate cancer. Finasteride shrinks enlarged prostates and may prevent some cases of prostate cancer. But it's no panacea. Health News. 2003 Aug; 9(8): 1-2.
- 11) Beer TM. Chemotherapy for Androgen-Independent Prostate Cancer (AIPC). 2004 ASCO Educational Book pp. 225-232.
- 12) Beer TM. Experimental Use of GnRH Antagonists as Second-Line Hormonal Therapy. Reviews in Urology. 2004: 6 Suppl 7: S33-8. (PMCID: PMC1472888)
- 13) Beer TM, Myrthue A, and Eilers KM. Rationale for the Development and Current Status of Calcitriol in Androgen-Independent Prostate Cancer. World Journal of Urology. 2005 Feb; 23(1): 28-32.
- 14) Oh WK and Beer TM. Current and Emerging Data on Novel Therapies in the Treatment of Asymptomatic Prostate Cancer. Oncology Consultations. 2007: 4(3): 1-10.
- 15) Beer TM and Eisenberger MA. Integration of Findings from ASCO 2006 into Clinical Practice. Interactive CD-ROM program. 2007.

Invited Lectures, Conference Presentations or Professorships

International and National

2000

Multidisciplinary Approach to Prostate Cancer Frontiers of Medicine, Palm Springs, CA

2001

Medical Management of Prostate Cancer 69th APC, Loma Linda University, Loma Linda,

CA

New Developments in Prostate Cancer 69th APC, Loma Linda University, Loma Linda, CA
The Medical Oncologist and Prostate Cancer Oncology Grand Rounds, University of Washington, Seattle, WA
Calcitriol and Docetaxel in the treatment of AIPC 2001 CaPCure Scientific Retreat, Lake Tahoe, CA

2002

Calcitriol and Docetaxel in AIPC 2nd International Prostate Cancer Congress, St. Thomas, VI
High dose calcitriol based therapy in prostate cancer treatment 2002 CaPCure Scientific Retreat, Washington, DC
Calcitriol based therapy for prostate cancer XXth Annual Chemotherapy Foundation Symposium, New York, NY
Calcitriol therapy for advanced prostate cancer 3rd Annual NCI/SUO meeting, Bethesda, MD

2003

Medical Management of Advance Prostate Cancer UCLA Oncology Grand Rounds, Los Angeles, CA
Medical Management of Advance Prostate Cancer West LA VA Oncology Grand Rounds, Los Angeles, CA
Aging and Prostate Cancer, Treatment of the Aging Patient with Cancer ASCO Satellite Symposium, Chicago, IL
Prostate Cancer and Aging, Geriatric Oncology Symposium, Los Angeles, CA
Vitamin D Receptor: A Novel Target in Prostate Cancer, New Paradigms in the Management of Prostate Cancer, Loyola University, Chicago, IL
Calcitriol based therapy for prostate cancer, Indiana University Grand Rounds, Indianapolis, IN
Advances in Strategies for prostate cancer, Loma Linda, CA
Emerging treatments for prostate cancer – Update on clinical trials, Monterey, CA
Androgen Independent Prostate Cancer: Standard treatment and the ASCENT Trial, San Francisco, CA
Vitamin D receptor as a target for prostate cancer therapy, Symposium, Western Section AUA, Las Vegas, NV

2004

Is Today's Chemotherapy Better Than Yesterdays' ICPC 2004, Whistler, Canada
Co-chair, Workshop on chemotherapy in prostate cancer ICPC 2004, Whistler, Canada
VDR – a novel target in Prostate Cancer Society of Urologic Oncology Annual Meeting, San Francisco, CA
Chemotherapy for Hormone Refractory Prostate Cancer, Systemic Therapy of Prostate Cancer: State of the Art (Educational Symposium at the 2004 ASCO Annual Meeting)
High-Dose Vitamin D as a Chemosensitizing Agent 4th International Prostate Cancer Congress, Bermuda
Drug therapy for advanced prostate cancer. US Food and Drug Administration Seminar Series
Medical management of advanced prostate cancer. Grand Rounds, Los Angeles VA, Los Angeles, CA
Round Table Discussion: Challenges in the Treatment of Symptomatic Prostate Cancer Patients. Denver, CO
New development in the management of advanced prostate cancer. 8th Congress of the Polish Society of Clinical Oncology, Warsaw, Poland
Prostate Cancer Research. University of Colorado, Denver, CO

2005

Estrogen: A sheep in wolfe's clothing? Seminars in GU Oncology, Dana-Faber Cancer Institute, Boston, MA
Treatment and Approaches for Patients with High-risk Disease. Clinical Hematology and Oncology 2005, Scripps Cancer Center, San Diego, CA
ASCENT: A double-blinded randomized study of DN-101 vs. placebo plus docetaxel in androgen-independent prostate cancer, 2005 ASCO, Chicago, IL
Prostate Cancer Oral Presentations, Session Chair, 2005 ASCO, Chicago, IL
Calcitriol ASCENT Trial, 4th International Symposium on Geniourinary Cancers, Los Angeles, CA
Practical Applications of new Agents in Genitourinary Malignancies, Practical Applications of New Agents in Oncology, San Antonio, TX
ASCENT: A double-blinded randomized study of DN-101 vs. placebo plus docetaxel in androgen-independent prostate cancer, ECCO, Paris, France

2006

Targeting the Vitamin D Receptor with High Dose Pulse Calcitriol, 13th International Workshop on Vitamin D, Victoria, BC
The place of systemic therapy in combined treatment of prostate cancer, "From the laboratory to clinical practice-Current perspectives in Oncology", Polish Society of Clinical Oncology/Polish Union of Oncology, Warsaw, Poland
What can we offer besides hormonal manipulations and chemotherapy, "From the laboratory to clinical practice-Current perspectives in Oncology", Polish Society of Clinical Oncology/Polish Union of Oncology, Warsaw, Poland
Intermittent Chemotherapy in Androgen-Independent Prostate Cancer, ASCO, Atlanta, GA
Best of ASCO Genitourinary Cancers, Best of ASCO, Beverly Hills, CA
Targeting the Vitamin D Receptor with High Dose Pulse Calcitriol, Prostate Cancer Congress, Boca Raton, FL
Targeting the Vitamin D Receptor with High Dose Pulse Calcitriol, Norway
The Case for AR-targeted therapy in AIPC, London, England
PSA-only androgen-independent prostate cancer: the condition and its natural history, Innovations and challenges in prostate cancer, Boston, MA
Vitamin D Receptor and Cancer Therapy, Emerging Strategies in Prostate Cancer Therapy, Prouts Neck, ME
Prostate Cancer Poster Discussion, Session Chair, 2006 ASCO, Atlanta, GA

2007

C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer (AIPC): Results from the ASCENT trial, 2007 Prostate Cancer Symposium, Orlando, FL
New Targets in Prostate Cancer, Session Chair and Discussant, 2007 Prostate Cancer Symposium, Orlando, FL
Novel Targets, New Options: Focus on the Nuclear Receptor VDR, American Society of Clinical Oncology Satellite Symposium: "Improving Upon Current Standards: Integration of Novel Therapies in the Treatment of Androgen-Independent Prostate Cancer", Orlando, FL
Focus on Prostate Cancer, Hoag Cancer Center, Newport Beach, CA
Progress in Identifying Aggressive Prostate Cancer, American Association for Cancer Research, Los Angeles, CA
Targeting Vitamin D Receptor for Prostate Cancer Therapy, Dana-Farber / Harvard Cancer Center Vitamin D Symposium, Boston, MA
Timing of Taxane Administration in Androgen-Independent Prostate Cancer: When to Refer and When to Treat, American Urologic Association Annual Meeting: Society of Urologic Oncology Program, Anaheim, CA
Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC), ASCO Annual Meeting, Chicago, IL

Vitamin D Receptor and Prostate Cancer Therapy, Nevada Cancer Institute, Las Vegas, NV

Is androgen deprivation a benefit or a curse?, Geriatric Oncology Consortium:

Advancing Cancer Care in the Elderly Conference, Washington, DC

Real World Settings, Real World Data: Management of Older Adults with Prostate Cancer, Geriatric Oncology Consortium: Advancing Cancer Care in the Elderly Conference, Washington, DC

2008

Management of Prostate Cancer, Hoag Cancer Center 4th Annual National CME Oncology Meeting, February, Newport Beach, CA

Annual Zoledronic Acid for Bone Loss Prevention, Genitourinary Cancers Symposium, February, San Francisco, CA

Medical Management of Docetaxel-Resistant Prostate Cancer, Genitourinary Cancers Symposium, February, San Francisco, CA

Androgen Independent Prostate Cancer, Challenging Cases in Urologic Oncology Conference, March, San Diego, CA

Managing Complications of Hormonal Therapy, Challenging Cases in Urologic Oncology Conference, March, San Diego, CA

Calcitriol in prostate cancer therapy, 3rd International Symposium: Vitamin D Analogs in Cancer Prevention and Therapy, May, Krefeld, Germany

Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC), 2008 ASCO Annual Meeting, June, Chicago, IL

Phase II study of first-line sagopilone combined with prednisone in patients with metastatic androgen-independent prostate cancer, 33rd ESMO Congress, September, Stockholm, Sweden

PANEL DISCUSSION: The Yin and the Yang of Ipilimumab for Prostate Cancer and Melanoma, Prostate Cancer Foundation 15th Annual Scientific Retreat, October, Lake Tahoe, NV

Sunlight, vitamin D and other questions from the OHSU Prostate Cancer Program, Huntsman Cancer Institute, November, Salt Lake City, UT

2009

Quality of Life in Advanced Prostate Cancer: Management Strategies, Meet the Expert – Advanced Prostate Cancer, February, Orlando, FL

Prostate Poster Walk: Prostate Cancer, 2009 Genitourinary Cancers Symposium, February, Orlando, FL

2009 Oncology Clinical Debates in Prostate Cancer, Hoag Cancer Center Oncology Education Seminar, April, Newport Beach, CA

Phase II study of first-line sagopilone combined with prednisone in patients with metastatic castration-resistant prostate cancer, 2009 ASCO Annual Meeting, May, Orlando, FL

Prostate Cancer in 2009, Mayo Clinic Medical Grand Rounds, June, Rochester, MN

Castration Resistant Prostate Cancer in 2009, 12th Congress of the Polish Society of Clinical Oncology, September, Sopot, Poland

2010

Chemotherapeutic Options in Castration-resistant Prostate Cancer: Optimizing Treatment Strategies, Duke School of Medicine and Medscape Oncology Online Continuing Medical Education Lecture Program, February, Webcast

Screening for Prostate Cancer in 2010, Hoag Cancer Center Oncology Grand Rounds, February, Newport Beach, CA

Community Oncology Clinical Debates in Castration-Refractory Prostate Cancer, Institute for Medical Education & Research 2010 Prostate Cancer CME Community

Program, May, Sacramento, CA
Pain as an Endpoint: Relevance for this Patient Population, Prostate Cancer SATURN Study Investigators Meeting, May, Scottsdale, AZ
Poster Discussion: Effect of ID1 expression change following chemotherapy on chemotherapy sensitivity, 2010 ASCO Annual Meeting, June, Chicago, IL
MDV3100 Phase I-II Trial in CRPC, PREVAIL North America Investigator meeting, September, San Francisco, CA
PREVAIL Critical Success Factors, PREVAIL North America Investigator meeting, September, San Francisco, CA
The Future of Oncology: Developing Personalized Medicine in Oncology, Elihu Root, M.D. Distinguished Lectureship Series at St. Lukes's Episcopal Hospital CME Internal Medicine Grand Rounds, October, Houston, TX
High Intensity Collaboration: An Essential Catalyst for Rapid Development of Novel Cancer Therapies, President's Cancer Panel: The Future of Cancer Research: Accelerating Scientific Innovation, October, Philadelphia, PA

2011

Castrate-Refractory Prostate Cancer: Current Clinical Debates and Emerging Agents on the Horizon, Institute for Medical Education & Research program, February, Phoenix, AZ
MAOA inhibition during docetaxel therapy: a strategy to block tumor adaptation to docetaxel, 2011 Innovative Minds in Prostate Cancer Today (IMPACT) Conference, March, Orlando, FL
Recent Advances in the Treatment of Castration-Resistant Prostate Cancer: Focus on Emerging Hormonal Therapies and Immunotherapies, Veritas Institute for Medical Education Prostate Cancer series, April, Webinar
Focus on Novel Chemotherapy Options and Bone-Targeting Approaches, Veritas Institute for Medical Education Prostate Cancer series, April, Webinar
Recent Advances in the Treatment of Castration-Resistant Prostate Cancer: Focus on Emerging Hormonal Therapies and Immunotherapies, Veritas Institute for Medical Education Prostate Cancer series, May, Webinar
Recent Advances in the Treatment of Castration-Resistant Prostate Cancer: Focus on Emerging Hormonal Therapies and Immunotherapies, Veritas Institute for Medical Education Prostate Cancer series, May, Webinar
Focus on Novel Chemotherapy Options and Bone-Targeting Approaches, Veritas Institute for Medical Education Prostate Cancer series, June, Webinar
Quality-of-life assessment in a randomized, double-blind study of sipuleucel-T in men with androgen-dependent prostate cancer, ASCO Annual Meeting, June, Chicago, IL
Randomized, double-blind, phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naïve castration-resistant prostate cancer (CRPC), ASCO Annual Meeting, June, Chicago, IL
Focus on Novel Chemotherapy Options and Bone-Targeting Approaches, Veritas Institute for Medical Education Prostate Cancer series, June, Webinar
Castration resistant prostate cancer: The State of Art, Multidisciplinary Educational Conference, November, Warsaw, Poland

2012

Castration Resistant Prostate Cancer: State of the Art in 2011, mCRPC: New Targets, New Therapeutic Approaches Medscape Oncology Town Hall, February, San Francisco, CA
Novel endocrine agents, Recently Available and Emerging Systemic Treatments for Prostate Cancer Symposium, February, San Francisco, CA
CA184-095: A randomized, double-blind, phase III trial to compare the efficacy of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients (pts)

with metastatic chemotherapy-naïve castration-resistant prostate cancer (CRPC), ASCO Annual Meeting, June, Chicago, IL
Castration resistant prostate cancer: state of the art in 2012 focus on cancer-directed therapies, ASCO Annual Meeting, June, Chicago, IL

2013

Highlights of the Day – The Prostate Cancer Oral Session, ASCO Annual Meeting Highlights of the Day II Session, June, Chicago, IL
Managing Advanced Prostate Cancer, Living with cancer webinar, September, online
Current and Future Treatment Algorithms in the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC), Research to Practice, Interactive Grand Rounds Series, September, Libertyville, IL
Current and Future Treatment Algorithms in the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC), Research to Practice, Interactive Grand Rounds Series, November, Warrenville, IL

2014

Current and Future Treatment Algorithms in the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC), Research to Practice, Interactive Grand Rounds Series, January, Las Vegas, NV
Enzalutamide decreases risk of death and delays progression in phase III trial of men with metastatic prostate cancer, ASCO Genitourinary Cancers Symposium's Presscast, January, San Francisco, CA
Enzalutamide in men with chemotherapy-naïve metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study, ASCO Genitourinary Cancers Symposium's Welcome and General Session 1, January, San Francisco, CA
Enzalutamide in men with chemotherapy-naïve metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study, Medivation headquarters, January, San Francisco, CA
New Approaches to Endocrine Treatment of Prostate Cancer: Androgen Receptor Antagonists – Enzalutamide, Research to Practice, Second Opinion Interactive Case-Based Discussions Focused on the Management of Metastatic Prostate Cancer, January, San Francisco, CA
Castration Resistant Prostate Cancer: New approaches to therapy in 2014, Wuxi Fox Chase Cancer Center grand opening ceremony, April, Wuxi, China
Challenging Cases in Prostate Cancer, Research to Practice, Oncologist and Nurse Investigators Consult on Actual Patients from the Practices of the Invited Faculty (part 1 of a 6-part CNE series), April, Anaheim, CA
Blending the Science and Art of Medicine in the Individualized Treatment of Metastatic Castration-Resistant Prostate Cancer: Real Cases, Difficult Choices – Make the Call, Peer View Live CME Symposium, June, Chicago, IL
Sustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancer, PCF Journal Club, August, Portland, OR/Santa Monica, CA
Abiraterone and Enzalutamide in Castration Resistant Prostate Cancer, Educational webinar sponsored by Bayer, October, online
Prostate cancer expert panelist, Dilemmas in Oncology Workshop, October, Olsztyn, Poland
Novel agents in CRPC treatment, Kidney Cancer and Prostate Cancer Symposium, October, Serock, Poland

2015

Clinical Challenges in Castrate-Resistant Prostate Cancer: How to Choose the Right Treatment for the Right Patient at the Right Time, Penn State College of Medicine and PeerView Institute for Medical Education Symposium, February, Orlando, FL

Conference Roundtable: Prostate Cancer with Tomasz Beer, MD, GLG Research Meeting, February, Orlando, FL

Patient-Centered Management in Metastatic Castration-Resistant Prostate Cancer Medscape Oncology CME Video Roundtable Discussion, February, Orlando, FL

Consensus Expert Panel Advanced Prostate Cancer Consensus Conference, March, St. Gallen, Switzerland

Personalizing Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC) American Urological Association Annual Meeting, May, New Orleans, LA

Enzalutamide (ENZA) in men with chemotherapy-Naïve metastatic castration-resistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL study. American Society of Cancer Oncologists Annual Meeting, May, Chicago, IL

Applying the Latest Evidence to Guide Treatment Decision-Making in CRPC: Real Cases, Difficult Choices- You Make the Call. PeerView Institute of Medical Education ASCO Symposium, May, Chicago, IL

Advances in Antineoplastic Therapy for Castration Resistant Prostate Cancer (CRPC). Japanese Society of Medical Oncology annual meeting, July, Sapporo, Japan

Prostate Cancer. Medical seminar in conjunction with JSMO, July, Sapporo, Japan

Enzalutamide and Abiraterone in Prostate Cancer. Prostate Cancer Research Institute's 2015 Prostate Cancer Conference, September, Los Angeles, CA

New Frontiers in Advanced Prostate Cancer, ZERO Webinar, September, online

2016

Integrative Clinical Genomics in Castrate-Resistant Prostate Cancer, Genitourinary Cancers Symposium, January, San Francisco, CA

Strategies for Selection and Optimal Sequencing of Current Treatment Options for Metastatic Castration-Resistant Prostate Cancer, Horizon CME Webcast, February, online

Managing a Patient with node-positive prostate cancer, Transforming Prostate Cancer Care in a Rapidly Evolving Treatment Landscape PeerView CME Symposium, May, San Diego, CA

New Frontiers in Advanced Prostate Cancer, ZERO Webinar, September, online

2017

AR-V7 – Ready for use in daily clinical decision making?, Advanced Prostate Cancer Consensus Conference (APCCC), March, St. Gallen, Switzerland

Advanced Prostate Cancer Searching for Optimal Therapy Sequence and Assessing Emerging Treatment Options, Creative Educational Concepts Grand Round Series, April, Chicago, IL

Precision Therapy for Metastatic Castration Resistant Prostate Cancer (mCRPC): the Impact of Molecular Discoveries, 105th Japanese Urological Association annual meeting, April, Kagoshima, Japan

Global trend and controversy in CRPC through APCCC, Expert meeting during 105th Japanese Urological Association annual meeting, April, Kagoshima, Japan

Global consensus of advanced prostate cancer, Satellite Symposium in conjunction with the 105th Japanese Urological Association annual meeting, April, Kagoshima, Japan

Clinical Considerations for a Patient with Hormone-Sensitive, Metastatic Prostate Cancer, PER Medical Crossfire: Personalized Sequencing in Castration-Resistant Prostate Cancer Symposia, June, Chicago, IL

Current & Emerging Treatment Options for Advanced Prostate Cancer, Strategies for Managing Symptoms and Treatment Side Effects, and Tools for Living Well with Prostate Cancer, Patient Power Advanced Prostate Cancer Virtual Town Meeting, October, Seattle, WA and live global online audience

2018

Prostate Cancer treatment paradigm: Focus on castration resistant prostate cancer

- (*mCRPC*), International lecture series hosted by Astellas Pharma International, January, Riyadh, Saudi Arabia
- Treatment sequencing in advanced prostate cancer: Newly diagnosed and castration resistant metastatic prostate cancer*, International lecture series hosted by Astellas Pharma International, January, Riyadh, Saudi Arabia
- Collaboration between physicians and pharmacists in the management of prostate cancer*, International lecture series hosted by Astellas Pharma International, January, Riyadh, Saudi Arabia
- Optimizing care for patients with advanced prostate cancer*, International lecture series hosted by Astellas Pharma International, January, Riyadh, Saudi Arabia
- Role of novel AR agents in treating mCRPC patients*, International lecture series hosted by Astellas Pharma International, January, Riyadh, Saudi Arabia
- Clinical considerations in mCRPC management*, International lecture series hosted by Astellas Pharma International, January, Jeddah, Saudi Arabia
- mCRPC clinical case studies*, International lecture series hosted by Astellas Pharma International, January, Jeddah, Saudi Arabia
- AR targeting in advanced prostate cancer*, International lecture series hosted by Astellas Pharma International, January, Jeddah, Saudi Arabia
- Newly Diagnosed metastatic prostate cancer: Clinical case studies*, International lecture series hosted by Astellas Pharma International, January, Jeddah, Saudi Arabia
- Evolving Standards of Care in Metastatic Prostate Cancer*, PRCA Grand Rounds lecture series, January, Rockville, MD
- Hepatic effects assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials*, Genitourinary Cancers Symposium, February, San Francisco, CA
- Looking to the future & Ask the experts*, Hormonal therapy in prostate cancer: Improving clinical outcomes in metastatic and non-metastatic disease – prIME Oncology Symposium, February, San Francisco, CA
- Changing landscape of CRPC and changing landscape of HSmPC*, Enzalutamide Scientific Advisory Board Meeting, March, Dallas, TX
- Evolving Standards of Care in Metastatic Prostate Cancer*, PRCA Grand Rounds lecture series, March, Long Beach, CA
- AR Targeting in Advanced Prostate Cancer*, PeerView's Symposium: Newest Advances and Strategies in Prostate Cancer, June, Chicago, IL
- Evolving Standards of Care in Metastatic Prostate Cancer*, PRCA Grand Rounds lecture series, June, Chicago, IL
- AR Targeting in Advanced Prostate Cancer*, Genitourinary Malignancies Regional Summit Series, July, Pasadena, CA
- Clinical considerations in mCRPC Management*, Genitourinary Malignancies Regional Summit Series, July, Pasadena, CA

2019

- Castration Resistant Metastatic Prostate Cancer*, National Military Hospital, January, Bogota, Colombia
- Castration Resistant Metastatic Prostate Cancer*, Sociedad Colombiana de Urologia, January, Cartagena, Colombia
- the M1 asymptomatic and Oligosymptomatic CRPC patient*, National Society of Urology, January, Bogota, Colombia
- The Current State and Promising Horizon of Precision Medicine*, 2019 Zero Summit, February, Washington, DC
- Advancing the Care for Non-metastatic CRPC*, Genitourinary Malignancies Regional Summit, April, Pasadena, CA
- Personalized Therapy and Sequencing in the Treatment of mCRPC*, Astellas Brazil – Meet the Professor (ASCO), June, Chicago, IL
- Prostate Cancer Updates in a Nutshell*, Prostate Cancer Masterclass, October, Cairo Egypt

Prostate Cancer Clinical Practice Update, Prostate Cancer Masterclass, October, Cairo, Egypt

Personalized Treatment of Prostate Cancer, Prostate Cancer Masterclass, October, Cairo, Egypt

Challenges in the Management of mCRPC from the Oncologist's Perspective, Prostate Cancer Masterclass, October, Cairo, Egypt

Challenges in the Management of mCRPC from the Urologist's Perspective, Prostate Cancer Masterclass, October, Cairo, Egypt

Congresses' Highlights: Latest Updates in mCRPC, Prostate Cancer Masterclass, October, Jeddah, Saudi Arabia

Sequencing Therapy in Prostate Cancer from the Oncologist's Perspective, Prostate Cancer Masterclass, October, Jeddah, Saudi Arabia

Sequencing Therapy in Prostate Cancer from the Urologist's Perspective, Prostate Cancer Masterclass, October, Jeddah, Saudi Arabia

Patient Centric Treatment in mCRPC from the Oncologist's Perspective, Prostate Cancer Masterclass, October, Beirut, Lebanon

Patient Centric Treatment in mCRPC from the Urologist's Perspective, Prostate Cancer Masterclass, October, Beirut, Lebanon

2020

Equipping Patients for Care, 2020 ZERO Summit, February, Washington DC

Advanced Prostate Cancer: Putting Survival into Perspective, ASCO 2020 Annual Meeting, May, Chicago IL (via virtual)

Evolving Landscape of the Prostate Cancer Care Continuum Challenging Cases in mHSPC, III Astellas Oncology Forum, October (Via webex)

Altering the Course of Cancer in Primary Care: Early Detection for Better Long-Term Outcomes, Satellite Symposium at the AAFP Family Medicine Experience (FMX) Conference, October (via webex)

2021

Cancer Patients and Covid-19 Vaccine, New York Times, January (virtual)

PARP Inhibitors in Metastatic CRPC, Chinese Health Professionals Development Alliance (HPDA), January (virtual)

PREVAIL 5-year Follow-up Series, Uromedica, March, Bogota, Colombia (via virtual)

PREVAIL 5-year Follow-up Series, HUV, March, Valle del Cauca, Colombia (via virtual)

PREVAIL 5-year Follow-up Series, Uroclin, March, Antioquia, Colombia (via virtual)

PREVAIL 5-year Follow-up Series, Hospital San Ignacio, April, Bogota, Colombia (via virtual)

Interim Results of PATHFINDER, A Clinical Use Study Using a Methylation-Based Multi-Cancer Early Detection Test, ASCO Annual Meeting, June, Chicago, IL (via virtual)

Multi-Cancer Early Detection Blood Based Testing, 30th Annual National Conference, September (via virtual)

2022

PSMA Therapeutics and the Future of Targeted Therapies, ZERO Prostate Cancer Summit, February, Washington, DC (via virtual)

Genitourinary Cancer and RCC, 2022 PRIMO Event, February, Waikoloa Hawaii

How to Follow-Up Patients Who Had PSMA PET as Baseline Imaging. APCCC, April, Basel, Switzerland

Multi-Cancer Early Detection Tests: Raising Awareness of Novel Cancer Control Strategies in Primary Care. HMP Global Education, April, East Windsor, NJ (via virtual)

The Future of Cancer Screening: Multi-Cancer Early Detection in Primary Care, Pri-Med, May, Boston, MA (via virtual)

Real World Data and Practical Considerations in the Use of Novel Hormonal Agents in CRPC. How Guidelines and Clinical Trial Data Inform the Modern Day Treatment of

*Advanced Prostate Cancer, PER Satellite Symposium at ASCO, June, Chicago IL*Regional and Local**1999**

Chemotherapy in Prostate Cancer ACS/Northwest Hospital Prostate Cancer Forum, Seattle, WA

Prostate Cancer in Native American Populations NW Tribal Cancer Control Proj. Clinician Training, Portland, OR

2000

Treatment of Advanced Prostate Cancer Oncology Nursing Society, Portland Chapter, Portland, OR

Neoadjuvant Therapy for Localized Prostate Cancer Oregon Urological Society Winter Meeting, Bend, OR

Hormonal Strategies for Advanced Prostate Cancer Oregon Urological Society Winter Meeting, Bend, OR

Role of Chemotherapy for Advanced Prostate Cancer Oregon Urological Society Winter Meeting, Bend, OR

The Emerging Role of Chemotherapy in Prostate Cancer St. Charles Hospital Tumor Board, Bend, OR

Management of Advanced Prostate Cancer Salem Hospital CRISP Conference, Salem, OR

Prostate Cancer Update for Primary Care Physicians 5th Ann. Specialties Update for Family Practice, Seaside, OR

Prostate Cancer, What's New Evergreen Hospital Grand Rounds, Kirkland, WA

Medical Management of Advanced Prostate Cancer Idaho Soc. of Clin. Oncology Annual Meeting, Sun Valley, ID

2001

Prostate Cancer Update 32nd Annual Family Practice Review, Portland, OR

Prostate Cancer Grand Rounds, North Bend Medical Center, Coos Bay, OR

Prostate Cancer at ASCO 2001 ASCO Review, Portland, OR

Multi-modality Therapy for High-risk Prostate Cancer 2001 Pacific Prostate Cancer Conference, Portland, OR

Clinical Trials in the Northwest 2001 Pacific Prostate Cancer Conference, Portland, OR

1 in 6 men will die of prostate cancer – what can we do about it? Grand Rounds, St. Charles Hospital, Bend, OR

Management of Androgen-Independent Prostate Cancer Tumor Board, St. Peters Providence Hosp., Olympia, WA

2002

Prostate Cancer Update 33rd Annual Family Practice Review, Portland, OR

Prostate Cancer at ASCO 2002 3rd Annual ASCO Review, Portland, OR

Endocrine therapy for prostate cancer Ashland Endocrine Conference, Ashland, OR

Treatment of Advanced Prostate Cancer Deaconess Hospital Tumor Board, Spokane, WA

What is the best treatment for localized prostate cancer? Benton County Med. Soc. Annual CME, Richland, WA

Chemotherapy in the treatment of advanced prostate cancer Pacific NW Prostate Cancer Conference, Seattle, WA

Innovative treatments in development in 2002 Pacific NW Prostate Cancer Conference, Seattle, WA

2003

Advances in Chemotherapy Strategies for Prostate Cancer, Eugene, OR
An Update on the Treatment Modalities and Clinical Trials for High Risk and HRPC Patients, Jacksonville, OR
Development of Calcitriol-Based Therapies for Prostate Cancer Univ. of Washington SPORE mtg., Seattle, WA
Advances in the Management of Advanced Prostate Cancer, IUN Series, Portland, OR
Medical Management of Advanced Prostate Cancer, Grand Rounds, SW Washington Med. Ctr, Vancouver, WA
Hormonal Therapy, Pacific NW Prostate Cancer Conference, Portland, OR
Current Research Initiatives in the Northwest, Pacific NW Prostate Cancer Conference, Portland, OR
New Developments in the Management of Advanced Prostate Cancer, Corvallis, OR

2004

Prostate Cancer Update, 35th Annual Family Practice Review, Portland, OR
A fresh look at prostate cancer, 11th Annual Internal Medicine Review, Portland, OR
Medical Management of Advance Prostate Cancer, OHSU Medical Oncology Grand Rounds, Portland, OR
Calcitriol in Prostate Cancer Therapy, 62nd Summer Lecture Series, Portland, OR
Aging and Prostate Cancer. OGEC Summer Institute, Portland, OR
Prostate Cancer Treatment. Cancer Control Training for the Indian Health Service
Development of calcitriol-based cancer therapy. Marquam Hill Lectures, Portland, OR
Prostate Cancer: What you need to know. Rotary Luncheon, Portland, OR
Chemotherapy and investigations therapies to treat advanced and metastatic disease, Pacific NW Prostate Cancer Conference, Seattle, WA
Current Research in the Northwest, Pacific NW Prostate Cancer Conference, Seattle, WA
Taxotere in the Management of Androgen-Independent Metastatic Prostate Cancer, Puyallup, WA
A multidisciplinary approach to prostate cancer, Sommer Memorial Lectures/OHSU Alumni Scientific Session, Portland, OR

2005

Evaluating Quality of Life: Clinical Trial Experience and Issues, Portland, OR
Prostate Cancer Training for the Latino Community, Portland, OR
Beyond Hormonal Manipulation: The Role of Chemotherapy for the Treatment of Advanced and High-risk Prostate Cancer, Spokane, WA

2006

Prostate Cancer: Willamette Falls Hospital Grand Rounds, Oregon City, OR
Advanced Prostate Cancer Survivorship Issues: Current immunotherapy and chemotherapy approaches, Pacific NW Prostate Cancer Conference, Seattle, WA
Breast and Prostate Cancer: Multidisciplinary Cancer Care for Women and Men, Portland, OR

2007

Advances in Prostate Cancer, Bend, OR
Advances in Prostate Cancer, Medford, OR
Prostate Cancer in 2007, Southwest Washington Medical Center Cancer Conference, Vancouver, WA
Prostate Cancer: When to Screen / When to Treat, 14th Annual Internal Medicine Review, Portland, OR
Prostate Cancer Research Program, OHSU Foundation Gift Planning Workshop, Portland, OR
Molecular Biology of Prostate Cancer, Graduate Cancer Biology Class, Portland, OR

Prostate Cancer Research Program, OHSU Foundation Planned Giving Council Meeting, Portland, OR
Advances in Prostate Cancer, Coos Bay, OR
Solving Prostate Cancer: The View from OHSU, 7th Annual Pacific NW Prostate Cancer Conference, September, Portland, OR
Updates in Prostate Cancer, OHSU Resident Noon Conference, Portland, OR

2008

Advanced Prostate Cancer, OHSU Hematology & Medical Oncology Fellows Grand Rounds, January, Portland, OR
What's New in Prostate Cancer, Meridian Park Hospital Primary Care Educational Conference, February, Portland, OR
Multidisciplinary cancer care, 2008 Payor Luncheon, April, Portland, OR
What's New in Prostate Cancer, Providence St. Vincent Internal Medicine Conference, April, Portland, OR
What's new in prostate cancer prevention and detection, OHSU Healthy Talks Community Lecture Series: Prostate Cancer Prevention, May, Portland, OR
Latest Advances from the OHSU Prostate Cancer Program, Advancements in Prostate Cancer Research and Care Luncheon, June, Portland, OR
The Prostate: More than a Gland, OHSU Department of Medicine Grand Rounds, September, Portland, OR
Sunlight, vitamin D and other questions from the OHSU Prostate Cancer Program, Human Investigations Program, November, Portland, OR
Evolving Multidisciplinary Management of Prostate Cancer, November, Portland, OR
Phase I Trial of Ipilimumab Alone and in Combination with Radiotherapy in Patients with Metastatic Castration Resistant Prostate Cancer, Northwest Urological Society's 55th Annual Conference, December, Portland, OR

2009

What's New in Prostate Cancer, 40th Annual Family Medicine & Primary Care Review, February, Portland, OR
Prostate Cancer Update, Salem Hospital's Department of Hematology Oncology, March, Salem, OR
Sunlight, vitamin D and other questions from the OHSU Prostate Cancer Program, OHSU MSTP Grand Rounds, April, Portland, OR
Latest Advances in Prostate Cancer, Mahina Young's Golf Tournament, May, Aurora, OR
Systemic Therapy for Prostate Cancer in 2009, Evolving Multidisciplinary Management of Prostate Cancer Series, August, Bend, OR
The future of prostate cancer care, OHSU Prostate Cancer Support Group, September, Portland, OR
How we beat prostate cancer, 9th Annual Pacific NW Prostate Cancer Conference, September, Portland, OR
 JOURNAL DISCUSSION: *Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer*, OHSU Prostate Cancer Journal Club, October, Portland, OR
Prostate Cancer in 2009, Indian Health Service Clinical Support Center's Clinicians Update Symposium, October, Portland, OR
How we beat Prostate Cancer, Ask the Health Experts lecture series, October, Portland, OR
Multidisciplinary care of prostate cancer, Evolving Multidisciplinary Management of Prostate Cancer Series, November, Seattle, WA
The future of oncology and the crucial contributions of surgery, OHSU Surgery Grand Rounds, November, Portland, OR

Progress in 2009 and a Vision for the Future, Advancements in Prostate Cancer Research and Care Program, December, Portland, OR
Multidisciplinary care of prostate cancer, Evolving Multidisciplinary Management of Prostate Cancer Series, December, Kennewick, WA

2010

Sunlight, vitamin D and other questions from the OHSU Prostate Cancer Program, Linus Pauling Institute Seminar Program, January, Corvallis, OR
Prostate Cancer in 2010: New Data, New Controversies, 41st Annual Family Medicine & Primary Care Review, February, Portland, OR
Sunlight, vitamin D and other questions from the OHSU Prostate Cancer Program, Achievement Rewards for College Scientists (ARCS) Foundation's Annual Meeting, March, Portland, OR
Systemic Therapy for Prostate Cancer in 2010, Novartis Hematology and Oncology Training Practicum, March, Portland, OR
Prostate Cancer in 2010: A focus on new developments, St. Charles Medical Center Grand Rounds Series, March, Bend, OR
Screening for Prostate Cancer in 2010, 17th Annual Internal Medicine Review, April, Portland, OR
 PANEL DISCUSSION: *PSA Perspectives*, Oregon Urology Foundation's Annual Symposium: "Urology Update", April, Eugene, OR
The Future of Oncology, OHSU Hematology & Medical Oncology Grand Rounds, April, Portland, OR
Castration-Resistant Prostate Cancer in 2010, Salem Hospital and OHSU's 2010 Prostate Cancer Symposium, April, Lake Oswego, OR
Advances in Prostate Cancer in 2010, OHSU Prostate Cancer Support Group, September, Portland, OR
Updated Results of the IMPACT Trial of Sipuleucel-T for Metastatic, Castration-Resistant Prostate Cancer (CRPC), Portland Oncology Journal Club, September, Portland, OR
New Treatments on the Horizon, Ask the Health Expert Lecture Series, September, Portland, OR
New Treatments on the Horizon, 10th Annual Pacific NW Prostate Cancer Conference, October, Seattle, WA/Portland, OR
Cabazitaxel: A New Option for mHRPC Following a Docetaxel Containing Regimen Roundtable Program, Roundtable Program, November, Portland, OR
New agents changing the face of advanced prostate cancer, OHSU Hematology & Medical Oncology Grand Rounds, December, Portland, OR

2011

Cabazitaxel: A New Option for mHRPC Following a Docetaxel Containing Regimen Roundtable Program, Roundtable Program, January, Salem, OR
Prostate Cancer: New Treatments on the Horizon, 11th Annual Pacific NW Prostate Cancer Conference, October, Portland, OR/Seattle, WA

2012

Report from 2011, OHSU Prostate Cancer Support Group, February, Portland, OR
Prostate Cancer in 2012, 19th Annual Internal Medicine Review, April, Portland, OR
Cancer Care of the Future, Columbia Forum, April, Astoria, OR
Castration Resistant Prostate Cancer: State of the Art in 2012 Focus on cancer-directed therapies, 12th Annual Pacific NW Prostate Cancer Conference, October, Portland, OR/Seattle, WA

2013

How to take a sabbatical and get away with it – 37 easy steps..., Division of Hem/Onc

faculty mentor meeting, April, Portland, OR
Castration Resistant Prostate Cancer: State of the Art in 2013 Focus on cancer-directed therapies, OHSU Knight Cancer Biology & Translational Research Seminar, May, Portland, OR
Castration Resistant Prostate Cancer: State of the Art in 2013 Focus on cancer-directed therapies, Dendreon Visiting Professorship Lecture, August, Seattle, WA
Castration Resistant Prostate Cancer: State of the Art in 2013 Focus on cancer-directed therapies, 13th Annual Pacific NW Prostate Cancer Conference, September, Portland, OR/Seattle, WA
Castration Resistant Prostate Cancer: State of the Art in 2013 Focus on cancer-directed therapies (Part 1), OHSU Hematology & Medical Oncology Grand Rounds, November, Portland, OR
Multi-modality therapy for high-risk prostate cancer (Part 2), OHSU Hematology & Medical Oncology Grand Rounds, November, Portland, OR

2014

A vision to transform cancer and the community: how the Knight Cancer Challenge will shape the future of bioscience, medicine and research in Oregon, OHSU Day at Intel, February, Hillsboro, OR
Prostate Cancer in 2014: Screening and New Treatment Advances, 45th Annual Primary Care Review, February, Portland, OR
The Knight Cancer Challenge: "Ending cancer as we know it", OHSU Urology Department Grand Rounds, March, Portland, OR
Prostate Cancer in 2014: Screening and New Treatment Advances, 21st Annual Internal Medicine Review, April, Portland, OR
The Knight Cancer Challenge: "Ending cancer as we know it", Elks' annual state convention, April, Milwaukie, OR
OHSU Knight Cancer Institute Extending Clinical Research into the Community, OSO Spring Oncology Conference, April, Portland, OR
PREVAIL: Results in context, Pacific NW Prostate Cancer SPORE seminar series, June, Multi-site video connection (Vancouver, BC, Seattle, WA & Portland, OR)
New developments in metastatic prostate cancer in 2014, OHSU Prostate Cancer Support Group, September, Portland, OR
New developments in metastatic prostate cancer in 2014, 14th Annual Pacific NW Prostate Cancer Conference, September, Portland, OR/Seattle, WA/Vancouver, BC, Canada
New developments in metastatic prostate cancer in 2014, Association of VA Hematology/Oncology 10th Annual Meeting, September, Portland, OR
Prostate Cancer in 2014: Screening and New Treatment Advances, Texas Club of Internists CME scientific session, October, Portland, OR
Signaling, Imaging of Solid Tumor Response—Pitch Talks, Discussion Provocateur Solid Tumors and Quantitative Oncology Programs' Retreat, November, Portland, OR

2015

Prostate Cancer Clinical Trials, NW Urological Physicians Clinic Group, June, Portland, OR
Chemotherapy in Prostate Cancer in 2015, Sanofi Prostate Cancer Preceptorship, August, Portland, OR
The State of the Art in Prostate Cancer Care, OHSU Knight Prostate Cancer Support Group, September, Portland, OR
Chemotherapy in Prostate Cancer in 2015, Prostate Cancer Symposium, September, Salem, OR
Current Management of Castration-Resistant Prostate Cancer, 15th Annual Pacific NW Prostate Cancer Conference, September, Portland, OR/Seattle, WA/Vancouver, BC, Canada

Prostate Cancer. OHSU Hematology & Medical Oncology Grand Rounds, September, Portland, OR
Chemotherapy in Prostate Cancer in 2015, Sanofi Prostate Cancer Preceptorship, October, Portland, OR

2016

Integrative Clinical Genomics in Castration-Resistant Prostate Cancer, OHSU Hematology & Medical Oncology Division Meeting, April, Portland, OR
Androgen Receptor Inhibition and Integrative Clinical Genomics in Castration-Resistant Prostate Cancer, Knight Cancer Research Group Series, June, Portland, OR
Chemotherapy in Prostate Cancer in 2016, Genzyme Prostate Cancer Preceptorship, August, Portland, OR
Chemotherapy in Prostate Cancer in 2016, Genzyme Prostate Cancer Preceptorship, September, Portland, OR
Advances in Antineoplastic Therapy for Castration Resistant Prostate Cancer (CRPC), 16th Annual Pacific NW Prostate Cancer Conference, September, Portland, OR/Seattle, WA/Vancouver, BC, Canada
Prostate Cancer Treatment and the Coming Era of Genomics, OHSU Knight Prostate Cancer Support Group, October, Portland, OR

2017

Advanced Prostate Cancer: Searching for Optimal Therapy Sequence and Assessing Emerging Treatment Options, OHSU Hematology & Medical Oncology Grand Rounds, February, Portland, OR
Recent Developments in Castration Resistant Prostate Cancer (mCRPC), OHSU Knight Prostate Cancer Research Program's clinical brown bag series, May, Portland, OR
Recent Developments in Castration Resistant Prostate Cancer (mCRPC), OHSU Hematology & Medical Oncology Grand Rounds, May, Portland, OR
State of the art in prostate cancer treatment, OHSU Knight Prostate Cancer Support Group, September, Portland, OR
Prostate Cancer, OHSU Knight Prostate Cancer Research Program's clinical brown bag series, November, Portland, OR
Evolving Standards of Care in Metastatic Prostate Cancer, PRCA Grand Rounds lecture series, November, Seattle, WA
Newly Diagnosed Metastatic Disease, Omniprex Prostate Cancer Symposium, November, Portland, OR
Castration-resistant disease: Personalizing therapy and treatment sequencing, Omniprex Prostate Cancer Symposium, December, Portland, OR

2018

Prostate cancer screening, 49th Annual Primary Care Review, February, Portland, OR
Big ideas inspire big philanthropy – and lead to big results, 33rd American Council on Gift Annuities conference, April, Seattle, WA
Clinical considerations in mCRPC management, OHSU Hematology & Medical Oncology Grand Rounds, May, Portland, OR
Evolving Standards of Care in Metastatic Prostate Cancer, PRCA Grand Rounds lecture series, May, Bend, OR
Prostate Cancer 101, OHSU Knight Prostate Cancer Research Program's clinical Brown Bag Series, June, Portland, OR
Current Management of Castration-resistant Prostate Cancer, Pacific NW Prostate Cancer Conference, September, Portland, OR

2019

Prostate Cancer Research, Lake Oswego Rotary Club, January, Lake Oswego, OR
Updates in prostate cancer, 7th International Conference on Advances in Hematology

and Oncology, June, Seattle, WA
 2019 *Breaking News on Prostate Cancer*, Pacific NW Prostate Cancer Conference,
 September, Portland, OR

2020

Cancer 101: Where We Are in 2020, Knight School, January, Portland, OR
Tackling Testosterone to Vanquish Prostate Cancer, Medicine Grand Rounds, April,
 Portland, OR
Prostate Cancer, C616, Advanced Topics in Cancer Biology, May, Portland, OR
Pathfinder, Hematology Oncology Fellow Didactics, May, Portland, OR
Pathfinder: A Prospective Trial of A Multi-cancer Early Detection Test, CEDAR Scientific
 Advisory Board, May, Portland, OR
Current Management of Castration-Resistant Prostate Cancer, Pacific NW Prostate Cancer
 Conference, September, Portland, OR
Expanding the Way We Screen for Cancer: A Path to a Multi-Cancer Early Detection Test,
 Early Detection Cancer Conference, October, Portland, OR (via virtual)
Prostate Cancer and Making Sense of nm-CRPC Treatment Options, Patient Power, Your
 Prostate Cancer Questions Answered Series, October, Portland, OR

2021

Tackling Testosterone to Vanquish Prostate Cancer, 52nd Annual Primary Care Review,
 February, Portland, OR
*Latest Developments in Blood-Based Multi-Cancer Detection Tests: Closer Than You
 Think...*, CRM Lunch & Learn Series, February, Portland, OR
Prostate Cancer, C616 Advanced Topics in Cancer Biology, May, Portland, OR
Update on New Developments in Prostate Cancer Care and Clinical Trials, Olympia USTOO
 Support Group, June, Olympia, OR (via virtual)
Emerging Multi-Cancer Early Strategies, OHSU Hematology & Medical Oncology Grand
 Rounds, August, Portland, OR
Emerging Multi-Cancer Early Strategies, OHSU Department of Medicine Grand Rounds,
 August, Portland, OR

2022

Pathfinder Study, Bay Area Hospital's Clinical Advisory Group, February, Coos Bay, OR (via
 virtual)
Emerging Multi-Cancer Early Detection Strategies, OHSU OBGYN Grand Rounds, March,
 Portland, OR
Multi-Cancer Early Detection in 2022, 6th Annual Knight Cancer Network Symposium,
 March, Portland, OR
Blood Based Molecular Early Detection of Cancer, C616 Advanced Topics in Cancer
 Biology, May, Portland, OR
Advances in Cancer Early Detection, Coos Bay Area Hospital Grand Rounds, June, Coos
 Bay, OR
Advances in Cancer Early Detection, OHSU Department of Medicine Grand Rounds,
 August, Portland, OR

Education Grants and Contracts:

1R13 CA93317 (Beer)	6/15/01-6/14/04	effort: <5%
National Institutes of Health	\$12,000 (total direct)	
Oregon Prostate Cancer Conference		

Educational Activity:

Outpatient Clinic 1 ½ days per week. Frequently attended by Oncology fellows as well as Radiation Oncology and Internal Medicine Residents.

Housestaff Teaching Oncology conference (1-2/year), Noon conference (1/year), Department of Medicine Grand Rounds (0.5/year), Resident lectures (1/month)

Graduate Student Teaching Lecturer for Cancer Biology (CELL 616)

Direct Mentoring**National Level**

I was invited to serve as a faculty mentor fellow sessions at the American Urological Association Annual Meetings in 2005 and 2007 and the 2007 Multidisciplinary Prostate Cancer Symposium. Faculty are selected from an international pool for their ability to mentor trainees as they contemplate a career in academic medicine.

2008 **Ilya Tsimafeyeu, M.D.**, Medical Oncologist, International Development and Education Award (IDEA) Program, Primary Mentor (Joshi Alumkal, M.D., Co-mentor). This is an international mentorship program sponsored by the American Society of Clinical Oncology.

Institutional Level- Individual Mentorships

1999 **Rebecca Sunenshine, MD**, Clinical vignette Presentation, Oregon chapter of the ACP annual meeting, 1999

2001 **Emily R. Janega, BS**, in Biology (Reed College) theses entitled: $\alpha v\beta 3$ integrin expression in human prostate cancer

2001-2004 **Natasha Tiffany, MD**, Fellow in Hematology and Medical Oncology. Clinical research training. Dr. Tiffany developed two clinical trials under my supervision.

Peer reviewed manuscript: "Tiffany NM, Wersinger EM, Garzotto M, and Beer TM. Imatinib mesylate and zoledronic acid in symptomatic androgen-independent prostate cancer. *Urology*, 63:934-939, 2004."

Peer reviewed manuscript: "Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, and Beer TM. High Dose Pulse Calcitriol, Docetaxel, and Estramustine in Androgen-Independent Prostate Cancer (AIPC): A Phase I/II Study. *Journal of Urology*, 174(3):888-92, 2005."

Abstract: "Tiffany NM, Wersinger EM, Garzotto M, and Beer TM. Androgen-independent prostate cancer (AIPC) treatment with zoledronic acid and imatinib mesylate (STI-571). *Proc Am Soc Clin Onc* 22:421, 2003."

Abstract: "Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, Beer TM. High-Dose Calcitriol, Docetaxel, and Estramustine in Androgen-Independent Prostate Cancer (AIPC): A Phase I/II Study. *Proc Am Soc Clin Onc* 23:424, 2004."

- 2001-2005 **Matthew Wagner, MD**, Urology Resident co-mentored with Dr. Garzotto in laboratory research (COX-2 expression and activity in prostate cancer). Received Rustin award for best medical student in Urology.
- Peer reviewed manuscript: "Wagner M, Garzotto M, Lemmon D, Eilers KM, and Beer TM. Prostate Specific Antigen Decline after GnRH Antagonist Withdrawal in Androgen Independent Prostate Cancer. Urology, 65(4):799, 2005"
- Peer reviewed manuscript: "Wagner M, Loos J, Weksler N, Gantner M, Corless CL, Barry JM, Beer TM and Garzotto M. Resistance of Prostate Cancer Cell Lines to COX-2 Inhibitor Treatment Biochem Biophys Res Commun, 332(3):800-7, 2005."
- Abstract: "Wagner M, Weksler N, Loos J, Beer TM, Barry JM, Garzotto M. Cox-2 expression and effects of selective inhibition in prostate cancer cell lines." Annual Northwest Urological Society Meeting. December 8, 2001.
- Abstract: "Wagner M, Weksler N, Loos J, Beer TM, Barry JM, Garzotto M. Cox-2 expression and effects of selective inhibition in prostate cancer cell lines." American Urological Assn Meeting, Abstract #542, 167:135, 2002.
- 2002 **Irene Panagiotou, MD**, Dr. Panagiotou did a 6-month research fellowship focused on outcomes research under my direct supervision
- Peer reviewed manuscript: "Panagiotou I, Beer TM, Hsieh YC, Mori M, Peters L, Klein T, and Garzotto M. Predictors of Delayed Cancer-Directed Intervention in Patients Who Choose Watchful Waiting for Localized Prostate Cancer in the PSA Era, Oncology (Basel), 67:194-202, 2004."
- Abstract: "Beer TM, El-Geneidi M, Panagiotou I, Peters L, Hsieh Y-C, Mori M, and Garzotto M, Delayed curative therapy in patients who initially choose watchful waiting in the PSA era. J Urol 169(4 Suppl):492, 2003 (Abstract 1844)"
- Abstract: "Garzotto M, Panagiotou I, Hsieh Y-C, Mori M, Peters L, Klein T and Beer TM. Predictors of Delayed Prostate Cancer-Directed Intervention in Watchful Waiting Patients in the PSA Era. J Urol 169(4 Suppl):460, 2003 (abstract 1724)"
- 2002 - 2003 **Mohamed El-Geneidy, MD**, Dr. Elgeneidi is doing a 1-year research fellowship focused on outcomes research under my direct supervision
- Peer reviewed manuscript: "El-Geneidy M, Garzotto M, Panagiotou I, Hsieh YC, Mori M, Peters L, Klein T, and Beer TM. Delayed Therapy with Curative Intent in a Contemporary Prostate Cancer Watchful Waiting Cohort. BJU International, 93:510-515, 2004."
- Abstract: "Beer TM, El-Geneidi M, Panagiotou I, Peters L, Hsieh Y-C, Mori M, and Garzotto M, Delayed curative therapy in patients who initially choose watchful waiting in the PSA era. J Urol 169(4 Suppl):492, 2003 (Abstract 1844)"
- Peer reviewed review: "Beer TM, El-Geneidi M, and Eilers KM. Docetaxel in the Treatment of Prostate Cancer. Expert Review of Anticancer

Therapy, 3(3):261-268, 2003.”

2002 – 2003 **Lisa Bland, MD candidate** Ms. Bland was a senior medical student who has been awarded a 1-year research fellowship by the OHSU GCRC. She received the NL Tartar Fellowship, the SOM Research Award, Department of Urology Outstanding Medical Student, the William Krippaehne Outstanding Medical Student in Surgery Award for her work during 2002 year and 2nd place in resident poster competition at the Western Section of the AUA. She was mentored directly by me in this effort.

Peer reviewed manuscript: “Beer TM, Berry W, Wersinger EM, and Bland LB. Weekly docetaxel in the elderly: a comparison of efficacy and toxicity in prostate cancer patients age 70 and older and younger than 70. *Clinical Prostate Cancer*, 2:167-172, 2003.”

Peer reviewed manuscript: “Beer TM, Tangen C, Bland LB, Thompson IM, and Crawford ED. Prognostic value of anemia in untreated metastatic prostate cancer: a multivariate analysis of SWOG 8894. *Journal of Urology*, 172(6, Part 1 of 2):2213-2217, 2004.”

Peer reviewed manuscript: “Bland LB, Garzotto M, DeLoughery TD, Ryan CW, Schuff KG, Wersinger EM, Lemmon D, and Beer TM. Phase II Study of Transdermal Estrogen in Androgen-Independent Prostate Cancer. *Cancer*, 103:717-23, 2005.”

Peer reviewed manuscript: “Beer TM, Bland LB, Bussiere JR, Neiss M, Wersinger EM, Garzotto M, Ryan CW, and Janowsky JS. Testosterone loss and estradiol administration modifies memory in men, *Journal of Urology*, 175(1):130-5, 2006.”

Peer reviewed manuscript: “Purnell JQ, Bland LB, Garzotto M, Lemmon D, Wersinger EM, Ryan CW, Brunzell JD, and Beer TM. Effect of transdermal estrogen therapy levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer. *Journal of Lipid Research*, 47(2):349-55, 2006.”

Peer reviewed manuscript: “Beer TM, Tangen CM, Bland LB, Hussain M, Goldman BH, Deloughery TG, Crawford ED. Prognostic Value of Hemoglobin Change After Initiation of Androgen Deprivations Therapy for Newly Diagnosed Metastatic Prostate Cancer: A Multivariate Analysis Of SWOG 8894. *Cancer*, 107:489-96, 2006.”

Abstract: “Bland LB, Tangen , Crawford ED, and Beer TM. Anemia Is An Independent Adverse Prognostic Factor in Untreated Metastatic Prostate Cancer: An Analysis of SWOG 8894. *Western Section of the AUA*, 2003.”

Abstract: “Beer TM, Bland LB, Garzotto M, Ryan CW, Janowsky JS. Effect of High Dose Estrogen May Enhance Memory in Men with Prostate Cancer. *Proc Am Soc Clin Onc* 23:417, 2004.”

Abstract: “Purnell JQ, Bland LB, Garzotto M, Lemmon D, Ryan CW, Beer TM. Transdermal Estrogen Therapy Improves Cholesterol Levels and Lipid Profiles in Men with Prostate Cancer. *Proc Am Soc Clin Onc* 23:734, 2004.”

Abstract: “Bland LB, Tangen CM, Thompson IM, Crawford ED, Beer TM. Prognostic Value of Anemia in Untreated Metastatic Prostate Cancer: A Multivariate Analysis of SWOG 8894. Proc Am Soc Clin Onc 23:399, 2004.”

Abstract: “Beer TM, Bland LB, Garzotto M, Purnell JQ, Ryan CW, Deloughery TG, Wersinger EM, Lemmon D. Transdermal estradiol in androgen-independent prostate cancer (AIPC). Proc Multidisciplinary Prostate Cancer Symposium 1:181, 2005”

Peer reviewed review article: “Lycette JL, Bland LB, Garzotto M, and Beer TM. The Case for Parenteral Estrogens for Prostate Cancer. Clinical GU Cancer, 5:198-205, 2006.”

- 2002-2003 **Charlotte Wheeler.** MPH Candidate (2003) Thesis: "*Diabetes and time to recurrence of prostate cancer: A medical record linkage analysis*" I was a member of her thesis committee.
- 2003-2004 **Diane Chepa.** CURE Student (Summer Internship for underrepresented minorities in research) Direct mentor.
- 2003 **Eric Fromme, M.D.** (Assistant Professor of Medicine)
5K07CA109511-02 Systematic Approaches to Supportive Care in Prostate CA
- Peer reviewed manuscript: “Fromme EK, Eilers KM, Mori M, Hiseh YC, and Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison to patient-reported symptoms from the QLQ-C30. Journal of Clinical Oncology, 22:3485-90, 2004.”
- Abstract: “Fromme EK, Eilers KM, Mori M, Hsieh Y-C, Beer TM. How Good is Physician Reporting of Chemotherapy Adverse Effects? A Comparison to Patient-Reported Symptoms From the QLQ-C30. Proc Am Soc Clin Onc 23:730, 2004.”
- 2003 - 2005 **Carrie Dul, M.D.** (Medical Oncology Fellow) Primary research mentor. Project: "*Individually Tailored Dosing of Docetaxel in Geriatric Prostate Cancer Patients*" NIH grant submitted.
- 2003 **Abdul Ahmet,** CURE program, Direct Mentor
- 2004 **Christopher T. Boniface,** summer college student (Direct Mentor)
- 2004 – 2006 **Jennifer Lycette, MD,** (Medical Oncology Fellow) Primary research mentor. Peer reviewed manuscript: “Lycette JL, Luoh SW, Beer TM, and Deloughery T. Acute Bilateral Pulmonary Emboli Occurring While on Adjuvant Aromatase Inhibitor Therapy with Anastrozole – Case Report and Review of the Literature, Breast Cancer Research and Treatment, 99(3):249-55, 2006.”
- Peer reviewed review: “Lycette JL, Bland LB, Garzotto M, and Beer TM. The Case for Parenteral Estrogens for Prostate Cancer. Clinical GU Cancer, 5:198-205, 2006.”
- 2004 – 2006 **Catherine O’Brien, MD,** (Medical Oncology Fellow) Primary research

mentor.

Project: “*Characterization of human prostate cancer chemotherapy response using tissue microarrays*” in progress.

Abstract: “Nelson PS, Huang A, True LD, Garzotto M, Wersinger EM, O’Brien CA, Ryan CW, Ellis WJ, Lange PH, Higano CS, Beer TM. Molecular Correlates of Prostate Cancer Response and Resistance to Neoadjuvant Mitoxantrone and Docetaxel.” InterProstate SPORE Meeting, Jan: 26, 2005.

Abstract: “O’Brien CA, Garzotto M, Higano CS, Wersinger EM, Kaimaktchiev V, Corles CL, Lange PH, Ryan CW, True LD, Beer TM. Predictors of early relapse in high risk prostate cancer patients treated with neoadjuvant mitoxantrone and docetaxel. Proc Am Soc Clin Onc 23 (16S):408s, 2005”

Abstract: “O’Brien CA, True LD, Higano CS, Garzotto M, Takayama T, Ellis WJ, Lange PH, Katovic NM, Ryan CW, Beer TM. Histologic patterns in radical prostatectomy (RP) specimens of high-risk prostate cancer patients treated with neoadjuvant chemotherapy are predictive of nodal metastases. Proc Prost Ca Symp 2006”

Abstract: “O’Brien CA, Mongoue-Tchokote S, Collins L, Spurgeon S, Peters L, Beer TM, Mori M, Garzotto M. Assessment of PSA and digital rectal examination (DRE) for the detection of Gleason \geq 7 prostate cancer in a referral population. Proc Am Soc Clin Onc 24 (18S): 249s, 2006”

- 2004-2006 **Matthew Taylor** (Medical Student) Primary research mentor.
Project: “*Phase II Study of Xyotax in Advanced Prostate Cancer*” developed, funded and recently activated (see clinical trials)
- 2004-2021 **Julie Graff, MD**, (Medical Resident)/(Oncology Fellow) Primary research mentor.
Abstract: “Graff J, Mori M, Li H, Garzotto M, Penson D, Potosky A, Beer TM. Predictors of overall and cancer-specific survival in patients with clinically localized prostate cancer (PC) treated with primary androgen deprivation therapy (PADT): Results from the Prostate Cancer Outcomes Study. Proc Am Soc Clin Onc 24 (18S): 244s, 2006”

Peer reviewed manuscript: “Graff JN, Mori M, Li H, Garzotto M, Penson D, Potosky A, and Beer TM. Predictors of Overall and Cancer-Free Survival in Patients with Localized Prostate Cancer Treated Initially with Androgen Suppressive Therapy: Results from the Prostate Cancer Outcomes Study. Journal of Urology, 177(4):1307-12, 2007.”

Abstract: “Graff J, Mori M, Li H, Garzotto M, Penson D, Potosky AL, Beer TM. Predictors of overall (OS) and cancer-specific survival (CSS) in patients with clinically localized prostate cancer treated with primary androgen deprivation therapy: Results from PCOS. Proc Prost Ca Symp 2006.”
- 2004-2007 **Joseph R. Bussiere** (MS candidate) Thesis advisory committee and co-mentor: “*The Effects of Testosterone Ablation on Verbal Memory Performance*”

Peer reviewed manuscript: "Bussiere JR, Beer TM, Neiss MB, and Janowsky JS. Androgen Deprivation Impairs Memory in Older Men, Behavioral Neuroscience, 119(6):1429-37, 2005."

Peer reviewed manuscript: "Beer TM, Bland LB, Bussiere JR, Neiss M, Wersinger EM, Garzotto M, Ryan CW, and Janowsky JS. Testosterone loss and estradiol administration modifies memory in men, Journal of Urology, 175(1):130-5, 2006."

2005-2006

Ryan Priest (MD Candidate)

Project: Prostate DCE-MRI: Prostate Cancer Screening and Staging by Dynamic-Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) Pharmacokinetics

Manuscript: "Spurgeon SEF, Mongoue-Tchokote S, Collins L, Priest R, Hsieh Y-C, Peters LM, Beer TM, Mori M, Garzotto M Assessment of Prostate-Specific Antigen Doubling Time in the Prediction of Prostate Cancer on Needle Biopsy, Urology, 69(5):931-5, 2007."

Manuscript: "Garzotto M, Mongoue-Tchokote S, Collins L, Priest R, Spurgeon S, Peters LM, Beer TM, Mori M. Nomogram For The Prediction Of Gleason ≥ 7 Prostate Cancer in Men With a PSA of ≤ 10 ng/ml. (in preparation)"

Abstract: "Garzotto M, Collins L, Priest R, Spurgeon S, Hsieh YC, Beer TM, Mori M. Nomogram for the prediction of high-grade prostate cancer on ultrasound-guided needle biopsy. Proc Am Soc Clin Onc 23 (16S):408s, 2005"

Abstract: "Spurgeon S, Garzotto M, Collins L, Priest R, Hsieh YC, Peters L, Beer TM, Mori M. Utility of PSA doubling time (PSADT) in the detection of prostate cancer in men with a serum PSA < 10 ng/ml. Proc Am Soc Clin Onc 23 (16S):408s, 2005"

2005-2007

Joe Chan, M.D. (Medical Oncology Fellow)

Protocol: "A phase II study of Paclitaxel Poliglumex (PPX) in Combination with transdermal estradiol for the treatment of androgen independent prostate cancer after docetaxel chemotherapy."

Abstract: "Chan JS, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether J, Chi KN, Young J, Shen C, Beer TM. Skeletal related events (SREs) in metastatic androgen independent prostate cancer(AIPC) treated with docetaxel-based chemotherapy: Results from ASCENT. (ASCO 2006)"

Abstract: "Chan JS, Lalani AS, Ryan CW, Berman C, Beer TM. C-Reactive Protein to Predict Risk of Skeletal Morbidity in Men with Androgen-Independent Prostate cancer: Results from the ASCENT Trial. (EUA 2007)"

Peer reviewed manuscript: "Chan JS, Beer TM, Quinn DI, Garzotto M, Sokoloff M, Dehaze DR and Ryan CW. A Phase II study of DN-101 (high-dose calcitriol) in combination with mitoxantrone and prednisone for androgen independent prostate cancer." (in preparation)

- 2006-2008 **Ian Schnadig, M.D.** (Medical Oncology Fellow), Primary Mentor
 Prognostic Significance of Patient-Physician Disagreement About Performance Status in Patients with Advanced Cancer - poster discussion at ASCO 2007; manuscript underway
- Comparison of Rescue Treatments for Breakthrough Chemotherapy-Induced Nausea and Vomiting - A Randomized Phase II Study - submitted for funding
- Evaluation of C-reactive protein (CRP) and Other Serum Biomarkers as Predictor(s) of Performance Status, Chemotherapy Toxicity and Serious Adverse Events in Patients Receiving Docetaxel for Metastatic Androgen-Independent Prostate Cancer - statistical analysis underway
- Pilot Study of a Treatment Algorithm to Manage Deferasirox-Associated Diarrhea - submitted for funding
- Pregabalin for the treatment of chemotherapy-induced neurotoxicity - submitted for funding
- Peer reviewed paper: Schnadig ID, Fromme EK, Loprinzi CL, Sloan JA, Mori M, Li H, Beer TM. Patient-Physician Disagreement About Performance Status Is Associated with Worse Survivorship in Patients with Advanced Cancer. *Cancer*, in press
- Presented abstract: Schnadig ID, Fromme EK, Loprinzi CL, Sloan JA, Mori M, Li H, Beer TM, Perrin N. Prognostic significance of patient-physician disagreement about performance status in patients with advanced cancer. *Proc Am Soc Clin Onc*: 25 (18S): 498s, 2007

- 2006 - **Joshi Alumkal, MD** (Assistant Professor), Junior Faculty, Primary Mentor (Mitchell Turker, co-mentor)
 FAMRI Young Clinical Scientist Award: The Role of DNA Methylation as a Predictor of Biochemical Recurrence after Radical Prostatectomy and *NKX3.1* Gene silencing in Prostate Cancer: Importance and Mechanisms” 7/1/2006-6/30/2009
- MRF: Epigenetic Therapies in Prostate Cancer: Identification of the Epigenome and Translation into Clinical Practice. 6/1/07-5/30/08
- OHSU OSCR K12 Grant: Elucidation of Clinically Significant Gene Silencing Mechanisms in Prostate Cancer 4/1/07-

PROJECTS

1. *EZH2* and its role in the initiation of gene silencing in normal prostate cells- This project involved stable overexpression of *EZH2* *in vitro* followed by assessment of DNA methylation of genes known to be repressed transcriptionally by *EZH2* and which are also commonly found to have DNA methylation in human cancers in addition to the *NKX3.1* gene, which is commonly lost in prostate cancer through mechanisms independent of DNA methylation.
2. The effect of XB154, a small molecule inhibitor of *LSD1*, which turns on (AR) Androgen Receptor-regulated genes and represses

tumor suppressor genes, on gene expression in prostate cancer using a candidate gene and genome-wide expression profiling with cDNA microarrays.

3. Impact of DNA Methylation on the Identification of Aggressive Prostate Cancer. This project involves the validation of a DNA methylation biomarker, which we previously found to be independently associated with an increased risk of prostate cancer recurrence.

- 2007 - 2014 **Christine Barnett, M.D.** (Medical Oncology Fellow), Primary mentor
Vitamin D consumption and blood levels and risk of prostate cancer, an analysis of the MrOS cohort
- 2013 ASCO Conquer Cancer Foundation Merit Award: Abstract 80: Genomic analysis of prostate cancer, 2013 Genitourinary Cancers Symposium in Orlando, Florida.
- 2007 - **David Qian, PhD** (Assistant Professor), Junior Faculty, Primary mentor
Fred Hutchinson Cancer Research Center/Pacific NW SPORE \$65,000 (annual direct)
SPORE Career Development Award
9/1/07-8/30/08
- Medical Research Foundation \$29,936
Defining the role of histone deacetylase in bone-marrow mesenchymal stem cells response to prostate cancer bone metastasis
3/1/08-2/28/09
- 2007 - 2012 **Renee Prins, MD** (Resident), Primary mentor
Prognostic factors in prostate cancer.
- 2008 - 2013 **Faisal Siddiqui, B.S.** (Medical Student), Primary mentor
RSNA Research & Education Foundation, RSNA Medical Student Grant for Prostate DCE-MRI: Prostate Cancer Screening and Staging by Dynamic-Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) Pharmacokinetics
- 2008 - 2009 **Luke Fletcher** (Student, Murdock Scholar Program), Co-mentor
(David Qian, Ph.D., Co-mentor)
- 2008 - 2009 **Brinda Gokul** (High school student), Co-mentor
(David Qian, Ph.D., Co-mentor)
- 2009 – 2010 **Marie Lafortune** (Student, Murdock Scholar Program) Co-mentor
(David Qian, Ph.D., Co-mentor)
- 2009 – 2009 **Elena De Jesus Hernandez** (High school student, Ted R. Lilley Cancer CURE Program), Co-mentor (David Qian, Ph.D., Co-mentor)
- 2013 - **Colin Bergstrom, B.S.** (Medical Student), Advisor
Internal Medicine Specialist, Oncology focus
- 2013 - **Jeremy Cetnar, MD** (Assistant Professor), Junior Faculty, Primary mentor
Lung cancer and genitourinary (bladder and prostate cancers)

- 2017 - **Amy Moran, PhD** (Assistant Professor), Junior Faculty, Co-mentor
(Lisa Coussens, PhD, Co-mentor)
- 2018 - **Ece Eksi, PhD** (Postdoctoral Scholar), CEDAR Researcher, Co-mentor
(Paul Spellman, PhD, Co-mentor)
- 2020 - **Zheng Xia, PhD** (Assistant Professor), Junior Faculty, Primary mentor

Institutional Level-Classroom Teaching

Medical Students Blood Pathophysiology small group instructor (2000 - 2005)
Biological Basis of Disease instructor (2001 – 2002)

Other AHEC MedStars Honors Program instructor (2001)
Human Investigations Program (HIP) lecturer (2002)
Monthly lectures on prostate cancer to rotating staff and students